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Abstract 
Currently, the most common form of radiotherapy is using high energy linear accelerators to 
generate an external photon beam directed towards the tumour mass. Other forms of 
radiation used in radiotherapy include charged particles such as electron beams, neutrons, 
pi-mesons, protons, and heavier charged ions such as 12C. Of these, proton radiotherapy has 
gained, and is gaining, much attention worldwide. Protons display special physical 
characteristics that provide a more localized delivery of radiation to the tumour site than can 
be achieved with photon-based radiotherapy. Many leading cancer centres worldwide have 
established new proton therapy facilities or will become operational within the next few years. 
With this expansion, it will be possible to treat more patients, and therefore new clinical 
indications are planned to be treated with protons. However, the conclusion that it is safe to 
expand this technology without additional knowledge based on scientific and radiobiological 
data cannot be directly drawn. Preclinical experiments reveal an enhanced efficacy for proton 
versus photon irradiation. But the cause for the increased efficacy of protons on the 
molecular level is not clear. Proton irradiation-induced DNA damage might be quantitatively 
or qualitatively different compared to photon irradiation-induced DNA damage, and only few 
studies have been done to elucidate this question. 
In this PhD thesis, I have investigated several molecular and cellular end points in response 
to photon and proton irradiation using genetically defined biological cell systems. A special 
focus has been placed on the involvement of DNA double strand break (DNA DSB) repair 
after proton vs. photon irradiation. A panel of different cell lines was used to reveal a possible 
differential sensitivity to proton radiation depending on the repair capacity due to the genetic 
background of the cell. All tested cell lines were more sensitive to proton irradiation in 
comparison to photon irradiation on the level of clonogenic cell survival. For both wild type 
cells used in the study (AA8 and CHO9), irradiation with protons decreased cell survival by 
1.1 ± 0.1 and 1.8 ± 0.2 fold at 2 and 5 Gy, respectively, when compared to photon irradiated 
cells. A cell line mutated in the nucleotide excision repair pathway was used as a control and 
showed the same sensitivity as the corresponding wild type cell line. As expected, mutant 
cells in homologous recombination (HR) and non-homologous end joining (NHEJ) were in 
general much more sensitive towards irradiation than wild type cells. But interestingly, 
exponentially growing cells deficient in HR were significantly more sensitive to proton 
irradiation than cells with intact HR (relative biological effectiveness, RBE10 wild 
type=1.24±0.03, HR-deficient=1.44±0.06). When these cells were irradiated in plateau 
(growth arrested) phase, there was no longer a difference in the RBE of the two cell lines 
(RBE10 wild type=1.29±0.03, HR-deficient=1.27±0.03), indicating a more critical role of HR 
after proton vs. photon irradiation, as HR is only active in S/G2 phase. On the other hand, 
ii 
exponentially growing NHEJ-deficient cells did not show a specifically enhanced sensitivity to 
proton irradiation (RBE10 wild type=1.2±0.05, NHEJ-deficient=1.09±0.10). However, after 
irradiation in plateau phase, these cells became highly radiosensitive and significantly more 
sensitive to proton radiation. Cells lacking NHEJ possess only minor backup repair pathways 
in plateau phase, which possibly can deal with some photon-induced DNA damages but not 
with proton-induced ones. These data point to a differential DNA damage complexity or 
amount of DNA damage after proton vs. photon irradiation. In an attempt to explore these 
findings further on a molecular level, we determined initial DNA DSBs, repair kinetics, cell 
cycle distributions, and chromosomal aberrations. No quantitative differences in initially 
induced γH2AX and 53BP1 foci could be determined in response to the two types of 
radiation. The repair kinetics of DNA damage in wild type cells were the same after both 
types of radiation (γH2AX, Rad51, and 53BP1 foci), even though proton irradiation resulted 
in more residual chromosomal DNA fragments and lethal chromosome aberrations. 
Interestingly, the repair kinetics in HR-deficient cells were significantly delayed after proton 
irradiation, leading to an elevated amount of residual γH2AX-foci 24 h after irradiation (45 % 
vs. 27 % γH2AX foci after protons vs. photons, respectively). Thus, these data show the 
same amount of initial DNA DSBs after both types of radiation and rather point to a 
differential damage pattern. As all previous experiments have been performed with Chinese 
hamster ovary (CHO) cells we used additionally U2OS cells to validate the importance of HR 
for the repair of proton irradiation-induced DNA damages in a human system. However, 
human U2OS cells, which are proficient in p53, did not show an increased proton 
radiosensitivity when HR was depleted. This was in contrast to the previously mentioned 
data obtained using p53-mutated CHO cells. To test another human cell type, we used a 
pancreas adenocarcinoma cell line with a non-functional, truncated BRCA2 protein, as 
BRCA2 is an important mediator for HR and often mutated in certain cancer types. These 
cells were more sensitive towards proton vs. photon radiation at higher dose levels, 
validating our finding in a human cell system. 
This work demonstrates for the first time that the genetic background of cells can strongly 
influence their response to proton radiation. When HR was missing in highly proliferative, 
p53-deficient cells, the proton radiosensitivity was significantly increased compared to wild 
type cells, indicating that HR is essential for the proper repair of a certain percentage of 
proton-induced DNA damages. Therefore, aggressively proliferating tumour cells lacking HR 
and cell cycle check points would be best treated with proton radiotherapy. Other mutations 
should be tested with regard to the differential sensitivity towards proton and photon 
irradiation. Furthermore, these data indicate a differential quality of DNA damage induced by 
proton vs. photon irradiation, which might become relevant for clinical stratification of patients 
carrying mutations in the DNA damage repair and response pathways. 
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Zusammenfassung 
Die gängigste Methode der Strahlentherapie ist heutzutage die Erzeugung eines 
Photonenstrahls mit hochenergetischen Linearbeschleunigern, der gegen das Tumorgewebe 
gerichtet wird. Weitere Bestrahlungsarten, die in der Strahlentherapie verwendet werden sind 
mit Partikeln erzeugte Strahlen wie Elektronen, Neutronen, Pi-Mesonen, Protonen und 
schwere, geladene Ionen wie Carbon-ionen. Von diesen ist die Protonentherapie die 
bekannteste Form und erlangt immer mehr an Beachtung. Protonen haben spezielle 
physikalische Eigenschaften, welche eine exaktere Bestrahlung des Tumors möglich 
machen als dies mit Photonen-basierter Strahlentherapie möglich ist. Viele führende 
Krebszentren weltweit besitzen mittlerweile eine funktionelle Protonentherapieanlage oder 
werden diese in den nächsten Jahren in Betrieb nehmen. Durch diese Expandierung wird es 
möglich mehr Patienten und somit mehr neue klinische Indikationen mit Protonen zu 
behandeln. Jedoch kann nicht einfach vorausgesetzt werden, dass es sicher ist, ohne 
weitere radiobiologische Grundlagenforschung, diese Technologie einfach für andere 
Indikation zu übernehmen. Präklinische Experimente zeigen eine stärkere Effektivität von 
Protonen im Vergleich zu Photonenstrahlung. Aber der Grund für diese besserer Effektivität 
ist auf molekularer Ebene noch nicht geklärt. Protonen-induzierte DNA Schäden sind 
möglicherweise quantitativ oder qualitativ verschieden verglichen mit Photon-iniduzierten 
DNA Schäden. Bis jetzt wurden nur wenige Studien durchgeführt, um diese Frage zu 
beantworten.  
In dieser Doktorarbeit habe ich die molekulare und zelluläre Reaktion von Zellen nach 
Photonen und Protonenbestrahlung auf mehreren Ebenen untersucht. Dafür wurden 
genetisch definierte Zellsysteme verwendet. Der Fokus lag auf der zellulären Beteiligung von 
DNS Doppelstrangbruch (DSB) Reparatur Systemen nach Photonen vs. 
Protonenbestrahlung. Verschiedenen Zelllinien (Wildtypen/Mutanten) wurden verwendet, um 
mögliche Unterschiede in der Strahlensensitivität nach Protonenbestrahlung in Abhängigkeit 
von der Reparaturfähigkeit und dem genetischen Hintergrund der Zelle aufzudecken. Alle 
getesteten Zelllinien waren, gemessen auf der Ebene des klonogenen Überlebens, sensitiver 
gegenüber Protonen als gegenüber Photonbestrahlung. Protonenbestrahlung verringerte das 
Zellüberleben in beiden Wildtypzellen (AA8 und CHO9) verglichen mit Photonenbestrahlung 
um 1.1 ± 0.1 und 1.8 ± 0.2 fach nach 2 und 5 Gy, respektive. Eine mutierte Zelllinie im 
Nukleotidexzisionsreparaturweg wurde als Kontrolle verwendet und zeigte dieselbe 
Sensitivität wie die dazugehörige Wildtypezelllinie. Wie erwartet, waren die Mutanten der 
Homologen Rekombination (HR) und des Nicht-Homologen End Joining (NHEJ) generell viel 
sensitiver gegenüber Bestrahlung als die Wildtypzellen. Hochinteressanterweise, waren 
exponentiell wachsende HR-defiziente Zellen signifikant sensitiver gegenüber 
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Protonenbestrahlung als Zellen mit intakter HR (relative biologische Effektivität, RBE10 
Wildtyp=1.24±0.03, HR-defizient=1.44±0.06). Wurden diese Zellen in der Plateauphase 
(wachstumsarretiert) bestrahlt, war der Unterschied im RBE zwischen den beiden Zelllinien 
nicht mehr vorhanden (RBE10 Wildtyp=1.29±0.03, HR-defizient=1.27±0.03). Dies zeigt eine 
wichtigere Rolle von HR nach Protonen als nach Photonenbestrahlung an, da HR nur in der 
S/G2 Phase aktiv ist. Auf der anderen Seite waren exponentiell wachsende NHEJ-defiziente 
Zellen nicht sensitiver gegenüber Protonenbestrahlung (RBE10 Wildtyp=1.2±0.05, NHEJ-
defizient=1.09±0.10). Dieselben Zellen waren nach Bestrahlung in der Plateauphase viel 
radiosensitiver und signifikant sensitiver gegenüber Protonenbestrahlung als der Wildtyp. 
Zellen ohne NHEJ Reparatur besitzen nur wenige Ersatzreparaturmechanismen in der 
Plateauphase. Ersatzreparaturwege können möglicherweise einige Photonen-induzierte 
DNA Schäden reparieren, jedoch womöglich keine Protonen-induzierten. Diese Daten 
deuten auf unterschiedlich komplexe DNA Schäden oder unterschiedlich viele DNA Schäden 
nach Protonen vs. Photonenbestrahlung hin. Weiterhin wurden diese Erkenntnisse auch auf 
molekularer Ebene untersucht: hierfür wurde die initiale Anzahl an DSB, Reparaturkinetiken, 
Zellzyklusverteilungen und chromosomale Aberrationen bestimmt. Es wurden keine 
Unterschiede in der Anzahl von initialen γH2AX und 53BP1 Foci nach Bestrahlung mit einer 
der beiden Strahlentypen festgestellt. Die DNA Reparaturkinetiken waren in den 
Wildtypzellen gleich (γH2AX, Rad51, and 53BP1 Foci), obwohl die Protonenbestrahlung 
mehr übrige Chromosomenfragmente und letale Chromosomenaberrationen nach sich zog. 
Interessanterweise war die Reparaturkinetik in HR-defizienten Zellen nach 
Protonenbestrahlung signifikant langsamer, was 24 Stunden nach Bestrahlung zu einer 
erhöhten Anzahl an nicht aufgelösten γH2AX Foci führte (45 % vs. 27 % γH2AX Foci nach 
Protonen vs. Photonen, respektive). Folglich zeigen die Daten gleich viele DNS DSB nach 
beiden Bestrahlungsarten und deuten eher auf eine unterschiedliche Struktur des Schadens 
hin. Da alle Experimente bis hierher mit Chinesischen Hamster Ovarial (CHO) Zellen 
durchgeführt worden sind, wurden zusätzlich U2OS Zellen verwendet, um die Wichtigkeit der 
HR für die Reparatur von Protonen-induzierten Schäden in einem humanen Zellsystem zu 
zeigen. Jedoch zeigten die humanen U2OS Zellen, welche p53 positiv sind, keine erhöhte 
Sensitivität gegenüber Protonenbestrahlung wenn HR nicht vorhanden war. Diese Daten 
waren widersprüchlich zu den vorher erwähnten Daten, in welchen p53-defiziente CHO 
Zellen verwendet wurden. Eine humane Pankreasadenokarzinom Zelllinie mit nicht-
funktionalem, kürzerem BRCA2 Protein, wurde als weiteres humanes Testsystem verwendet. 
BRCA2 ist ein wichtiger Vermittler für die HR Reparatur und oft in bestimmten Krebsarten 
mutiert. Diese Zellen waren nach Bestrahlung mit höheren Dosen vermehrt sensitiver 
gegenüber Protonen vs. Photonen, was unsere Entdeckung in einem humanen Zellsystem 
bestätigen konnte. 
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In dieser Arbeit wird zum ersten Mal gezeigt, dass der genetische Hintergrund der Zellen die 
Zellantwort gegenüber Protonenbestrahlung stark beeinflussen kann. Wenn HR in schnell 
proliferierenden, p53-defizienten Zellen fehlte, war deren Sensitivität gegenüber 
Protonenbestrahlung im Vergleich zu Wildtypzellen signifikant erhöht. Dies zeigt, dass HR für 
die richtige Reparatur eines bestimmten Anteils von Protonen-induzierten DNA Schäden 
essentiell ist. Diese Daten weisen darauf hin, dass aggressive, schnell wachsende Tumoren, 
denen HR und Zellzykluskontrollmechanismen fehlen, am besten mit Protonentherapie 
behandelt werden. Weitere Mutationen sollten im Hinblick auf die unterschiedliche 
Sensitivität nach Protonen und Photonenbestrahlung getestet werden. Weiterhin weisen die 
Daten auf einen qualitativ unterschiedlichen, induzierten DNA Schaden nach Protonen vs. 
Photonenbestrahlung hin. Dies könnte für die klinische Stratifizierung von Patienten mit 
Mutationen in DNA Reparaturwegen und in der Stressantwort auf DNA Schäden genutzt 
werden. 
vi 
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 1.1 Cancer and cancer treatment 
1 
1 Introduction 
1.1 Cancer and cancer treatment 
Cancer is a malignant disease, which is characterized by uncontrolled growth of a cell mass 
(tumour), its invasion into normal tissue, and often times its spread throughout the body. The 
name arises from early reports where swollen blood vessels of a huge tumour under the skin 
gave a picture of a crab (in astrology: cancer). Today we know about 100 different kinds of 
cancer. Cells from almost every tissue of the body can give rise to cancer. Classification of 
the different types is due to the site of origin: carcinoma – cancer of epithelial origin, sarcoma 
– originate from mesenchymal tissue, leukaemia – result from haematopoietic cell lineages 
(1). To rank the severity of the disease, an international TNM classification is used. T0-T4 
indicate the expansion of the primary tumour, N0 – N3 display how many lymph nodes are 
infiltrated by tumour cells, and M0 – M1 stand for absence or presence of metastases.  
According to the World Health Organization, cancer causes 20 % of deaths in the Europe. 
With more than 3 million new cases and 1.7 million deaths per year cancer remains the most 
important cause of death and morbidity in Europe after cardiovascular diseases. Lung, 
stomach, liver, colorectal, oesophagus and prostate cancers are the most frequent types 
among men whereas breast, lung, stomach, colorectal and cervical cancers are the most 
frequent ones among women (Fig. 1.1, 1.2). European trends in incidence are favourable in 
the more prosperous countries from Northern and Western Europe, except for obesity related 
cancers and tobacco-related cancers, in the case of women (2). 
 
Figure  1.1 Cancer incidences by gender in Europe in 2006 (2) 
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Early malignant cells gain certain mutations in important control genes, which result in a 
growth advantage. Normally those cells get cleared by the immune system. But they further 
evade several control mechanisms and cell death pathways, which are normally activated in 
cells to prevent them from becoming “uncontrolled”. When the tumour is growing, new blood 
vessels have to be formed, which is promoted by the secretion of angiogenic factors. If the 
cells gain the ability to move and invade into the blood stream or lymph system and build a 
new cell colony at a distant site in the body, this process is called metastasis, which is the 
most severe problem. 90% of cancer deaths result from metastatic disease. Compromise of 
normal organ functions can lead to morbidity and mortality. Therefore it is very important to 
detect the primary tumour at an early stage. Huge screening programs and prevention 
campaigns resulted in a decrease of cancer mortality in Europe Union. Mortality rates 
decreased by 9% in men and 8% in women from 1990 to 1994 and 2000 to 2004 (3), which 
shows a favourable trend that is similar to the US and which has also been found in Japan. 
On the other hand, worldwide prognosis is not that good. According to WHO estimations 
(from 2004) deaths from cancer worldwide will rise to an estimated 12 million in 2030. This 
trend is mainly attributed to low-income countries, which have no adequate programs for 
cancer prevention and treatment. 
 
 
Figure  1.2 Distribution of cancer deaths by gender in Europe in 2006 (2) 
 
Cancer prevention is possible with a healthy lifestyle and early diagnosis. Some of the most 
common tumour types, like breast, colorectal and cervical cancer, can be cured if detected 
early enough. Screening programs with annual cervical pap tests or mammography and 
colonscopy every 5 years detect very early stages of those cancer types. 
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Three main treatment options are available, namely surgery, radiotherapy, and 
chemotherapy. Surgery is the oldest treatment form and leads to good therapeutic results in 
early non-metastatic tumours. It is often followed by concomitant radiation therapy or 
chemotherapy to ensure that all malignant cells, including metastatic cells, have been 
removed. The latter two treatment modalities take advantage of the fact that tumour cells are 
different from normal cells. Due to the loss of control mechanisms, they are much more 
sensitive to genotoxic stress. Radiotherapy gives good results for long-term control of many 
tumours of the head and neck, lung, cervix, bladder, prostate, and others. It is actually often 
used if a tumour cannot be excised because it is situated close to or within a critical organ 
(e.g. brain, lung). In addition, many patients receive chemotherapy at some point in their 
treatment schedule. Symptom relief and arrest of the disease are often obtained with these 
drugs, but very few cancers (among them lymphomas) can be cured by chemotherapy alone 
(4).  
 
1.2 Role and rationale for radiotherapy in management of cancer 
X-rays were first produced in 1895 and have been used for cancer treatment since, but 
several decades passed before it became a standard treatment option. After Wold War II 
with the usage of nuclear weapons the interest in the effect of radiation on humans and cells 
grew. 1951 the first clinical cobalt-60 unit was implemented in London, Ontario, Canada (5). 
Already in 1956 the first patient was treated with a medical linear accelerator in Stanford. 
Since then over 40 million of patients have been treated primarily with the help of a medical 
linear accelerator. Radiotherapy is a good example of a multidisciplinary field. Physicians, 
physicists, and biologists came together to make the use of X-rays a major treatment option 
today. More than 50 % of all cancer patients receive radiotherapy at some point during their 
illness (6, 7).  
All treatment options follow the goal to cure the disease with as few side effects as possible, 
leading to a high therapeutic index. However, administration of some radiation to healthy 
tissue and organs is unavoidable. A too high single dose delivered to a critical organ like lung 
or rectum leads often to severe side effects or even mortality. Therefore the total dose is 
fractionated over the treatment time. Conventional treatment protocols use 30 fractions with 
each 2 Gy over 6 weeks. This is done due to several important reasons which led to the 4 
R’s of radiobiology. 
 
4 
1.2.1 Four R´s of Radiotherapy 
The four R´s determine the final response of tumour and normal tissue after irradiation. Due 
to these four main biological response mechanisms to radiation, normal-tissue toxicity can be 
minimized and tumour control can be maximized. 
 
Recovery (Repair) of the normal tissue from sublethal and potentially lethal damage after 
exposure to radiation can occur in between the fractions. Radiotherapy counts on the fact 
that repair and control mechanisms are functional in normal tissue and less efficient in 
tumour cells. Therefore normal tissue can repair damages more accurately in between the 
fractions. For convenience, fractions are given in 24 hour intervals. The intervals could also 
be shortened, as most DNA damage is repaired 6 hours after irradiation. 
The term sublethal damage (SLD) repair was first described by Elkind et al. who showed in 
vitro that splitting a high total dose into two equal fractions separated by a time interval (30 
min – 8 hours) would increase the survival of the cells (8). Under these conditions sublethal 
radiation damage is repaired. However, if the entire dose is given without a break, the 
damages have a higher chance to interact and to form a non-repairable lethal damage. In a 
second case when the dose is administered slowly over a longer time period, sublethal 
damage repair occurs during the time of exposure. This is called the dose-rate effect. Dose 
rates below 1 Gy/min can lead to a better survival of cells as they start to repair during the 
time of radiation exposure. For higher dose rates this can be excluded (9). 
A potentially lethal damage (PLD) is lethal under normal circumstances, but under certain 
conditions this damage can be repaired and is not lethal. If cells are kept in a density-
inhibited state for 6-12 hours after irradiation before plating them for clonogenic survival 
assays, they show an enhanced survival (10). This was also demonstrated in vivo where 
tumour cells were removed only 2-8 hours after irradiation and assayed for their reproductive 
capacity (11). In general, PLD is repaired if cells are situated in suboptimal growth conditions, 
where they do not attempt the complex processes leading to mitosis and cell division. Under 
these conditions they have time to repair damages. Whether PLD repair is clinically relevant 
is a matter of debate. However, radioresistant tumours seem to be able to repair PLD (5). 
Hypoxic tumour cells are within suboptimal growth conditions and might also profit from PLD 
repair. 
 
Repopulation is the proliferation of cells to fill the gap left by cells that died. Normal cells 
harbour a very stringent regulation of “when it has to die”. A percentage of normal cells will 
receive lethal damages or will not repair the damage properly. Those cells die via 
programmed cell death pathways. Other healthy cells start to divide and to fill the gap. This 
will help to keep the tissue intact even though it is not the same as non-irradiated one. But 
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repopulation does also occur in the tumour. Rapid repopulation is an important factor leading 
to bad outcomes. Especially for head and neck cancers, it was proposed that treatment be 
completed as soon as possible after initiation (12). In general it is believed that any 
unnecessary treatment breaks should be avoided to prevent tumour regrowth. 
 
Redistribution of cells within the cell cycle is the return toward a more even cell cycle 
distribution, after the selective killing of cells in radiosensitive phases of the cell cycle 
(M/G1/early S phase cells). Surviving cells, which were predominantly in a resistant phase at 
the time point of irradiation (late S/early G2 phase), move together to a more radiosensitive 
phase and might be more efficiently killed with the next fraction. Also normal cells, which 
arrested in late G2 phase, are more radiosensitive. This might be another advantage, 
because normal cells with non repaired damage should not survive (5). 
 
Reoxygenation of the tumour mass will sensitize the tumour cells for the next fraction.  In 
1968 it was shown by van Putten that the percentage of hypoxic cells in the tumour did not 
change after 4 fractions compared to the untreated tumour (13). This phenomenon indicated 
that hypoxic cells can become oxygenated in the course of the treatment, which was called 
reoxygenation. Hypoxic tumour cells are more radioresistant. Normally oxygen takes part in 
the radical reactions and leads to better damage fixation and more efficient cell killing. This is 
called the oxygen enhancement ratio (OER). Oxygenation of the tumour cells makes them 
again more susceptible to radiation. Therefore long treatment breaks (such as over 
weekends) are helpful with regards to reoxygenation. 
 
1.2.2 Molecular stress responses after ionizing radiation exposure 
1.2.2.1 Radical formation and scavengers 
Ionizing radiation (IR) can be either of electromagnetic (X-ray and γ-ray) or particulate 
(carbon, neutron, proton ions) origin. As the word ionizing radiation implies, radiation is used 
to ionize atoms in the cell, this can happen directly or indirectly (Fig. 1.3). Particles (also 
called hadrons) act dominantly through direct ionizations, meaning they damage DNA or 
other molecules through direct particle interactions. However, the percentage of direct 
actions depends on the particle mass and speed. When a particle becomes slowed down 
(through interaction with matter) the direct interaction probability increases. As part of this 
thesis, proton ions will be explained later on. Photons from high frequency electromagnetic 
radiation are mainly indirectly ionizing. As they pass through the cell, they interact with 
loosely bound planetary electrons of atoms and give up part of their energy to the electron as 
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kinetic energy. This so-called secondary electron is a fast-moving charged particle. The 
photon itself becomes deflected, proceeds with reduced energy, and if energetic enough may 
 
Figure  1.3 Direct and indirect actions of radiation. A secondary electron generated by the absorption 
of an X-ray photon interacts directly with DNA (direct action). If a secondary electron interacts with 
water molecules, hydroxyl radicals (OH.) can be produced, which in turn might generate damage to 
DNA (indirect action) (adapted from (5)). 
 
energize another electron. Many of those fast secondary electrons can directly or indirectly 
ionize other atoms. The predominant interaction takes place with water molecules, which 
compose the most abundant medium in the cell. An ion radical and a free electron are 
generated. The highly reactive ion radical will react with water molecules forming highly 
reactive hydroxyl radicals (OH.). These can diffuse and account for most of the damage 
produced in the cell. In the presence of oxygen even more reactive oxygen species (ROS) 
can be formed. Radical reactions lead to a cascade and take place until the restoration of 
electronic charge equilibrium is reached. Chemical modifications may damage almost any 
component of the cell, including proteins, lipids, DNA, etc., with DNA damage being the most 
toxic one (5, 14, 15). In contrast to the very fast events during radiation exposure, the actual 
cell death takes time, as do secondary cancers, evolving over years after radiation treatment 
(16). 
To protect themselves from radical-mediated damage, cells have developed several 
scavenging mechanisms or take up antioxidant molecules e.g. glutathione, peroxiredoxin I 
and II, SOD, ascorbic acid (17, 18). These systems can cope with the daily environmental 
levels of radicals, but not with the huge amount produced after exposure to clinically relevant 
doses of radiation. Hence it was shown that administration of antioxidants like DMSO to cells 
could minimize the effect of radiation (19).  
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From experiments with cytosolic microbeam irradiation it became obvious that radicals 
propagate throughout the cell and thereby harm the cell at more distant sites, which includes 
the nucleus (20, 21). Furthermore the generation of mitochondria-dependent reactive 
oxygen/nitrogen after irradiation might play a role (22, 23). Damaged mitochondria may 
produce ROS and this stress signal is forwarded via adjacent mitochondria through Ca2+-
dependent mitochondrial permeability. It was reported that ROS persist in normal diploid 
fibroblasts with functional p53 for up to two weeks after X-ray exposure. In cells with depleted 
p53, ROS levels were decreased in magnitude and duration (24). Late responses to radiation, 
like the abundance of ROS for up to 2 weeks, might be important for the proper reaction of 
the cell. 
 
1.2.2.2 Signal transduction 
Ionizing radiation can activate nuclear and membrane-cytoplasmic signal transduction 
pathways. On the nuclear level, generation of DNA damage activates the PI3K-like kinases 
ATM, ATR, and DNA-PKcs, which in turn can regulate cytoplasmic signalling pathways. ATM 
was found to negatively regulate the anti-survival JNK1/2 signalling pathway and positively 
regulate signalling through ERK1/2 (25, 26). Whereas in the other direction, cytoplasmic to 
nuclear signalling, MEK1/2-ERK1/2 positively affect ATM, as inhibition of the former reduced 
homologous recombination and completely abrogated autophosporylation of ATM at S1981 
(27). If DNA double strand breaks affect the ERK1/2 pathway in a positive way depends on 
the extent of DNA damage, namely the dose (28).  
An example of membrane to nucleus signalling is the translocation of the EGF receptor 
(EGFR) into the nucleus together with Ku70/80 and protein phosphatase 1, which leads to an 
increase of DNA-PKcs activity and therefore to an increased DNA repair activity (29). When 
tumour cells over-express EGFR or express certain EGFR isoforms, radioresistance occurs 
due to promotion of DSB repair via activated DNA-PKcs (30). EGF receptors become initially 
activated up to 10 min after exposure and reactivated ~ 60 – 180 min later. The initial 
activation of EGFR1 leads to the cleavage, release and activation of presynthesized 
paracrine ligands (e.g. pro-transforming growth factor α, TGFα), which in turn promotes 
growth and survival of irradiated and distant non-irradiated tumour cells often having the 
receptor over-expressed (31). 
Another effect on the membrane level is the activation of acidic sphingomyelinase after 
exposure to radiation, which increases the concentration of ceramide in the cell and 
facilitates the clustering of receptors, promoting their activation (32).  
Not only phosphorylation modulates cellular signalling after radiation exposure. Protein 
phosphatases (PPTases) are very sensitive to oxidation or nitrosylation. The huge amount of 
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ROS/RNS produced after radiation exposure decreases their activity and therefore increases 
the activity of certain rapidly phosphorylated receptors after irradiation (33). 
Cytosolic signal transduction pathways are induced within minutes after radiation exposure, 
such as MAPK and PI3K pathways. The different pathways can lead to the expression of 
pro-/anti-apoptotic genes as well as genes needed for proliferation. All these pathways 
interact to determine the final outcome like cell death, survival, or sensitization/resistance to 
the next fraction of radiation (33).  
Irradiation can also regulate the level of protein synthesis. Rapid activation of the MAP 
kinase ERK1/2 resulted in an early transient increase in cap-dependent mRNA translation 
over mTOR. Translation of mRNAs, encoding proteins involved in DNA repair and cell 
survival, leads to radioprotection in normal cells. In contrast this increase in translation has 
not been found in transformed cells, which have often up-regulated basal ERK activity and 
constitutively active mTOR signalling (34).  
A complex interplay of all these pathways and modifications determines the response of the 
irradiated cell. Here, the genetic status of the cells and the extent of the damage will 
influence the outcome. Accordingly, tumour cells and normal tissue cells must respond 
differently.  
 
1.2.2.3 Cell death mechanisms 
Different types of cell death occur after exposure to ionizing radiation e.g. apoptosis, 
autophagy, necrosis, senescence, and mitotic catastrophe. Which type will occur depends on 
the cell type. Fast apoptotic response takes place within hours after irradiation and is limited 
to thymocytes, lymphocytes, and other cells in rapidly proliferating tissues as in hair follicles, 
small intestine, and developing embryos (35). Endothelial cells can also activate a fast 
apoptotic response but only after high doses (above 15 Gy) (36). Autophagy is another type 
of programmed cell death, which is characterized by the formation of autophagic vesicles in 
the cytoplasm. Senescence is a state where cells lose their ability to proliferate but stay 
metabolically active. Necrosis is not a form of programmed cell death, as cells die without 
any signalling to the environment and will not be removed by immune cells. Necrotic areas 
were reported after radiotherapy (37, 38). 
Solid tumours and most normal cells die at a relatively long time after exposure to radiation, 
often attempting mitosis one or several times (39). Cell death, which occurs after few 
attempts of mitosis, can be executed by apoptotic or autophagic proteins but is called mitotic 
catastrophe. Cells with several aberrant nuclei and micronuclei cannot proceed any more 
through mitosis and will die. An irradiated cell can still divide itself for several cycles, but 
eventually always one daughter cell dies and the surviving daughter cells will die at the next 
attempt to divide. In this case the cell is not called a survivor in radiobiological terms, as a 
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surviving cell has to form a colony of at least 50 cells before it is called a survivor. Because 
of this the clonogenic survival assays are important for determining the ultimate response of 
individually irradiated cells.  
 
1.3 Conventional Radiotherapy 
In the early days of radiotherapy, treatment planning was based on a two-dimensional X-ray 
image, and calculations were performed by hand. Uncertainties about the actual tumour 
margin, the tumour volume, and the true radiation dosage delivered to cancerous and 
healthy tissue were common. The big improvements in radiotherapy and also for other 
disciplines came with the fast progress in imaging modalities (computer tomography, MRI, 
and PET). Today’s treatment planning has access to three-dimensional X-ray based images 
of the tumour and applies increasingly complex computer algorithms to formulate a treatment 
plan specifically for the 3D image (3D conformal radiation therapy). Now a radiation 
oncologist can no longer work without high performance computers. 
Historically, radiotherapy is divided into three fields, sealed source radiotherapy 
(brachytherapy), unsealed source radiotherapy (systemic radioisotope therapy), and external 
beam radiotherapy, which is the main field.  
During brachytherapy the radiation source is placed inside or next to the treatable site. It is 
used as an effective treatment for cervical, prostate, breast and skin cancer. The main 
advantage is that irradiation only affects a narrow localized area. High doses of localised 
irradiation can be used while the dose to the surrounding healthy tissue is often low.  
During systemic radioisotope therapy soluble radioactive substrates are given to the patient 
orally or intravenously. These substances have similar properties as their non-radioactive 
physiological forms. In common use is radioactive iodine-131 to treat thyroid cancer. Due to 
its physiological function it will concentrate in the thyroid and produce beta and gamma 
radiation directly at the site of interest. But the patient will excrete radioactive substance over 
a period of time and has to be monitored.  
External beam radiotherapy is the most prominent form of radiotherapy using mainly X-rays. 
State of the art devices today are medical linear accelerators producing high energetic X-
rays. In general electrons are extracted from an electron “gun” usually made of tungsten and 
the electrons become accelerated within a high voltage linear accelerator tube. A limiting 
factor for the beam energy is the voltage of this tube. The high energy electrons become 
abruptly stopped by a metal target usually made of tungsten or other high Z materials. At this 
moment a big part of the kinetic energy of the electrons is converted to X-rays, which can be 
further shaped and selected for target coverage.  
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In conventional external beam radiotherapy (2DXRT) radiation is delivered to the patient from 
several directions: often front or back and from several sides (Fig. 1.4). Radiation fields 
resemble “boxes” which cannot spare critical tissues lying within this box (Fig. 1.4A).  
 
Figure  1.4 Two exemplified treatment plans for conventional radiotherapy (A) and IMRT (B) of a 
nasopharynx tumour (red = GTV; purple = CTV), isodose lines are plotted reaching from red to blue. 
(A) Two opposing beams of uniform intensities (yellow arrows). (B) Schematic view of multiple beams 
with different intensities from any number of angles (here 8 angles) to generate a highly conformal 
dose distribution with relative sparing of the brain, brainstem, and parotid glands (40). 
 
This box shape is due to the depth-dose distribution of X-rays, which deposit most of its 
energy just under the skin and some residual dose to the tissue behind the tumour (Fig. 1.5, 
grey line).  
3D planning allowed for accurate dose calculations to irregular shapes and critical organs, 
e.g. in the head and neck region, but corrections in dose delivery could not be made. 
Therefore intensity-modulated radiation therapy (IMRT) was developed, which allows 
modulation of the intensity of each radiation beam. Each field can have many areas of high 
intensity radiation along with lower intensity areas, thus allowing an adapted dose distribution 
to the irregular shape of the tumour or the critical organs (Fig. 1.4B). With the possibility to 
spare critical organs, IMRT is used now for prostate cancer where the rectum and the bulb of 
the penis can be spared, for head and neck cancer where xerostomia (dry mouth due to loss 
of salivary glands) can be reduced, and for breast cancer where the dose delivered to lung 
and heart can be decreased (40). 
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Figure  1.5 Depth dose distribution in tissue of a 10 MV X-ray beam (grey line), of several single 
proton beams with a pristine Bragg peaks (blue lines), and of a proton spread-out Bragg peak (red line) 
(Wikipedia, proton therapy). 
 
Some concerns exist about the longer overall treatment time per fraction (15 – 30 min) during 
IMRT, which might give tumour cells the time for more efficient repair leading to decreased 
cell killing (41). But in vivo data showed that the lower cell killing was compensated by rapid 
reoxygenation (42). Another approach tries to decrease overall treatment time and the repair 
time in between fractions by hypofractionation schemes (16 fractions over 3 weeks vs. 25-28 
fractions over 5-6 weeks). These are especially used for palliative care of fast growing, 
incurable head and neck tumours and increasingly as accelerated scheme for early-stage 
breast cancer patients (43-45). 
However, more accurately delivered radiotherapy together with more accurate tumour 
volumes bears the danger of underdosing or even missing parts of the area of interest during 
treatment due to minor errors in positioning (46). As a control mechanism, the treatment is 
virtually simulated on the patient before the actual treatment start. Markers on the skin will 
help to position the patient. Some accelerators even have an integrated X-ray imaging 
system making the accurate positioning of critical organs directly on the patient table 
possible. This is called image guided radiotherapy (IGRT). 
Furthermore, some target volumes are naturally moving during treatment, such as the lung 
during breathing. Four-dimensional conformal radiation therapy (4D CRT) measures the 
motion of tumours and includes this in the treatment formula configurations. This ensures 
that the tumour is targeted during motion and as much as possible healthy tissue is spared. 
All these technical improvements can diminish side effects and increase the actual dose to 
the cancerous tissue, which is the ultimate goal of a radiation therapist. Highly trained staff is 
needed, and the consumption of time per patient is rather high, which makes radiotherapy 
expensive. But new technologies have never been cheap. In the next century radiotherapy 
will become increasingly multidisciplinary. Together with new advances in personalized 
medicine and concurrent treatment regimens the patients will further benefit. 
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1.4 Proton Radiotherapy 
1.4.1 History and rationale for proton radiotherapy 
Robert Wilson proposed in 1946 the use of light particles like protons and helium ions in 
cancer therapy, as they result in excellent dose distributions (47). In contrast to photons, 
protons penetrate the tissue only to a certain depth (range) depending on their initial energy. 
Along their path the tissue absorbs a relatively low dose from the protons. At the end of their 
range they stop and deposit most of their energy at the so-called Bragg peak, and no further 
dose reaches the distal tissue (Figure 1.5, blue lines). This makes protons an ideal irradiation 
source to solely cover the tumour volume but little of the normal tissue. Physicians saw the 
superior advantage for treatment of neoplasias of the brain, close to the brain stem, etc., and 
only ten years later the first cancer patients were treated with protons (48).  
Protons are 1836 times heavier than electrons. When they move through tissue they interact 
with orbiting electrons through Coulomb forces. Because of their positive charge they attract 
electrons, resulting in ionization of atoms and formation of loose secondary electrons. Overall 
they lose relatively little energy during each ionization process and are minimally deflected 
due to their large mass. If a proton passes close to a positively charged nucleus of an atom it 
can get slightly deflected (Coulomb interaction with atomic nuclei). However, if the proton 
strikes a nucleus, it can lead to breakage while the proton loses a huge fraction of its energy 
and is significantly deflected (non-elastic collisions). During this process secondary proton 
and neutron irradiation is produced, which has to be kept in mind. In an elastic collision the 
nucleus stays intact but the proton loses as well a big fraction of its energy. The rate of 
energy loss is about proportional to the inverse of the square of the proton’s mean speed. A 
proton with a higher energy can travel farther because it is not interacting very strongly with 
matter. Only at a certain velocity a proton does experience stronger interactions until it is so 
slow that it finally deposits all of its energy due to maximal interactions with electrons at the 
Bragg peak, named after Sir William Henry Bragg (49). 
 
With regard to the next chapters some definitions have to be introduced. The linear energy 
transfer (LET) is a measure of the energy, which is transferred to a material/tissue per µm 
(keV/µm) when ionizing radiation passes through it. For low LET radiation (< 10 keV/µm) 
secondary electron effects are very important. In the case of high LET radiation (> 10 
keV/µm) the relative contribution of secondary electrons to the yield of complex lesions is 
only about 10% compared to direct effects (50). The LET range of protons can be from 0.5 – 
30 keV/um (1000 – 1 MeV protons). 
To measure the impact of the dose deposited in a biological system (cells, tissues, whole 
body) the relative biological effectiveness (RBE) is determined. It is the ratio of the dose of 
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photons (250 keV x-rays) divided by the dose of protons which is needed to result in the 
same biological effect. A RBE > 1 shows that this type of radiation is biologically more 
effective because a lower dose is needed to result in the same biological effect. 
The oxygen enhancement ratio (OER) describes the enhanced radiosensitivity of aerated 
cells in contrast to hypoxic cells (factor 3), which disappears if cells are irradiated with high-
LET radiation (51). Radiation forms radicals, which produce highly toxic peroxides in the 
presence of oxygen. Oxygen is needed to fix the damage when indirectly ionizing radiation is 
used. This is also the case for low LET protons (52, 53). 
As a sole Bragg peak will never cover the usual size of a tumour, a spread out Bragg peak 
(SOBP) is usually formed (Fig. 1.5, blue vs. red line). Several mono-energetic beams of 
different energies are overlaid to result in the SOBP. With the SOBP the realization of the 
dream of unique tumour irradiation is prevented, as the proximal dose to the skin tissue is 
increased compared to conventional photon therapy (Figure 1.5, red line). The broader the 
SOBP, the bigger is the entrance dose at the plateau region (Fig.1.4 very left area of red line 
before it crosses the grey line), and unfortunately this is a major draw back to high energy 
photons, as skin can get injured severely by protons, which enter the tissue. To prevent this 
site effect several beams are used from multiple sides to cover the tumour volume (54). 
 
Before the first patients were irradiated with protons, several studies were performed by 
laboratories in Berkeley and Harvard. After whole-body irradiation experiments with mice the 
end point of LD50 (dose where 50% of the mice died 30 days after exposure) resulted in an 
RBE of 0.8 - 1.0 (55), but when LD50 within 6 days was analyzed an RBE ~ 1.2 was observed 
(56). These data went along with earlier primate experiments and indicated a higher 
sensitivity of gastrointestinal tissues to protons compared to conventional radiation (57). Ten 
years later, after Withers and Elkind developed the mouse jejunal crypt assay, the first 
fractionation experiments with protons displayed an RBE of 1.23 (±0.02), which was 
independent of fraction size (58, 59). In the same period two important studies showed for 
fractionation and single-dose proton exposure an RBE = 1.15 for acute mouse skin reactions 
(58, 60). Before the initiation of clinical trials in Boston, the group determined RBEs for 
various normal murine tissues, which ranged from 1.09 – 1.32 (lens to tail vertebra 
respectively) (61). Even RBE-values for a spontaneous mouse mammary carcinoma were 
determined (62). All of these studies resulted in important in vivo data, which led to the 
implementation of the RBE of 1.1 into the clinic.  
In terms of specific indications for protons, they were proposed early on as a neurosurgical 
tool (63). Experiments with rabbit and goat brains revealed a discrete lesion after 200 Gy 
proton irradiation exposure (64, 65). Damage was restricted to a small area deep in the brain, 
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sparing surrounding brain tissue. Later on pituitary neoplasias of human patients were and 
are still treated using protons. 
The second very specific indication was the treatment of uveal melanomas, a cancer of the 
eye (66). Interest in proton therapy grew due to the successful therapy of these special 
melanomas. But all of those early patients and even patients today were treated in a physics 
institute, which owned an accelerator to produce a pure high energy proton beam to 
accomplish proton therapy. At the hospital of the Loma Linda University the first hospital 
based proton therapy facility was implemented in 1990. Today a hand full of hospital based 
facilities are in operation and several more are under construction. This comes 54 years after 
the first patient was treated with proton therapy, and in this time different technical advances 
have been developed and will be explained in the next chapter. 
 
1.4.2 Equipment and technical advances 
Protons are the positively charged nuclei of hydrogen atoms, which are surrounded by a 
negatively charged shell electron. The source for protons is hydrogen gas. At the Paul 
Scherrer Institute an internal “cold cathode” ion source is used to extract the protons 
(Varian/Accel), but the most frequently used cyclotrons contain an external ion source 
(electron cyclotron resonance (ECR) ion source from IBA), which is a so-called hot-plasma 
ion source. In general electrons are accelerated and ionize the plasma. Special extraction 
geometry of the source helps to extract the positively charged protons, which normally tend 
to follow the electrons to keep the plasma in a neutral charge. After extraction protons need 
to be accelerated to clinically relevant desired energies of 70 - 250 MeV. For this two 
different types of accelerators exist, cyclotrons and synchrotrons. 
A cyclotron uses dipole magnets in order to generate a region of uniform magnetic field, and 
has an electric field. Protons will be injected perpendicular to the magnetic field region and 
travel on a semicircular path. When reaching the gap with a high-frequency alternating 
voltage, they will be accelerated. Now the protons have gained energy, which results in a 
higher velocity. In order to reach the gap in the same time interval again, they travel now on 
a larger radius than before. They become accelerated like this for several rounds until they 
reach the desired energy, which is achieved in milliseconds (ms). 
Synchrotrons are circular accelerator rings with electromagnetic resonant cavities at specific 
intervals around the ring, which accelerate protons while they are circulating. Here the 
particles follow the same radius, and therefore the strength of the magnetic field must be 
increased and synchronized with the proton energy, which increases with each turn. It 
delivers its protons in pulses (seconds). Variation of the proton energy is achieved by 
extracting protons with the desired energy providing a flexible solution with excellent beam 
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qualities. In contrast, cyclotrons have a fixed energy, and if protons of lower energies are 
needed they have to be degraded downstream of the accelerator. This leads to a reduction in 
beam quality, which minimizes the efficiency of the system. However, synchrotrons are much 
bigger (~ 30 m radius vs. ~ 12 m) and more expensive than cyclotrons, though costs for an 
accelerator cover a small portion of the costs of a facility. 
After extraction of the beam it has to be transported to the treatment room using huge 
bending magnets, which steer and focus the beam. For real time assurance of the beam 
quality, ionizing chambers check deviations of the beam position, the total beam current, and 
the beam size, and uniformity. 
In order to cover the whole tumour volume two different delivery systems exist. As the pure 
beam has a diameter of about 1 cm it is not able to cover larger tumour volumes. With the 
passive scattering technique a larger field size can be achieved by scattering of the beam. 
Sometimes a single scattering foil made of lead is sufficient to broaden the beam to the 
desired size. For larger fields the reduction in beam quality is too huge and therefore a 
double-scattering technique is applied (49). A second Gaussian-shaped scatterer, contoured 
with two different materials which help to minimize the energy loss and production of 
secondary radiation, is used. The SOBP is formed with a range modulator consisting of 
absorbers with variable thickness. Furthermore the shape of the specific tumour is mirrored 
by custom milled molds or compensators. Due to all these interfering steps, efficiency with 
the double scattering technique can be down to 10% for typical treatment fields (67). 
With the spot scanning technique a “pencil beam” is magnetically scanned over the target 
volume. This technique requires not necessarily compensators nor collimators, as the target 
is scanned and the beam energy can be varied through selected extraction of proton 
energies from a synchrotron allowing adaptation for each spot. Though, at the Paul Scherrer 
Institute (PSI) in Villigen, Switzerland, the beam of each spot is still degraded by range 
shifters. Physicists at the PSI have pioneered the proton spot scanning technique for a very 
compact gantry. The first veterinary patients were treated in 1994 and in 1996 the first 
human patient could be treated (68). During discrete spot scanning the beam is switched of 
while the magnet settings are changed and the next spot can be applied. Covering of the 
target volume is reached by simply scanning it. The scan follows in x-y direction whereas the 
orthogonal direction is changed by table positioning. If the scan starts at the most distal layer, 
the proximal layers accumulate already a certain dose, and therefore intensity modulation of 
the beam is needed for more proximal layers to reach a uniform target dose. With scanning it 
is possible to construct dose distributions with complex shapes and accurate conformation of 
the dose, which provides additional dose sparing of the healthy tissues compared to 
scattering. Secondly, no scatterers are needed, which reduces nuclear interactions outside 
the patient leading to a smaller neutron ion contamination. Spot scanning gives a high 
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flexibility, which makes it possible to generate intensity modulated proton therapy (IMPT) 
plans, which means that non-uniform dose distributions are delivered from several treatment 
fields. A steeper dose gradient with high dose conformality, a further reduction in integral 
dose, and a lower sensitivity to several uncertainties would be reached (69). Furthermore the 
dimensions of the gantry are reduced by a factor of 3. Difficulties like the complex technical 
set up to generate a very narrow pencil beam are only problematic in the beginning. But spot 
scanning is problematic with regard to organ motion. If one spot is delivered to the wrong 
position it can have quite a huge impact. This problem is solved by rescanning the volume a 
second time, with each scan delivering half of the dose. When IMPT is used, it would be also 
possible to track organ motion (69). 
Another more sophisticated issue is the patient positioning and immobilization, which is 
similar to IMRT. However, the range of the proton beam is also affected by bony structures 
moving in the path of the beam. Therefore the positioning of the target volume and of the 
surrounding structures is important and has to be verified with an X-ray image before every 
treatment session (67). 
Beam scanning was pioneered at Berkeley and the PSI in Switzerland developed the first 
compact spot scanning Gantry. Now the MD Anderson Cancer Centre in Houston and the 
Rinecker Proton Therapy Centre in Munich have commissioned hospital based spot 
scanning gantries. All future facilities or the ones under construction will also implement the 
spot scanning technique, as it seems superior to scattering (statement by MD.Anderson 
staff). The whole construction and implementation costs of such a facility are about 100 
million USD and can reach 150 million (70) 
A development, which possibly would make proton therapy more widely available, is the 
laser-based generation of proton beams (71). So far these lasers can generate 23 MeV 
protons, which were already tested for biological efficiency. Protons are delivered in pulses 
and not continuously and therefore more biological studies are needed to verify the biological 
effectiveness (72, 73). High frequency lasers are still under construction. They could produce 
clinical relevant proton energies but would still need a gantry for guidance of the beam and 
extensive shielding for the scattered and secondary radiation. 
 
1.4.3 Experience in the clinics and the need for randomized trials 
Until 2010 about 67 000 patients were treated with protons worldwide (March 2010 by Martin 
Jermann, PTCOG Secretary). The niche for uveal melanomas and pituitary adenomas 
promoted proton therapy during the last 50 years. Soon other indications, which are 
obviously profiting from the excellent dose distribution were irradiated with protons: paediatric 
intracranial tumours, chordomas and chondrosarcomas. Once hospital-based proton facilities 
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started being built in the 1990s more patients were able to be treated with protons, other 
indications were included like prostate cancer, non-small lung cancer, hepatocellular cancer 
and today also breast cancer. 
Two different types of treatment goals exist. As first, disease sites, which favour higher doses 
for cure (local control), are treated with bigger doses per fraction (dose escalation in the 
tumour volume). This can be either achieved by hypofractionation (fewer fractions with higher 
doses, if the surrounding tissue is not extremely radiosensitive) or by keeping the fraction 
size as in conventional radiotherapy and increasing the dose per fraction slightly. Examples 
are uveal melanoma, skull base, paraspinal tumours (chondrosarcoma and chordoma), and 
unresectable sarcomas (74-76). The second option is to use the increased precision for 
minimizing unwanted side effects. Here the actual dose targeting the tumour is the same as 
in conventional radiotherapy, but the dose to the healthy tissue is reduced. This treatment 
option is very common for paediatric neoplasms (e.g. medulloblastoma with sparing of 
healthy brain tissue) and prostate cancer (to spare the rectum) (77, 78). In both cases the 
therapeutic ratio is thought to be increased.  
On the basis of the biological studies in the 1980s the RBE of 1.1 was implemented into the 
clinics. The photon equivalent dose is 0.9 Gy of protons for 1 Gy of photons which is applied 
everywhere in the treatment volume. In the actual proton therapy the dose to healthy tissue 
is diminished due to the superior dose distribution but the biological effective dose at sites 
irradiated with protons is thought to be equivalent to conventional photon radiation therapy 
due to the RBE factor used. Therefore the effectiveness of protons regarding tumour cell 
killing is equal compared to conventional therapy. With this approach it is only possible to 
reduce adverse side effects. 
Many studies deal with treatment planning and dose painting, which show the superiority of 
protons (Figure 1.6). However, clear evidence from clinical trials is still missing. There was 
increasing demand from the medical society to show that morbidity is really reduced or an 
improved local tumour control is reached with proton radiotherapy. Normally the better 
effectiveness of a new treatment regimen has to be approved by randomized clinical trials. 
But in the field of radiation oncology many improvements were implemented due to its logical 
advantage (e.g. Cobalt machine  Linac  IMRT) (79). Reasons for the few clinical proton 
therapy trials in the past were limited beam energies, as not all centres had access to 
megavoltage beams, limited technology, and limited beam availability. Furthermore ethical 
discrepancies exist. Protons deliver less dose to critical structures and for that reason one 
cannot randomize a child to a treatment that gives higher dose to healthy tissue like with 
photon irradiation. As third point, it is difficult to gather comparable patient populations as 
most of them have encountered gross tumour resection and/or chemotherapy in advance. 
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In 2007 only 4 randomized trials studying proton therapy with 700 patients were available. 
From a combination of trials and case studies, only few have clearly demonstrated a better 
clinical efficacy of protons (79, 80). 
 
 
Figure  1.6 Examplary treatment plans for a tumour of the skull base comparing a proton therapy and 
a IMRT plan. Isodose regions indicate the dose delivered to the tissue ranging from high dose (red) to 
low dose (blue) (copied from procure training center page). 
http://www.procure.com/ProtonTherapy/TumorsTreated/Other.aspx 
 
For example many case studies exist for paediatric intracranial tumours, which are not 
comparable and therefore the evidence level of clinical efficacy is low. Whereas in the case 
of prostate cancer, at least for some studies a reduction in long term rectal and genito-urinary 
damage could be detected. Others revealed a small difference. The advantage of precise 
dose delivery by protons may be reduced in those studies due to errors in patient set-up and 
internal organ movement during treatment. Especially errors in patient set-up destroy the 
better therapeutic ratio gained with the increased precision. The errors are in the 2 – 5 mm 
range but can affect drastically the outcome. (79, 81). For two other indications, ocular 
tumours and chordomas of skull base, protons resulted in a superior efficacy (80). 
With more custom built proton facilities, consisting of several treatment rooms, many more 
patients will be treated. Collaboration of these therapy centres world wide will increase the 
number of good quality randomized clinical trials. This has to be done within an acceptable 
time frame so that decisions can be made before more centres are constructed. On the other 
hand reduction of late side effects and secondary malignancies would only be possible to 
validate within a ~ 10 - 20 year patient follow-up study. It is problematic to prove that saving 
more healthy tissue during treatment is beneficial for the patient. Only in the case of 
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paediatric patients it becomes evident as their still dividing tissues (even brain) can 
propagate mutations and lead to secondary cancers at later time points.  
Studies on dose escalation and not only on the reduction of side effects would validate the 
second type of treatment goals for proton therapy. If the dose constraints to organs at risk 
could be kept the same, a study like this might be possible. 
Finally the advantage of protons might be just too small to be detectable by tumour control or 
normal tissue complication analysis for certain tumour sites. 
 
1.4.4 Molecular stress responses after proton beam exposure 
Money should be as well invested in basic research due to uncertainties about the RBE. 
According to the tissue, cell line, end point, or physical beam characteristics investigated, it 
can vary heavily. Furthermore the applicability of chemotherapy regimens together with 
proton therapy has not been validated yet. 
All studies determining the RBE were summarized in 2002 by Paganetti (82), showing little 
variation in vivo (mean RBE 1.1) and rather huge variation in vitro (mean RBE 1.2) (Fig. 1.7).  
 
Figure  1.7 Experimental proton RBE values (relative to 60Co) over dose/fraction for (A) cell 
inactivation in vitro and (B) measured in vivo in the centre of a SOBP. In (A) closed symbols show 
data points for Chinese Hamster cell inactivation and open symbols stand for other cell lines. In (B) 
closed symbols show RBE values for jejunal crypt cells and open symbols stand for RBEs of all other 
tissues. Circles represent RBEs for < 100 MeV beams and triangles for > 100 MeV beams (by 
Paganetti (82)). 
 
The huge variation of the RBE of in vitro studies might be due to the different genetic 
background of the cells. Immortalized cell lines rather resemble cancer cells with their 
various mutations, and it would be interesting to see if and how these mutations affect the 
RBE of protons. On the other hand, in vivo healthy tissues without mutations, which were 
used in the mouse studies, responded in a similar range indicating the response of healthy 
tissue with less genetic variations. Furthermore huge variations can also be generated due to 
the use of protons with different energies. Many studies have been performed with energies 
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below 30 MeV (range of below 1 cm; LET=20 keV/um) showing significantly larger and 
different biological effects than high energy protons. For example low energy protons induce 
significantly more apoptosis (83-85). Biological data regarding low-energy protons (below 70 
MeV) will not be discussed further, as the work in this dissertation is dealing with treatment 
relevant high-energy protons. Clearly a SOBP consists of a mixture of Bragg peaks and 
some percent of the damage is produced in the high-LET region (> 100 keV/µm) but is 
estimated to be ~ 2% (86). 
Despite the assumption of many physicists and others that the cellular responses induced by 
protons and photons are rather equal some molecular studies of the recent years showed 
differences between low-LET proton and photon irradiation. Almost all of these studies were 
performed at the Loma Linda proton beam facility. With 250 MeV protons a more immediate 
apoptosis induction was reported for irradiated thyroid follicular cells, which must have 
encountered more severe damage (86). Treatment of 2 different pancreatic tumour cell lines 
with 10 Gy protons caused a significant number of cells to become polyploid which indicates 
severe problems of these cells during cell division (87). Unfortunately this finding was not 
compared to photons. Two studies reported a faster ROS production in neural precursor cells 
and a more effective peroxidation of low-density lipoproteins by protons in vitro, though 
irradiation was conducted with Bragg peak protons or very high doses (88, 89). Irradiation of 
mouse brains with 2 Gy and expression analysis revealed altered expression patterns of 
oxidative stress and antioxidant-associated genes. IL-19, MPP4 and Epx were up-regulated 
and Mb was down-regulated after exposure. Yet this was not compared to photons, which 
also induce severe oxidative stress (90). A Japanese group revealed that particle irradiation 
(carbons and protons) suppresses the metastatic potential of HT1080 cells in contrast to 
photons which promote cell migration and invasive capabilities already at low dose levels. 
This finding provides the rationale that proton irradiation might be superior due to a lack of 
radiation induced tumour cell migration and metastasis formation (91). 
Beside molecular studies, which address therapy related and basic research questions, 
space research is also interested in the effects of proton exposure. In space the most 
prominent particles are protons (92). Bandstra analyzed the effect on trabecular bone volume 
fraction and mineral density after long-term incubation (4 months) of mice following an acute 
2 Gy whole body proton irradiation. With 0.5 Gy no difference could be detected versus the 
control whereas with 1 Gy a reduction in those parameters was visible which became 
significant with 2 Gy. However acute whole body irradiation in space with 2 Gy of 
monoenergetic protons is not realistic. But with regard to clinical doses to bone structures 
this study indicates that bone-forming and bone-resorbing cells might respond differently to 
proton irradiation, which is important with respect to paediatric patients. 
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These few studies point to a differential molecular response of cells after proton irradiation 
compared to photons. Even if treatment plans account for an RBE of 1.1, it is not known if 
the response of each single tumour on the molecular level is the same. Different unknown 
parameters could influence the RBE. Therefore it is also risky to combine proton 
radiotherapy with chemotherapeutics. 
So far we leaped the topic of DNA damage induction and repair after proton irradiation, which 
will be introduced and discussed at the end of the last chapter. 
 
1.5 The DNA damage response 
Cells have to suffer from DNA damage every second due to metabolic stresses, naturally 
occurring radiation like UV-light, or just because of collapsed replication forks. Several 
treatment approaches for cancer intend to induce DNA damage like chemotherapeutics or 
ionizing radiation. To deal with these toxic lesions cells have evolved mechanisms to detect 
them (sensors), signal their presence (transducers) and promote their repair (effectors), 
which is called the DNA damage response (DDR) (93, 94). This multifaceted response 
includes activation of cell cycle checkpoints and transcriptional induction and 
posttranslational modifications of various proteins involved in DNA repair, apoptosis, etc. (94). 
Activation of this program enhances the ability of the cell to repair and survive the 
encountered DNA damage. However, if residual damage is left, a chronic DDR activation 
triggers cell death by apoptosis or cellular senescence (95). Out of this complex response 
the sensing of DNA damage, checkpoint activation and DNA repair mechanisms will be 
presented.  
 
1.5.1 Sensing of the DNA double strand breaks 
It is well established that the following three kinases PI3 like kinases: ataxia telangiectasia 
mutated (ATM), ATM and Rad3-related (ATR), and catalytic subunit of DNA-dependent 
protein kinase (DNA-PKcs), are the conductors of the DSB damage/checkpoint orchestra 
with ATM as the main player (96). The kinases phosphorylate H2AX, a histone variant that 
makes up about 10 – 15 per cent of total cellular histone H2A, at sites of DSBs (97). All three 
of these proteins are not able to detect the DSB by themselves. Recruitment of ATM to the 
break requires the MRN protein complex. It contains three proteins, Mre11, Rad50 and NBS1 
where Rad50 binds directly to DNA breaks and the adaptor protein NBS1 recruits ATM to the 
break. MRN assembles at DSB sites faster than any other protein and does not depend on 
any other protein to induce repair foci formation (98). When ATM reaches the DSB it 
undergoes autophosphorylation (S1981) and changes from an inactive dimer to an active 
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monomer (99) leading to H2AX phosphorylation of relatively large chromatin regions 
(megabases) and to alterations in the chromatin structure. Mre11 is involved at a later step 
when its exonuclease activity digests the ends of the break, which may not be compatible for 
repair. DNA-PKcs can also phosphorylate H2AX, but only ATM promotes γH2AX formation to 
maximal distance and maintains γH2AX densities at DSBs (100). However, DNA-PKcs 
seems to be more important than generally assumed because its absence results in the 
down-regulation of ATM (101). Ku70-Ku80 complex senses DSBs, binds directly to them, 
and recruits DNA-PKcs (both together are called the DNA-PK complex). The third protein 
complex capable of phosphorylating H2AX is ATR-ATRIP. ATRIP (ATR interacting protein) 
recruits ATR to damage sites. However, ATR is not important for the initial response to DSBs 
produced by IR, instead it phosphorylates H2AX at single-stranded DNA and at stalled or 
broken replication forks. Therefore, when DSBs become processed for homologous 
recombination, the ssDNA stretches will activate ATR (96). This activation down-stream of 
ATM is needed to fully activate all components of the DDR effector pathways as ATM and 
ATR phosphorylate not only H2AX but a distinct set of proteins that participate in the DDR 
(102). An important function is the activation of cell-cycle checkpoints. The pause of cells in 
G1, S and G2 phase of the cell cycle provides more time to repair DNA damages. All 
movements through the cell cycle are driven by cyclin-dependent kinases (CDKs). CDK 
activity is affected by the binding of its specific cyclins, which are differentially expressed 
during the cell cycle, by its phosphorylation status, and through special CDK inhibitors 
(CDKIs). In the following the three most important checkpoints induced after irradiation will 
be described. 
 
1.5.2 G1 checkpoint 
Depending on the stage of the cell cycle where the DNA damage arose, different signalling 
pathways are triggered. When exposed to IR, most of the untransformed eukaryotic cells 
arrest at the G1 checkpoint, as this is the phase containing the highest percentage of cells. 
The aim is to avoid transition of the cell with damaged DNA into S phase to prevent 
replication of damaged templates, which would consequently lead to the creation of more 
DSB in the sister chromatids. In general the transition from G1 to S phase is a critical point 
as it is the ultimate decision of the cell to divide a further round. Once the chromosomes 
have been duplicated the cell has to divide at one point. The block is achieved by two 
different mechanisms activated at the same time while the first mechanism is implemented 
faster than the second one.  
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For the fast stop, the cell division control protein 25A (Cdc25A), a phosphatase leading 
normally to the activation of CDK2, is phosphorylated through ATM dependent activation of 
Chk2 and primed for proteasomal degradation. Therefore CDK2 cannot be activated. 
Secondly, modulation of the inhibitory p53 interaction with Mdm2 results in a fast activation of 
p53 followed by a longer time period until its target genes are transcribed. Hereby Chk2 
phosphorylates p53, which leads to its stabilization and dissociation from Mdm2. On the 
other site, ATM phosphorylates Mdm2 and p53, preventing the nuclear export of p53. 
Accumulation of p53 in the nucleus is followed by the transcription of its target genes. One of 
these is the CDK inhibitor p21.  
The combination of these two levels of regulation results in a fast and long-standing cell 
cycle arrest (96). However, many tumour cells lack p53 and often a proper G1 checkpoint, 
which results in a different response towards radiation induced damage (103, 104). 
 
1.5.3 Intra-S phase checkpoint 
In the S phase three checkpoints exist, the replication checkpoint is initiated when the 
progression of replication forks becomes stalled, the S-M checkpoint makes sure that the 
entire genome is duplicated before progression to mitosis continues, and the third one is 
initiated in response to DSBs that are generated outside the active replication loci – called 
intra-S phase checkpoint (105). Normal cells, which were irradiated react with a fast but 
reversible decrease in DNA synthesis by reducing the rate of origin firing and strand 
elongation. However, there are cell mutations leading to the lack of this checkpoint and to so-
called radioresistant DNA synthesis (RDS). Target is again the CDK2 kinase, which is 
dephosphorylated by Cdc25A and Cdc25C. When Chk1 and Chk2 become activated by ATM 
and ATR they phosphorylate Cdc25A/C leading to their inactivation. An increase in 
phosphorylated CDK2 slows the progression through S phase. In this phase single stranded 
DNA can be abundant and therefore ATR is also involved in the early response. But also 
another pathway including BRCA1 and NBS1 exists as NBS1 can restore Chk2 deficiency. 
Phosphorylation of NBS1 by ATM is required for the phosphorylation of structural 
maintenance of chromosome 1 (SMC1), which is necessary for sister chromatid cohesion 
(SCC). SCC is essential for proper repair, as the homologous chromatids stay close together 
and facilitate the search for homology. This ATM-NBS1-SMC1 pathway is a separate one to 
the ATM/ATR-Chk2/Chk1-Cdc25A/C-axis.  
A slowing down of the replication fork progression and elongation minimizes the chances of 
encountering a damage site before it is repaired. However, all cells from G1 and S phase 
have still the possibility to be arrested in G2 (96). 
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1.5.4 G2/M checkpoint 
There are two additional checkpoints in G2. The early checkpoint meets cells that are 
irradiated while in G2 involving also ATM-Chk2-Cdc25A/C. It is blocking the cell cycle 
progression at the end of G2 by inhibiting the mitotic cyclinB-CDK1 complex. 
Dephosphorylation of CDK1 is prevented by degradation of Cdc25A and C. The pathway 
blocks the movement of the cells into mitosis with a fast but short drop in the mitotic cell 
number (4, 96). A counteracting kinase is Akt whose activation suppresses DNA damage 
processing and checkpoint activation of cells that stayed in late G2 at the time point of 
irradiation exposure. Cells form γH2AX foci but fail to recruit repair factors, which can be 
reversed if Akt is inhibited (106). Akt is often over-activated in tumours and can lead to this 
behaviour. In that case tumour cells accumulate chromosome aberrations. This has often 
been seen in advanced cancers (107). 
The later checkpoint leads to a long G2 delay including cells that have been previously 
irradiated while in G1 or S phase. After their transient blocks with attempts of repair, cells 
progress to G2 phase where they reach hours later and may experience a second delay. 
This stop can last many hours depending on the applied dose. Importantly, this late G2 
checkpoint is independent of ATM and relies on many other regulatory branches. Until that 
point DNA damages have already been processed and are able to activate ATR/ATRIP. ATR 
activates Chk1, which in turn leads to the degradation of Cdc25A/Cdc25C. Further regulators 
have been described. BRCA1 has been reported to activate Chk1 and contribute to the G2 
arrest. Polo-like kinases target Cdc25C independent of ATM and ATR. Plk3 negatively 
regulates the phosphatase whereas Plk1 is an activator. This checkpoint is also regulated on 
the level of cyclin B, which is sequestered in the cytoplasm. Also a decline in the mRNA 
levels of cyclin B has been reported. For a prolonged arrest, p53 dependent activation of p21, 
GADD45, and 14-3-3 proteins was shown. But the arrest can also occur in p53-mutated cells.   
These multiple mechanisms make sure that a cell which still harbours DNA damage is 
arrested. A long duration of this arrest implies problems of the cell to repair all DNA damages. 
Pausing too long in G2 may lead to the activation of cell death or senescence pathways.  
If cells have been irradiated in mitosis the spindle assembly checkpoint (SAC) is triggered 
and leads to a delayed progression of mitosis. This is the only time point, which is not 
controlled by ATM/ATR pathways. Cells in the M phase are generally the most radiosensitive 
ones (96, 108). 
 
1.6 DNA damage repair mechanisms 
Depending on the phase of the cell cycle and the nature of the induced DNA damage, 
different DNA-repair mechanisms are activated. Non-homologous end joining (NHEJ), single 
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strand break repair (SSBR), base excision repair (BER) and nucleotide excision repair (NER) 
are active throughout the cell cycle. Whereas homologous recombination (HR) is only able to 
work when the sister chromatid DNA strands are available, which is the case in late S and 
G2 phase. If the damage persists after several attempts of repair, it can be transferred to the 
next cell cycle phase where another pathway might be successful. However, not all DNA 
damages are of a certain category. Damages can be very close thus forming a clustered 
DNA damage site. At such sites it is difficult for certain proteins to recognize the damage or 
to dock for repair. Even the repair of simple base damages might take hours when situated in 
such a damage cluster. If those were generated in S phase the probability increases that a 
replication fork runs into the damage and generates a double strand break. Or single strand 
breaks can have base damages in their near vicinity. During base excision repair single 
strand breaks are temporarily formed. If this nick is opposite of the original SSB a DSB is 
formed. Especially these clustered damages and the DNA double strand breaks lead to the 
severity of ionizing radiation induced cell toxicity. All of those aspects and the exact repair 
mechanisms will be explained in the following chapters. 
  
1.6.1 DNA single strand break and base/nucleotide excision repair 
A DNA double strand break is the most severe damage when not repaired because it causes 
loss of complete chromosomal regions. However, after radiation exposure DNA single strand 
breaks and base damages are up to 50 times more frequent than DSBs. Proteins of the base 
excision repair pathway repair these numerous lesions efficiently (109).  
Due to metabolic stresses or UV-light exposure proteins of the single strand break repair 
(SSBR) and base excision repair (BER) pathways encounter such lesions every day and 
help to maintain genome integrity. But a single strand break generated by IR is often a “dirty” 
break, which blocks the access for polymerases (pol). End-processing is achieved by AP 
endonucleases, and polynucleotide kinase-phosphatase (PNKP), or tyrosyl DNA 
phosphodiesterase (Tdp1) (110). For proper resynthesis and end ligation a 3’ hydroxyl end 
and a phosphate 5’ end is needed and these enzymes prepare the ends. When the nick is 
clean, poly(ADP-ribosyl)ation by poly (ADP-ribose) polymerase (PARP) is thought to aid the 
sequestration of other DNA repair proteins, like XRCC1 and ligase III. As the following steps 
of SSBR use the same proteins like BER it is often mentioned as a part of it. 
In the case of base damages, almost every special type is detected and removed by 
specialized proteins called glycosylases. There are several of such enzymes, which are 
specific for a particular class of base damage. Mainly they hydrolyze the N-glycosidic bonds 
to generate abasic sites (APs). A specialized enzyme called 5’ AP endonuclease 1 (APE1) 
cuts the DNA backbone leaving a 3’ hydroxyl adjacent to a 5’ deoxyribosephosphate (dRP), 
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which generates a SSB. Other DNA glycosylases/AP lyases such as endonuclease III (NTH1) 
and 8-oxoguanine DNA glycosylase (OGG1) conduct both steps, base excision and DNA 
cleavage. However, APE1 still has to generate a 3’ OH and PNKP can add a phosphate to 
the free 5’ end if it is missing. 
From now on repair is equal between SSBR and BER. A decision between short patch (SP) 
and long patch (LP) repair has to be made. Short patch repair replaces only the damaged 
base, which is carried out by DNA polymerase β (pol β). The genetic information is copied 
from the existing non-damaged strand, which can be also carried out by polymerase λ (111). 
These enzymes have also a lyase domain that removes the 5’ dRP left behind by APE1. 
Finally, ligase III along with its cofactor XRCC1 connects the ends. 
For long patch repair 2 - 10 nucleotides are cut out and replaced. Here DNA synthesis 
occurs by DNA polymerases δ and ε together with the processivity factor PCNA, which are 
the normal replication polymerases. However, also polymerase β can perform long patch 
repair (112). The polymerases perform a displacing synthesis leaving a free 2-10 nucelotides 
long 5’ DNA end. These 5´ flaps are removed by FEN1, the flap endonuclease. Finally the 
two DNA ends are connected by ligase I. 
Which of the two pathways is chosen can be influenced by various factors like type of the 
lesion, cell cycle stage, and whether the cell is terminally differentiated or actively dividing. 
However, it is not at all known for all lesion types and many studies were solely performed in 
vitro (113). Furthermore the relative concentration of each repair factor is expected to impact 
sub-pathway selection and efficiency. In vivo studies showed a more relevant contribution of 
the PCNA-dependent LP-repair for oxidative DNA damage and SSBs. Parp-1 and XRCC1 
play an important role. XRCC1 accumulation at the irradiation-induced SSBs is promoted by 
PAR formation. Only then PCNA and other factors could be efficiently recruited (113, 114).  
XRCC1 has a crucial role in coordinating BER and SSBR. It shows no catalytic activity but is 
a scaffold protein stabilising and modifying the activity of other proteins. Interaction partners 
are DNA ligase IIIα, APE1, Pol β, PNK, PCNA, and PARP1 and 2 (115, 116). When XRCC1 
levels of normal prostate tissue cultures were compared to malignant ones, increased levels 
were accompanied by higher polymerase β and δ levels (117). Rare XRCC1 variants were 
found in radiotherapy treated cancer patients, which showed acute normal tissue 
cytotoxicities (118, 119).  
In summary, BER and SSBR are two important pathways to repair radiation induced breaks 
and base damages. However, if they are deregulated or mutated they are involved in cancer 
development and adverse therapy responses. 
 
A third repair pathway nucleotide excision repair (NER) has to be mentioned. It deals with 
distorting base damages for example induced by UV-light (T-T dimmers). It is divided into 
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global genome repair (GGR), which removes damages in non transcribed regions and 
transcription coupled repair (TCR), which deals with damages induced in transcriptionally 
active regions of the genome. They differ with regard to the damage recognition step. XPA 
and RPA serve for further damage detection and dictate the helicases XPB and XPD 
(ERCC2 homolog in hamster cells) to the lesion. A 30 base pair oligonucleotide is removed 
and resynthesized by polymerase β together with other factors. Ligation is carried out by 
DNA ligase I (120). But NER is in general involved in the repair of UV-light induced DNA 
damage and not in the repair of ionizing radiation induced damages (121). However, 
irradiation of hypoxic cells causes distorting crosslinks where a purine is attached by two 
covalent bonds to the sugar-phosphate backbone. Those lesions can be exclusively removed 
by NER (122). 
 
1.6.2 DNA double strand break repair 
DNA double strand breaks (DSBs) are generated by different means, maybe accidentally, or 
during DNA replication if the fork meets a DNA break, or indirectly by camptothecin and other 
drugs, or through direct exposure to ionizing radiation. Already one unrepaired DSB can lead 
to cell death. However, after exposure to 1 Gy of IR ~ 20 DSBs are generated. Those can be 
located in heterochromatic or euchromatic regions of the genome, they can be complex or 
simple, and they occur in different phases of the cell cycle leading to differential responses. 
After DNA damage response proteins have marked the breaks and maybe led to chromatin 
relaxation, the two main repair pathways, homologous recombination and non-homologous 
end joining try to fix the damage. Both pathways are completely different from each other 
regarding the set of proteins/enzymes they use, the speed, the accuracy, and activity pattern 
during the cell cycle. Furthermore backup pathways exist, which can jump in if a main 
pathway is lacking. However, they are not as efficient. If cells lack NHEJ or HR they become 
radiosensitive demonstrating their importance (123). 
 
1.6.2.1 Homologous recombination 
When cells progress through S phase replication produces a second copy of the genome in 
form of a sister chromatid. It provides a template for accurate repair by homologous 
recombination (HR). As explained earlier the MRN complex and ATM mark the DNA breaks 
(Fig. 1.8). MRN is also thought to tether the broken DNA ends together. Furthermore the 
cohesion proteins SMC5/6 might be important in keeping the homologous sister chromatids 
in proximity (124). Now, the first and most critical step during homologous recombination is 
the nucleolytic degradation of the 5’-ended DNA strand in order to have a single strand, 
which searches for homology in the sister chromatid (125). Although the processes leading 
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to resection have not been understood completely, important known players are Mre11 and 
CtIP. Mre11 exhibits only a 3’-5’ exonuclease activity, which is the wrong polarity and also 
CtIP does not perform the 5’-ended strand resection. But both exonucleases are important 
for efficient end resection, because they are required at DSBs with modified ends (Pardo, 
2009). After initiation by Mre11 and/or CtIP the processive single-strand exonuclease Exo1 
carries out extensive 5’-3’ resection (125, 126). During the 3’- single stranded DNA is formed 
it is immediately stabilized and protected by binding of the single strand binding protein 
replication protein A (RPA). As next Rad51 proteins have to be loaded onto the single strand. 
Since RPA binds more avidly to ssDNA than Rad51, additional help is needed for efficient 
loading of Rad51 onto RPA-coated ssDNA to form the presynaptic Rad51 filaments. In  
 
 
Figure  1.8 Model of homologous recombination (HR) repair. After DSB recognition by ATM and the 
MRN complex the DNA ends get resected in 5’  3’ direction. Here Mre11 and CtIP most probably 
have an end cleaning role and Exo1 does the long resection step. RPA binds immediately to the 
ssDNA and becomes replaced by Rad51 with the help of BRCA2 and other Rad51 paralogs. In turn 
Rad52 and Rad54 are attracted. The BLM and WRN helicases interact with Holliday junctions and 
assist also the loading of other proteins. After sister chromatid pairing two possible ways for finishing 
HR exist: (1) Non-crossing-over where after a first synthesis step the strands become disengaged and 
finish then the gap filling reaction, or (2) Crossing-over resulting from complete gap filling while the 
chromatids are still engaged and final resolution of the Holliday junction. Some DNA polymerases are 
described but their exact involvement has not been understood, yet. Ligation occurs with the help of 
ligase I (130). 
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mammalian cells the crucial mediator is BRCA2 and potentially Rad52. BRCA2 can directly 
interact with several Rad51 molecules and bring them to ssDNA (Fig. 1.8) (127). Formation 
of the Rad51 nucleoprotein filament initiates the search for homology in the sister chromatid. 
The search for homology is random by testing segments of the dsDNA in an iterative fashion 
until homology is found (128). Now the chromatin remodeler Rad54 stimulates strand 
invasion in an ATP dependent manner (125, 129). Further helpers during homology search 
and strand invasion include Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3. Pairing of the 
two strands occurs with the help of Rad52. From this stage several HR pathways can 
complete the repair. In synthesis dependent strand annealing (SDSA) the information is 
copied from the intact strand and afterwards the newly synthesized strand reverts to its 
original position. Having replaced the missing information repair can be completed. 
Alternatively the two sister chromatids can exchange strands and built a so-called Holliday 
junction. Here the sequence is copied during branch migration. This step might involve the 
Rad51 paralogs Rad51B, Rad51C and Rad51D. Due to gross sterical forces the helicases 
BLM, WRN and the topoisomerase TopIIIa are also localized at the junction helping to 
untangle the DNA (Fig. 1.8).  
For resolution of the Holliday junction a nuclease is needed, which is most likely the Slx1-
Slx4 nuclease complex. Further proteins involved in the resolving step are Rad51C and 
XRCC3. Now two possibilities to cut the strands generate either a chromatid exchange or not 
(Fig. 1.8). In each case the genetic information is accurately restored. The exact identity and 
involvement of the DNA polymerases is still uncertain but in vitro studies revealed 
polymerases δ, ε and η to promote repair synthesis (131, 132). Finally, gaps are sealed with 
the help of ligase I. As many specific steps have to be completed in an ordered fashion, 
homology directed repair can take up to 6 hours or more but is very accurate.  
In the case of a double strand break lying in between two repeated sequences oriented in the 
same direction another repair process called single strand annealing (SSA) can occur 
(131). In this case the two 3’ overhangs are simply aligned and annealed within the region of 
the repeated sequences. Overhanging single stranded DNA will be digested, and gaps will 
be filled plus sealed. This process is Rad51-independent but involves common HR proteins 
including RPA, Rad52 and Rad50. Mismatch repair proteins deal with the 3’ tails. Evidently 
sequences lying between the repetitive repeats are often lost, which can lead to large 
genomic deletions. SSA does play a role in DSB repair. However, the repeats in the human 
genome exhibit high sequence diversity and mismatches suppress SSA drastically. In normal 
cells it might play a fairly limited role for DSB repair but in Rad51 disrupted cells SSA is 
increased appearing to be a backup mechanism (131, 133). 
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Compared to oxic conditions, irradiation under hypoxia produces a greater number of DNA 
crosslinks, which are lethal for a cell (134). In this case a third repair mechanism becomes 
important, interstrand cross link (ICL) repair. ICL in mammals uses different sets of 
proteins from other repair pathways including ERCC1 and XPF from NER, Rad51 and Rad52 
from HRR, and proteins of the FANC group, which play a critical role for ICL repair. In 
eukaryotes the primary mode creates a DSB as intermediates, which is preferentially 
repaired via HR with the help of a complex orchestra of FANC proteins (135). 
 
1.6.2.1.1 The DNA repair protein Rad51 
The mammalian Rad51 protein is structurally, biochemically, and genetically identical to the 
bacterial RecA and the yeast Rad51 recombination proteins. Rad51 plays a pivotal role in the 
process of gene conversion and its regulation (136). Its inactivation results in embryonic 
lethality of mice and chicken DT40 lymphoma B-cells (137, 138). The maintenance of genetic 
stability relies mainly on the high fidelity HR repair. Cells harbouring mutations in Rad51 or 
other HR genes (e.g. BRCA1, BRCA2, Rad54, XRCC3) exhibit high levels of genetic 
instability (139). On the other site HR contributes to genetic instability if the pathway is over-
activated in a non-physiological way. Inappropriate recombination reactions, like between 
repeat sequences or mutant alleles, result in deletions, translocations, duplications, or loss of 
heterozygocity (LOH) (140, 141). In ATM-defective cells Rad51 foci formation is markedly 
increased, which is in agreement with the high levels of HR between direct repeat sequences 
in ATM-/- cells (142, 143). Up-regulation of spontaneous HR has been also described in p53-
defective cells (144-147). Alterations of the p53 protein stimulate HR repair of γ-ray-induced 
damages independently of its role in the G1/S checkpoint (148). Over-activated HR may lead 
to chemo- and radiotherapy resistance (136, 149). For this reason HR repair has to be tightly 
regulated in order to prevent inaccurate repair leading to genetic instability and tumour 
formation. For this purpose the expression level and activity of the essential HR protein 
Rad51 is regulated carefully. Binding of p53 to the Rad51 promoter leads to a suppression of 
Rad51 mRNA transcription and to reduced Rad51 protein levels (144, 150). Additionally, p53 
can impair nuclear Rad51 foci formation at generated DSBs through direct interaction (151, 
152). Mutations of p53 influence the protein-protein interaction with Rad51 and abolish its 
regulatory functions (147). Beside the regulation by tumour suppressors Rad51 is also up-
regulated by oncogenes like the Bcr/Abl fusion kinase (153). Furthermore Rad51 expression 
is regulated during the course of the cell cycle where it is induced in S phase, rising until G2 
and decreasing in G0/G1 cells (154, 155). HR events in G1 might lead to gross chromosomal 
aberrations and are therefore prevented.  
In summary, a basal level of Rad51 activity seems to be essential for the processing of 
spontaneous and S phase generated DNA lesions. If expression control is lost the fine 
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balance between different components of the DNA repair systems gets destroyed. Many 
tumour tissues reveal a significant increase of Rad51 mRNA contents (e.g. breast, uterus, 
small intestine, lung, stomach) when compared to normal tissue (156). Since high Rad51 
protein levels are restricted to tumour cells, Rad51 is used as a tumour specific antigen (157). 
Further it is an independent predictor for tumour recurrence as well as tumour progression, 
which makes Rad51 expression a clinical relevant prognostic marker (158). Down-regulation 
of Rad51 by anti-sense techniques sensitizes cells to DNA-damaging agents and 
radiotherapy, making it a target for future therapy approaches (159, 160). 
 
 
1.6.2.1.2 The DNA repair protein XRCC3 
XRCC3 and some other genes were identified by their ability to complement mutated rodent 
cell lines for their hypersensitivity to ionizing radiation meaning “X-ray repair cross-
complementing” (161, 162). XRCC3 is one of the Rad51 paralogs, which evolved through 
gene duplication of Rad51 and further diversification. Therefore and because of the mutant’s 
hypersensitivity to DNA cross-linking drugs it was believed to take part in HR repair. Soon it 
was reported that XRCC3-complementation in Irs1sf cells (XRCC3-/-) could highly elevate 
the frequencies of HR repair in this cell line (163). Furthermore XRCC3 influences Rad51 
focus formation without affecting Rad51 protein level. Therefore it is required for the 
assembly or stabilization of the Rad51 filament (164). Unresolved DNA damage in XRCC3 
mutants leads to centrosome fragmentation and increased chromosome mis-segregation, 
which points to a potential role as a tumour-suppressor gene (165). Rad51c, another Rad51 
paralog, forms a complex together with XRCC3 (166). This complex functions as resolvase 
at Holliday junctions and modulates together with Rad51 the progression of the replication 
forks at DNA damages (167, 168). Stabilisation of XRCC3 seems to be dependent on the 
interaction with Rad51c. Depletion of Rad51c results in a sharp reduction of the XRCC3 
protein level. Mutating the ATPase domain in XRCC3 also leads to a destabilisation of the 
complex. Dissociation and formation of Rad51C-XRCC3 complexes seem to underlie a fine 
balance and to depend on ATP binding plus hydrolysis by XRCC3 (169, 170). Beside its 
resolving function XRCC3 may prevent long-tract gene conversions by facilitating an earlier 
termination of gene conversion (171, 172). However, XRCC3 has also been described to be 
involved in earlier steps of HR. XRCC3 can form distinct foci at the sites of DNA damage 
within 10 minutes after exposure to radiation independently of Rad51, which might facilitate 
formation of Rad51 nucleofilaments. Association of XRCC3 with RPA indicates also an early 
association at the breaks (173, 174).  
During the whole process of HR XRCC3 is an important protein influencing initiation of the 
Rad51 nucleofilament and the proper processing of HR intermediates. Deficient cells have 
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elevated levels of chromosome aberrations and the variability of the HR genes XRCC3 and 
Rad51D may play a role in breast cancer risk (175). 
 
 
1.6.2.1.3 The breast cancer susceptibility protein BRCA2 
Inheritance of one defective copy of the breast cancer susceptibility gene, BRCA2, 
predisposes those individuals to breast and ovarian cancer. This applies to about 10-30% of 
genetically predisposed individuals. BRCA2 mutations show a high penetrance, with a 50% 
risk of developing cancer before the age of 50 and 80% risk before the age of 70 (176). The 
BRCA2 protein is a large protein with a molecular weight of approximately 385 kDa (127). In 
1995 the gene was cloned and it was characterized by a very large exon 11, which encodes 
essential peptide motifs for the interaction with Rad51 (177, 178). Rad51 and BRCA2 were 
shown to co-localize in nuclear foci in somatic cells after treatment with IR (179). In BRCA2-
deficient cells the formation of Rad51 foci was impaired leading to the suggestion that 
BRCA2 is required for the recruitment of Rad51 to sites of DSBs (180). Accumulation of 
spontaneous chromosomal aberrations during cell division in cell culture implicate that 
BRCA2 is involved in the maintenance of genome stability (181). Disruption of the interaction 
between BRCA2 and Rad51 leads to radiation and chemosensitivity and a reported defect in 
the G2/M transition (127, 177). In BRCA2-deficient Chinese hamster cells a defective S 
phase checkpoint was described (182). Over the years BRCA2 was acknowledged to be an 
important facilitator for HR, which plays a direct role. The protein was not found to be 
involved in NHEJ as deficient cells display normal levels of end joining (183). Further support 
for the important role in HR is the ease how BRCA2 and Rad51 can be co-
immunoprecipitated from cell-free extracts (184). The generally conserved BRC motifs in the 
BRCA2 gene are likely to interact with a unique motif or region in Rad51, which appears to 
be the Rad51 core domain together with BRC3 and BRC4 (176, 184). Several in vivo studies 
revealed the biological function of the various domains of BRCA2. Capan-1 cells have only 
one remaining BRCA2 allele, which is solely coding for the first six BRC motifs without the 
ssDNA-binding domain. This indicates that BRCA2 needs to bind as well ssDNA to fulfill its 
helper function. BRCA2 loaded with Rad51 binds to ssDNA and by displacing RPA it helps to 
form the Rad51 filament (127, 180). Before Rad51 proteins can form nucleofilaments they 
have to translocate into the nucleus, which appears to be as well regulated by BRCA2 in 
response to genotoxic stress (185). Even an influence on both BER pathways was reported 
where the final ligation of BER intermediates was impaired in Capan-1 cells (186). 
The role of BRCA2 in facilitating orderly homologous recombination is highly important to 
maintain genomic integrity. In the absence, replication errors produce a mutation prone 
phenotype that is a key factor for carcinogenesis.  
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1.6.2.2 Non-homologous end joining 
The fastest and most straight forward way to repair a DSB is simply to rejoin the broken ends. 
This process is called non-homologous end joining (NHEJ). Blunt ended breaks or breaks 
with complementary overhangs are sealed efficiently with relatively high fidelity (187). 
However, DNA ends are altered after treatment with ionizing radiation, which leads to their 
procession before ligation and then NHEJ is often mutagenic. Even if this repair process is 
error-prone, it appears to be very powerful because of the potential to ligate any kind of 
DSBs without the need for homologous sequences within a reasonable time (124, 125).  
Binding of the Ku heterodimer (Ku70/80) to the free DNA ends occurs within seconds after 
break formation. The high abundance of this complex and its high affinity make this possible 
(188, 189). The DNA end is threaded through the Ku complex’s central fissure structure (Fig. 
1.9) (190). Ku70/80 serves for at least two main goals, which are tethering of the different 
broken DNA ends and serving as a recruitment platform for additional NHEJ factors (191). A 
conformational change induced by the binding to DNA ends promotes the recruitment of the 
large DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which can bind to DNA 
and Ku70/80 (192). The association with Ku bound to DNA activates its serine/threonine 
kinase activity, which leads to extensive autophosphorylation and phosphorylation of H2AX 
and other target proteins. How essential this phosphorylation capacity of DNA-PKcs is for 
certain steps in NHEJ is unclear. However, the protein itself is important to promote later 
steps and to recruit other factors (124). MRN is also recruited to the ends but beside a 
possible support during DNA end tethering by Rad50 no other function is known. The 
nuclease activity of Mre11 is not needed for NHEJ (124).  
After treatment with IR most of the DNA ends are not compatible for ligation. For this reason 
different proteins are very versatile in processing the various modifications. The 
endonuclease Artemis interacts with DNA-PKcs, which is required for its activity. It cleaves 
3’-overhangs, 5’-overhangs, hairpins, flaps, and gaps (193). In Artemis-deficient fibroblasts, 
which were arrested in G0/G1 about 10% of radiation induced DSBs remain unrepaired (194). 
Another enzyme, the mammalian polynucleotide kinase (PNK), is recruited through its 
interaction with XRCC4. With the 5’-kinase and 3’-phosphatase activities it generates 
ligatable ends. A third enzyme, Aprataxin, does remove adenylate groups from 5´phosphates 
and also interacts with XRCC4 (125). 
Ku70/80 recruits two polymerases (pol λ and pol µ), which are able to fill single-stranded 
gaps after pairing of partially complementary overhangs or after nucleotide processing. It has 
to be mentioned that both polymerases can work template independent (195). 
Once DNA ends have been made compatible, they are ligated by the DNA ligase IV-XRCC4-
XLF complex. DNA ligase IV is very versatile and can ligate a wide variety of DNA ends. In 
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the absence of XRCC4 it is still capable of ligating compatible 4 nucleotide overhangs but the 
presence of XRCC4, XLF and Ku70/80 improves its efficiency and versatility. XRCC4 has no 
biochemical activity it serves as an adapter and stabilizing partner for several proteins 
involved in NHEJ. XRCC4-like factor (XLF) has a similar structure as XRCC4 and is needed 
for efficient ligation of incompatible DNA ends (191).  
 
 
Figure  1.9 Model for non-homologous end joining. (1) After generation of a DSB with overhangs by IR 
it is detected and bound by the Ku70/80 heterodimer (red). (2) The flexible CTR of Ku80 recruits DNA-
PKcs (blue), which leads to inward translocation of Ku and positions itself at the ends. (3) DNA end 
processing by several possible enzymes like Artemis, and PNKP (pink). (4) Autophosphorylation of 
DNA-PKcs, which might also happen at an earlier time point. (5) Resulting in the release of DNA-PKcs 
from DNA. (6) Finally, the XRCC4/DNA ligase IV complex (green/grey) ligates the ends with the help 
of XLF (purple) (196). 
 
NHEJ is evolutionary conserved and because of its speed and abundance throughout the 
cell cycle it is the predominant DSB repair pathway in mammalian cells. Patients with 
mutations in ligase IV or XLF are highly sensitive to IR, immunodeficient, and show 
microcephaly (197). Whereas ligase IV knock out mice dye early during embryogenesis, 
mice lacking Ku and DNA-PKcs are viable showing that low levels of end joining can still 
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occur in these mice (197, 198). However, all mutants in NHEJ show a highly sensitive 
phenotype towards IR exposure. 
 
1.6.2.2.1 The role of DNA-Pkcs in double strand break repair 
The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is with about 470 kDa the 
largest protein kinase known in biology and plays an essential role in non-homologous end 
joining (199, 200). By the Ku-complex DNA-PKcs is recruited to the free DNA ends and both 
built the DNA-PK complex. Ku70 and Ku80 form an asymmetrical ring, which allows the 
complex to bind in the major groove closest to the DSB and the minor groove distal to the 
break. A flexible arm at the C-terminal region of Ku80 was shown to recruit DNA-PKcs to the 
break site (Fig. 1.9, step 2). The arm is thought to position a DNA-PKcs molecule next to 
itself and may also stabilize adjacent DNA-PKcs at the opposite side of the DSB, which leads 
to the so-called “synapsis of the ends” (190, 201). This alignment of the ends was shown to 
be more efficient when Ku and DNA-PKcs worked together (202). The whole DNA-PK 
complex is acting as activator and scaffold for the following NHEJ steps. 
DNA bound DNA-PKcs is forming a channel where the DNA fits in and differs from the 
conformation of unbound DNA-PKcs (203). Its interaction with the second DNA-PK complex 
in trans-position at the other break end is needed for kinase activation (201). DNA-PKcs 
autophosphorylates itself at the known ABCDE, and/or PQE autophosphorylation clusters, 
and at one site in the activation loop of the kinase (196). Furthermore the kinase was shown 
to phosphorylate several proteins in vitro, but little evidence exists for in vivo functional 
relevance (204-206). Its major target seems to be itself (196, 207). 
In the case of a kinase dead protein version the DNA-PK complex inhibits repair by blocking 
accessibility to the ends (208). This let to a significant observation where cells expressing 
threonine to alanine mutations in the ABCDE cluster are more radiation sensitive than cells 
lacking DNA-PKcs completely (209). DNA-PKcs presence is protecting the ends from most 
DNA-modifying enzymes and is blocking other repair pathways. Consequently, activation of 
the kinase is essential for complete NHEJ. Another conformational change of DNA-PKcs 
seems to orchestrate the end processing by Artemis, pol µ, PNK and more. Later it directs as 
well XRCC4/ligase IV to the break for the final sealing procedure (201). Further 
autophosphorylation of DNA-PK induces complex dissociation. Co-immunoprecipitation of 
purified DNA-PK proteins in the absence of ATP was possible but not if ATP was 
administered showing that DNA-PKcs will finally be released (202). Cellular phosphatases 
influence the DNA-PK phosphorylation status in vivo (210). In general it is thought that they 
allow for complex recycling (196). However, not everything has been clarified yet, like the 
significance of DNA-PKcs being able to phosphorylate many other target proteins. 
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It was shown that the absence of Ku80 or XRCC4 in CHO cell extracts leads to strongly 
reduced NHEJ efficiency and fidelity in the ligation of special substrates whereas DNA-PKcs-
deficiency leads to a milder effect (211). Therefore a non-essential but facilitating role of 
DNA-PKcs in NHEJ was proposed. However, recently the first human mutation in the DNA-
PKcs gene has been identified leading to a radiosensitive T-B-SCID patient. In contrast, 
spontaneous mutations were identified in dogs, mouse, and horse models before. This 
hypomorphic missense mutation (L3062R) in a human did not change expression level or 
autophosphorylation status of the protein whereas the same mutation in an animal model let 
to complete loss of kinase activity. Therefore some functions of DNA-PKcs might be unique 
to humans (207). However, human colon cancer HCT116 cells lacking DNA-PKcs are viable, 
although showing defective proliferation and genomic instability (212). DNA-PKcs might not 
be essential for repair of metabolically induced DSB but appears to be highly important for 
the repair of IR induced DSB. In response to IR it is not only involved in repair but also in 
signal transduction of the complex responses to IR (213). 
 
1.6.2.2.2 The role of p53-binding protein 1 
p53-binding protein 1 (53BP1) was identified to be a p53 binding partner that could promote 
the transcriptional activity of p53 (214, 215). Nowadays it has been classified as a mediator 
and adaptor of the DNA-damage response. It is a huge protein with a molecular weight of 
450 kDa, has no characterized enzymatic activity, and serves instead as a recruitment 
platform for other DDR proteins (216). The protein contains two BRCA1 carboxy terminal 
(BRCT) domains and a tandem Tudor domain. Tudor domains recognize methylated 
histones and methylated lysine 79 of H3 and can target 53BP1 to DSBs (217, 218).  
53BP1 was described to be involved in checkpoint activation. Abrogation results in a decent 
defect in G2/M cell cycle arrest and in a partial intra-S phase checkpoint defect (219-221). 
This was observed at low doses of IR and others have reported the opposite (222, 223). 
53BP1 was found to act in some cell lines upstream of ATM where it is required for efficient 
ATM Ser1981 autophosphorylation (224, 225). Like MDC1 and BRCA1 it mediates Chk2 
phosphorylation following IR (225). 
Secondly, 53BP1 is involved in direct DSB repair. After cells encountered genotoxic stress 
53BP1 rapidly translocates from a diffuse nuclear distribution towards IR induced foci (IRIFs) 
(224, 226). Because of this localization to DSBs and the induction of genome instability in 
deficient cells, 53BP1 was believed to play a role in DSB repair. For the repair of DSBs, 
which are located in heterochromatin, it colocalizes along with γH2AX, NBS1 and Mre11 to 
promote ATM-dependent NHEJ (194, 227). However, the formation of foci is not in general 
dependent on ATM, NBS, DNA-PKcs or wild type p53 as foci form in the respective deficient 
mutant cells (224). Rad9, the yeast homolog, is necessary for efficient NHEJ and 53BP1 
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Tudor domains have been reported to enhance the activity of the DNA ligase IV/XRCC4 
complex in vitro (228, 229). Furthermore 53BP1 foci formation is not induced by agents that 
block DNA replication (224). Additionally, 53BP1 is involved in the choice between HR and 
NHEJ in S-phase BRCA1-deficient mouse cells where it promotes erroneous NHEJ repair 
(230). These findings indicate that 53BP1 is involved in efficient NHEJ but not necessarily in 
the classical NHEJ pathway (222).  
For efficient recruitment of 53BP1 to the breaks ubiquitylation of Lys119 of H2AX by RNF8 
and the direct interaction with MDC1 is required whereas phosphorylated H2AX is needed for 
the sustained retention at IRIFs (231-233). The acetylation of histone residues by the Tip60 
HAT was also shown to be crucial for foci formation, which forms a more open and mobile 
chromatin structure (234). With regard to chromatin 53BP1 influences its mobility in the 
surrounding of a DNA damage focus, which might increase the likelihood that two ends meet 
for repair. Modulating chromatin mobility may be facilitated by the interaction of 53BP1 with 
dynein motor proteins (235, 236). In summary 53BP1 is an important DNA damage response 
protein, which helps in checkpoint activation, in the choice of DSB repair pathways, and 
facilitates non classical NHEJ. Disruption leads to growth retardation, immune deficiency, 
radiation sensitivity, and susceptibility to cancer (233). However, the exact mechanisms have 
still to be elucidated. 
 
1.6.2.2.3 The scaffold protein XRCC4 in NHEJ 
The XRCC4 protein has no known enzymatic function. It is rather a scaffold protein that 
promotes the efficiency of DNA ligase IV to join ends with low homology by stabilizing 
intermediates of the process (199, 237). Structural studies revealed a globular head domain 
and a coiled coil C-terminus of which two proteins form a dimer (238). Its complex with DNA 
ligase IV consists of 1 ligase and 2 XRCC4 molecules and it interacts as well with Ku serving 
as a flexible tether between Ku and the ligase (239, 240). During this process XRCC4 is 
phosphorylated by DNA-PKcs. However, this modification is not essential for break ligation 
but may be supportive (241, 242). The DNA-binding ability of XRCC4:DNA ligase IV is not 
strong and appears to be mediated by DNA-PK (243). As mentioned earlier, XRCC4-
deficiency is embryonic lethal and it appears to be more important for the repair of enzyme 
induced breaks than for radiation-induced DSBs (244). However, a mutation in the xrcc4 
gene in hamster cells let to the stimulation of Rad51 foci assembly after γ-ray exposure. 
Therefore HR can overtake repair at the break even at late NHEJ steps in a sequential 
manner (245). Depletion of XRCC4 in G1 checkpoint-defective cells let as well to an over-
stimulation of HR. DSB produced in G1 could be transferred to S/G2 phase and processed 
by HR (246). Ectopically expressed XRCC4 fragments compete in a dominant-negative 
fashion with full-length XRCC4 for binding to ligase IV, which leads to a sensitization of MDA-
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MB-231 breast tumour cells to ionizing radiation (247). This finding indicates that a sterical 
blocking of the ligase inhibits further processing of the break by other repair pathways. 
Overall XRCC4 is an important repair protein for fast and efficient repair of DSBs. The 
classical NHEJ pathway is the preferred choice for repair. Lack or mutations of XRCC4 is 
leading to a switch to HR or alternative end joining and can promote carcinogenesis (240). 
 
1.6.2.2.4 Alternative non-homologous end joining 
In the absence of core NHEJ-factors like ligase IV, XRCC4, and DNA-PKcs end joining can 
still take place but with slower speed. In the last decade this form of end joining was given 
several names: alternative NHEJ (alt EJ), back-up NHEJ, and microhomology-mediated 
NHEJ (MMEJ). However, little is known about the exact enzymes involved and if there are 
different branches (191). In general it was reported that alternative pathways are at least 
about 10-fold slower than NHEJ (199, 248). Yet, the repair time might also depend on the 
complexity of the damage.  
MMEJ seems to be used on a normal basis when too much DNA damage is saturating the 
Ku-pathway or when the Ku protein is unable to bind the DNA ends in the case of 
polypeptides cross-linked to the DNA ends (124, 249). The pathway uses imperfect 
microhomologies of about 5 - 20 nucleotides. Therefore, it requires resection of the ends, 
which is normally a prerequisite for HR repair. Components of NHEJ and HR (MRN, Ku, Lig4, 
CtIP, Rad52) are involved and seem to be used when the two classical pathways, NHEJ and 
HR, have failed to repair the damage. Factors of the DDR response regulate the uncontrolled 
use of mutagenic MMEJ. ATM partly suppresses DNA end degradation by Mre11 but over-
expression of Mre11 increases alternative end joining in an ATM-independent manner (250, 
251). Lack of 53BP1 results in an ATM-dependent increase in DNA end resection and to 
increased MMEJ repair (252). This pathway is more error-prone than classical NHEJ but 
seems to be used when the amount of damage is too huge. As it uses the resection enzymes, 
which are also involved in SSA it can also be termed “micro SSA” (125, 199).  
Other people impaired classical NHEJ in HR-defective cells, which excludes an involvement 
of HR for still occurring repair but rather proposed also the existence of an alternative NHEJ 
pathway with backup functions (B-NHEJ) (253). In assays using HeLa cell extracts it was 
shown that the majority of DNA end joining activity derived from ligase III (254). But also 
DNA ligase I and DNA ligase IV showed a significant contribution to the end joining activity. 
Ligase III is also involved in BER and SSBR therefore it is difficult to study its specific 
involvement in B-NHEJ. In higher eukaryotes knockout of LIG3 is lethal (255). Using an end 
joining reporter assay in DNA ligase IV-deficient MEFs additionally silenced for DNA ligase III 
reduced DNA end joining to further 80% (256). Other identified factors are Parp-1, XRCC1 
and histone H1. The first two are well known BER and SSBR factors. Parp-1 binds to free 
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DSB ends in direct competition with Ku and non-DSB lesions (257). In vitro assays showed 
that the abundance of histone H1 around the break site significantly increased the activity of 
ligase III compared to ligase IV and it enhanced the function of Parp-1 (258).  
In vivo and in vitro end joining assays validated a more enhanced activation of B-NHEJ in G2 
phase than in G1 phase (240). Furthermore by letting cells grow to plateau phase (growth 
inhibited state) they show a significant reduction in end joining activity that could be corrected 
by recombinant ligase IIIα. This is pointing to a connection between growth signalling and B-
NHEJ (254, 259). Therefore terminally differentiated cells like neurons (in G0 phase) might 
not be able to use this backup pathway and rely on classical NHEJ or SSA. 
Interestingly, a high fidelity NHEJ pathway was described for human embryonic stem cells, 
which are using the canonical NHEJ pathway but without DNA-PKcs. When these cells 
differentiated, a progressive decrease in the accuracy of NHEJ was observed (260). 
In summary the relevance, regulation, and separation of these alternative NHEJ pathways is 
not clear. Proteins of pathways like HR and BER/SSBR seem to act very versatile and can 
work in alternative end joining mechanisms. 
 
1.6.2.3 Choice and hierarchy of double strand break repair pathways 
As indicated before the availability of the repair pathways is differentially regulated 
throughout the cell cycle (HR or alt-NHEJ). However, more parameters can impact the 
balance between DSB repair pathways like the cell type, status of the chromatin compaction, 
complexity of the DNA damage, and the degree of DNA damage burden (261). 
Immediately after exposure to IR several proteins will compete for DNA ends. This passive 
competition between Ku, MRN, and Parp-1 may already partially determine the choice of the 
pathway (257, 262). Ku exhibits the higher affinity for free DNA ends therefore it dominates 
DSB repair in the first place. Parp-1 is sequestered as well by other forms of DNA lesions, 
which limits its contribution to DSB repair (257). Ku regulates the choice between different 
NHEJ pathways (classical versus backup-NHEJ) (263). Actively proliferating cells need to 
repair their damage as fast as possible. NHEJ between compatible ends is twice as efficient 
as NHEJ between incompatible ends whereas HR is additionally 3 times less efficient. With 
NHEJ being the fastest DSB repair pathway it might be the first choice for repair and only 
after failure other pathways can continue (264, 265). However, in the late S phase and early 
G2 phase both, HR and NHEJ, contribute significantly to ionizing radiation-induced DSB 
repair (266). The increased cell survival of S phase cells after exposure to IR, called S phase 
radioresistance, was shown to depend on active HR (267). HR is tightly regulated to prevent 
deleterious genomic rearrangements in M and G1 phase. But later on in S/G2 phase sister 
chromatids ensure accurate repair. Replication induced DSBs are exclusively repaired by HR. 
These breaks harbour one free DSB end and a SSB end and would be erroneously repaired 
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via NHEJ. Radiation induced SSBs and non-DSB damages are converted to such lesions 
when they encounter a replication fork (268).  
The active regulation is done by CDKs, which influence expression levels, activation status, 
and interaction status of certain HR proteins. Rad51, Rad52, and CtIP expressions increase 
during S phase (154, 269, 270). Phosphorylation of BRCA2 in M and early G1 phase at 
serine 3291 blocks its interaction with Rad51 and therefore HR. However, immediately after 
irradiation this phosphorylation was rapidly decreased to promote HR (271). On the other 
hand phosphorylation of critical threonine residues (T2609, T3950) in DNA-PKcs is reduced 
in irradiated S phase cells, which is consistent with decreased DNA-PK activity in S phase 
HeLa cells (272, 273). The point of no return for HR repair is reached at the DNA resection 
step and therefore this step is tightly regulated. CtIP proteins are phosphorylated at several 
sites by CDK, which lead to up-regulated DNA end-resection and an increase of HR repair in 
S phase (269). Due to the serine327 phosphorylation CtIP can interact with BRCA1 and 
BRCA1 might therefore also regulate end-resection (270). Two other studies suggest a 
regulation of resection by 53BP1 and BRCA1, with BRCA1 being a positive regulator and 
53BP1 being a negative regulator (90, 230, 274). 
Several lines of evidence propose DNA-PKcs to be an active regulator in the choice between 
HR and NHEJ. Depletion of the whole protein increased HR but chemical inhibitors let to a 
decrease of HR activity (275-277). Another laboratory identified a splice variant lacking the 
kinase domain, which is expressed along full length DNA-PKcs solely in quiescent cells. By 
this means HR is limited in differentiated cells (278). It is believed that kinase inactive DNA-
PKcs cannot dissociate from the DNA ends any more and thereby block it for HR. 
Surprisingly, another kinase inactive mutant harbouring a single lysine to arginine change 
close to the kinase active site resulted in HR stimulation (261). All kinase inactive mutants 
can still be recruited to the repair focus but influence HR differently. Here ATM plays a role. 
ATM levels are lower in cells lacking DNA-PKcs, but could be restored in the K3752R mutant 
(261, 279). ATM can also phosphorylate threonine2609, but serine2056 is solely 
autophosphorylated by DNA-PKcs itself. Phosphorylation of both sites regulate the 
accessibility of repair factors to DSBs, and therefore HR might be increased above wild type 
level as only one site is phosphorylated by ATM (261). However, the clear role of ATM in 
pathway choice is still not known, but it appears to be a positive regulator of HR (25, 280). 
This picture of all the interaction partners and modifications shows the complexity and fine 
balance involved in this delicate process. Both pathways share some repair proteins, which 
might all be involved in the choice like BRCA1, H2AX, Parp-1, Rad18, DNA-PKcs, and ATM 
(261). Even if NHEJ factors are recruited more rapidly to DSBs than HR factors, both seem 
to stay a period of time at the same DSB site (281). Therefore the interplay of multiple 
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proteins regulates the choice directly at the break. However, this precisely balanced choice is 
often deregulated in tumour cells. 
In many studies the hierarchy of NHEJ and HR was analyzed looking for the repair of simple 
endonuclease induced DSB (264, 282). These are very efficiently rejoined by classical NHEJ. 
However, about 30% of the ionizing radiation induced DSBs reside within lesion clusters 
(283). A clustered lesion is a lesion containing 2 or more breaks/modifications within 2 helical 
turns of the DNA. Much more non-DSB clusters do exist after irradiation, which can be 
converted to DSBs (284, 285). For example two opposing tetrahydrofurans (stable AP site 
analogs) are cleaved to form a DSB by AP endonucleases and these are partially 
inaccurately repaired by NHEJ (286). Or repair intermediates produced by a defective 
fanconi anaemia (FA) repair pathway (repair of crosslinks) will be overtaken by NHEJ, which 
is not able to act properly. In this case inappropriate usage of NHEJ leads to cellular toxicity 
(287). In contrast, other groups showed that repair proficient cells did not generate additional 
DSBs post-irradiation (288). Gulston et al. quantified that a fraction of 10% of clustered 
damage is finally converted to DSBs (289). The composition of all induced DNA damages 
can differ as well with regards to the quality of radiation. 1 GeV low-LET protons induced 
relatively more DSBs compared to abasic and oxybase clusters than ionizing photons (290). 
These differences in the complexity of the DNA damage might influence pathway choice.  
In recent publications the importance of HR and SSA after exposure to ionizing radiation was 
demonstrated. When HeLa cells were exposed to equipotent doses of Bleomycin or X-rays 
with regard to DSB production, Rad51-foci could only be observed in irradiated cells 
indicating the use of HR after X-ray exposure (265). Another hint for the involvement of HR is 
the radiosensitivity of HR-deficient cells exposed in G1 phase meaning that NHEJ alone is 
not efficient in repairing certain DSBs (291). Furthermore after HR complementation by 
human XRCC3 cDNA cells showed a greater radioresistance than parental cells but 
resistance to mitomycin C was only partially restored. This suggests as well an important role 
for HR in the repair of complex DSBs (291). Even SSA is more important for the repair of 
complex DSBs than NHEJ in hamster S phase cells. For human fibroblasts it was shown that 
about 15% of X-ray induced DSBs are repaired via HR in G2 (292). DSBs, which were 
induced in G2 after irradiation and were processed by HR required Artemis and ATM. 
Artemis endonuclease is required for efficient DSB repair and seems to promote end 
processing in heterochromatic DNA regions (292). 
These studies clearly show the action of HR after production of DNA DSBs by ionizing 
radiation. However, the influence seems to depend on the cell system with its genetic 
background. In earlier studies with high doses of radiation (> 20 Gy) the detection of HR 
involvement was prohibited as HR appears to be saturated at high radiation doses. Therefore 
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future studies should use physiologically relevant radiation doses to be able to measure the 
contribution of HR (266). 
 
1.6.3 Chromosomal aberrations 
Mis-repair or no repair of DNA damages can lead to chromosomal aberrations, which do not 
necessarily result in cell death but mutations. Less severe mutagenic events are accepted in 
order to prevent severe deletions at a later time point. For example translesion DNA 
synthesis (TLS) across an abasic site located at a break will lead to the expense of a point 
mutation but can prevent severe deletions by NHEJ (293).  
Ionizing radiation is very efficient in inducing chromosomal aberrations. In general survival 
correlates with incomplete or improper repair and progression of these cells into mitosis. 
Dicentric- and micronucleus-formation induce mitotic catastrophes after exposure to IR (294). 
But cells with reciprocal translocations often survive because they encounter no problems 
during mitosis (4). 
If sticky DSBs are formed after irradiation they may restitute to their original configuration, or 
they fail to join and a deletion will be visible at the next mitosis, or broken ends from different 
sites may rejoin and give rise to grossly distorted chromosomes (5). The later possibility will 
lead mainly to mitotic catastrophe but a cell might survive with a deletion if the genetic 
information was not essential. 
Metaphase spreads are usually prepared at the first metaphase after X-ray exposure and 
then aberrations can be separated into two classes: chromosome aberrations and chromatid 
aberrations. Chromosome aberrations result from early interphase irradiation, before the 
chromosomes have been duplicated. The break is generated in a single chromatin strand 
and the aberration will be duplicated during the next replication round. If breaks of two 
different chromosomes are ligated, dicentrics are formed after replication. If two breaks in the 
two different arms of a chromosome are ligated, a ring will be formed. In both cases the 
aberrations are always accompanied by two identical acentric fragments (Fig. 1.10). In 
contrast if the cell nucleus is irradiated when the cell has duplicated its DNA the break occurs 
only in one of the chromatid arms and leaves the opposite arm undamaged leading to gaps 
and breaks. These breaks occurring on a single chromatid arm are called chromatid 
aberrations. An exception here is the isochromatid deletion. Though little chance exists that 
breaks are generated in both chromatid arms those can be incorrectly joined to a sister union 
and a fragment (Fig. 1.10). At the next mitosis this aberration will be lethal. However, not only 
DSBs induced in S phase but also single-strand breaks induced in early interphase can be 
converted to one-sided DSBs during replication and look like a chromatid aberration. As 
mentioned before symmetric translocations and small interstitial deletions can be nonlethal  
 
 1.6 DNA damage repair mechanisms 
43 
 
Figure  1.10 Exemplary formation of three major aberrations types induced after irradiation. (A) DSBs 
are induced in 2 different G1 phase chromosomes. The ends can be joined incorrectly leading to an 
interchange between the two chromosomes. The Chromosome with two centromeres is called 
dicentric. (B) Two DSBs are generated in the two different arms of a chromosome. Incorrect joining 
leads to a ring formation. In (A) and (B) acentric fragments will be duplicated. (C) DSBs are induced in 
a postreplication (G2 phase) chromosome. Both sister chromatids are effected and incorrect joining 
can lead to the formation of a sister union and a fragment (from (5)). 
 
chromosomal changes. But if a tumour suppressor gene may be lost this is associated with 
tumorigenesis (5). With the classical Giemsa-staining technique for chromosomes these 
inter-/and intrachanges cannot be visualized and quantified. 
An unexpected and dangerous finding (e.g. for astronauts) is that targeted cytoplasmic 
irradiation with alpha particles induces mutations in mammalian cells (21). This is dangerous 
as the cytoplasmic traversal is almost not followed by cell death of the target cells but more 
likely by transformation. 
Many studies were performed in rodent cells as the 22 chromosome sets can be easily 
analyzed. It was demonstrated that impairment of NHEJ causes aberrations in all cell cycle 
phases implicating its importance for DSB repair. HR seems not to be error free and B-NHEJ, 
which is highly error prone, seems as well to contribute to the huge aberration burden in 
DNA-PK-deficient CHO cells. However, also in HR-deficient mutants the frequency of 
chromosome exchanges is increased compared to the parental cells but less than in NHEJ-
deficient cells. Both pathways are important for correct repair in G2 and S phase irradiated 
cells (108, 295). 
Ionizing radiation-induced chromosomal aberrations correlate with cell killing in p53-defective 
CHO cells (108). Also human p53-defective cells might propagate aberrations more 
efficiently to the next mitosis, which leads thereafter to mitotic cell death. 
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1.6.4 DNA damage after proton beam exposure 
Some molecular studies were looking for the amount of DNA damages, chromosomal 
aberrations, and changes in DNA damage gene expression after exposure to proton 
irradiation in vivo (mice), and in vitro (cell systems), or in silico (modelling studies). 
Unfortunately only few directly compared their results to photon radiation exposure.  
A study, which irradiated genomic T7 DNA with different types of radiations, found that 
radiation types with similar LETs (X-rays, γ-rays, protons) do not produce similar spectra of 
initial complex damages. Protons produced the highest ratio of DSBs to non DSBs clusters 
indicating a differential DNA damage induction (290). A Japanese group quantified a bigger 
amount of initial γH2AX foci 30 minutes after proton compared to photon radiation exposure 
in two different cell lines. However, 30 minutes after exposure to low doses of 0.5, 1, and 2 
Gy the amount of foci do not necessarily represent the initial amount of DSBs. A big part of 
the photon induced DNA damage could have been already repaired. Anyways 12 hours after 
exposure to IR DSB repair was finished following both types of radiation, which correlates 
with the minor RBE they found (296). In thyroid follicular cells 20% fewer free 3’ DNA ends 
were quantified 1h post-irradiation with photons in contrast to protons. This late time point is 
rather indicating the amount of less repairable damage after proton exposure and not the 
initial amount of breaks (86). The DNA damage induced by low-LET protons seems to be 
more severe in comparison to photon irradiation. Consequently this would lead to another 
composition or amount of chromosomal aberrations. Green et al. found an RBE of 1.7 for 
micronuclei induction and overall larger micronuclei were detected after proton versus photon 
radiation exposure, which indicated quantitatively more unrepaired DNA damages and more 
severe classes of damages (86). Exposure of heparinized blood to different doses of 60 MeV 
protons showed a similar dose-response relationship to that of 60Co γ-rays with regard to 
dicentric and ring formation. But irradiation at greater depths within the spread-out Bragg 
peak induced a higher aberration frequency at low proton doses than in γ-ray samples (297). 
A more efficient transmission of a significant fraction of complex-type exchanges to third-
generation lymphocytes was found after proton irradiation in comparison to carbon ion 
irradiation (298). Irradiated peripheral blood cells are normally cleared from the organism 
after a certain time period depending on the dose. However, in vivo studies indicated that the 
mutant frequency in the lacZ gene of mouse brains was significantly increased only 8 weeks 
after exposure and stayed high until 16 weeks thereafter (299). Mutation analysis in 
lymphocytes does not reflect the response of late responding tissues. Unfortunately these 
results have not been compared to photon irradiation. Overall protons seem to induce more 
severe chromosome aberrations. 
Modelling studies are very helpful to get an idea of the lesion complexity. At high-LET 
radiation exposure the contribution of secondary electron tracks to the induction of clustered 
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lesions is almost negligible, though they seem to dominate at low-LET radiation types,  below 
~ 10 keV/µm. Ottolenghi et al. proposed that the larger biological efficiency of protons is 
related to the larger energy density within a small radius around the primary track (50). 
Expression profile analysis of DNA damage signalling genes in mouse brains, which have 
been exposed to 2 Gy of protons displayed a down-regulation of Chk1, Parp, and Rad52 and 
an up-regulation of Rad51/1, and Brca1. Even without the photon control arm, this indicates 
an interesting modulation of the DNA damage response with regard to proton exposure (300). 
Until today studies have indicated that protons induce more severe and complex DNA 
damages, which might be even differentially processed. Therefore, in this work and future 
work this topic has to be addressed in more detail. 
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1.7 Aim of the study 
There is presently a widening gap between the rapid introduction of proton therapy in clinical 
practice worldwide and the apparent lack of solid radiobiological evidence and data to 
support the expansion of new clinical indications, particularly when combined with other 
treatment modalities. 
Radiobiologic experiments conducted several decades ago revealed an approximately 10% 
higher biologic effectiveness of protons (RBE) compared to photons. Many in vitro and in 
vivo experimental approaches have been performed to better define the observed RBE (82, 
301, 302). These studies confirmed that the continued employment of a generic RBE value 
of 1.1 is reasonable, even though the RBE can vary heavily according to tissue, cell line, or 
the end point investigated. However, the cause for this increased RBE on the physical-
chemical and molecular-cellular level is far from clear. Many researchers assumed no big 
differences on the molecular level, as the oxygen enhancement ratio of protons and photons 
appeared to be equal (52, 53). Yet, several studies showed a bigger efficiency in cell killing, 
in ROS production, or in micronuclei generation after proton versus photon radiation 
exposure (86, 88, 89). Unfortunately, all of these studies have been done in different centres 
with a small number of cell lines and cannot be generalized toward a common conclusion. 
Differences have been demonstrated with regard to DNA repair kinetics, and chromosomal 
aberration induction (86, 296, 297, 299). Modelling studies proposed a larger amount of 
small DNA fragments after proton irradiation (50, 303). 
DNA is known to be the most important target for radiation-induced effects, and some studies 
indicate a differential DNA damage induction after proton radiation exposure. Therefore, the 
goal of the present study was to investigate in vitro whether the DNA damage induced by 
proton radiation exposure differs or equals the damage after photon radiation exposure. Our 
questions were: 
1) Does proton radiation induce a bigger amount of DNA damage than photon radiation? 
2) Is the DNA damage after proton exposure more complex than after photon exposure? 
3) Is the hierarchy of different repair machineries changed after proton compared to 
photon radiation exposure? 
4) Is the DNA damage generated by proton as compared to photon irradiation more 
often mis-repaired or even not repaired? 
We addressed these questions by using 1) an indirect approach screening several DNA 
repair mutants for their survival after proton compared to photon irradiation, 2) quantification 
of the initial DNA damage and of the repair kinetics of different repair proteins after both 
types of radiation, and assessment of 3) chromosomal aberrations to detect eventually mis-
repaired DNA damage. 
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2 Materials and Methods 
2.1 Cell lines and cell culture 
All cell lines used during this thesis were cultured in 5% CO2 atmosphere at 37°C. Hamster 
cells (listed in Table 2.1) were kept in Ham’s F-10 nutrient mixture supplemented with 10% 
FCS and penicillin-streptomycin (100U/ml-100µg/ml). 
 
Tabelle  2.1 Hamster cell lines 
Cell line Deficiency Mother 
cell line 
Origin Kindly provided by Ref. 
AA8   Ovary M. Zdzienicka, Leiden, NL 
and M. Löbrich, Darmstadt, 
GER 
(304) 
UV-5 ERCC2-/- AA8 Ovary M. Zdzienicka, Leiden, NL (304) 
Irs1sf XRCC3-/- AA8 Ovary M. Zdzienicka, Leiden, NL 
and L. Thompson, 
Livermore, CA, USA 
(305) 
1SFK8 XRCC3 complemented Irs1sf Ovary L. Thompson, Livermore, 
CA, USA 
(170) 
CHO9   Ovary M. Zdzienicka, Leiden, NL (306) 
XR-C1 DNA-PKcs-/- CHO9 Ovary M. Zdzienicka, Leiden, NL (211, 306) 
Em-c11 XRCC1-/- (C389Y 
substitution leading to 
protein instability) 
CHO9 Ovary M. Zdzienicka, Leiden, NL (307) 
V79   Lung M. Zdzienicka, Leiden, NL (308) 
V-C8 BRCA2 truncation 
(biallelic nonsense 
mutations) 
V79 Lung M. Zdzienicka, Leiden, NL (308) 
V79B   Lung M. Zdzienicka, Leiden, NL (309) 
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CL-V4B Rad51c-/-; deletion of 
ATP-binding site 
V79B Lung M. Zdzienicka, Leiden, NL (309) 
 
Human osteosarcoma U2OS cells (see Table 2) were kept in DMEM supplemented with 10% 
FCS, glutamine (2 mM), sodium pyruvate (1 mM) and penicillin-streptomycin (100U/ml-
100µg/ml). Human pancreatic adenocarcinoma cells BxPC-3 and Capan-1 (listed in Table 2) 
were kept in RPMI 1640 supplemented with 10% or 15% FCS respectively, glutamine (2 mM) 
and penicillin-streptomycin (100U/ml-100µg/ml). 
 
Tabelle  2.2 Human cell lines 
Cell line Deficiency Origin p53-status Kindly provided by Ref. 
U2OS  Bone (osteosarcoma) +/+ A. Sartori, Zurich, 
CH 
(310) 
Capan-1 
 
BRCA2-/-;  
LOH at BRCA2 
locus+truncation 
mutation in the 
2nd allele 
Pancreas (from 
metastatic site: liver) 
mutated Purchased from Cell 
Line Service (CLS), 
Eppelheim, GER 
(186, 
275) 
BxPC-3 BRCA2-/+;  
LOH in one 
BRCA2 allele 
Pancreas mutated H. Friess, Munich, 
GER 
(186) 
 
All cells were cultured in TPP plastic flasks or in 10 cm Petri dishes (Falcon) for clonogenic 
assays.  
Every 2 month cells were tested for mycoplasma infection with the MycoAlert® Assay (Lonza, 
Rockland, USA). This assay can detect mycoplasma in the supernatant of cell cultures by 
measuring the abundance of mycoplasma specific enzymes. Together with a special 
substrate these enzymes produce ATP. This ATP is converted in a second Luciferin based 
reaction to light and oxiluciferin what can be easily measured in a fluorescence reader. 
Hamster cells, Capan-1 and BxPC-3 cells were never tested mycoplasma positive. U2OS 
cells were treated for two weeks with 25 µg/ml Plasmocin (Invitrogen, Basel, CH). After 
another two weeks the cells were mycoplasma free and only then used for experiments.  
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2.2 Reagents and Antibodies 
Tabelle  2.3 Reagents 
Reagents Manufacturer 
Alamar Blue Biosource Int. 
All cell culture media and supplements Gibco, Invitrogen 
MycoAlert® Assay LONZA 
Plasmocin Invitrogen 
OPTIMEM Gibco, Invitrogen 
Lipofectamine™ 2000 Invitrogen 
Lipofectamine® RNAiMAX Reagent Invitrogen 
RNAse A Quiagen 
Demecolcemide Sigma 
Giemsa Sigma 
Entellan Merck 
Dako Fluorescence Mounting Medium Dako 
All other chemical reagents were of highest purity grade Sigma-Aldrich®, Merck 
 
 
Tabelle  2.4 Antibodies 
Antibodies Manufacturer Ref. 
number 
Anti-ß-actin ab (clone AC-15), mouse monoclonal Sigma A5441 
Anti-Rad51 ab, mouse monoclonal Abcam Ab213 
Anti-p-DNA-PKcs (Ser2056) ab, rabbit polyclonal Abcam Ab18192 
Anti-XRCC4 ab, rabbit polyclonal Abcam Ab145 
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Anti-XRCC1 ab, rabbit polyclonal Cell Signaling Technology® #2735 
Anti-XRCC3 ab, rabbit polyclonal Abcam Ab6494 
Anti-53BP1 ab, rabbit polyclonal Cell Signaling Technology® #4937 
Anti-γH2A.X (Ser139) ab (clone JBW301), mouse 
monoclonal monoclonal 
Millipore #05-636 
Anti-Chk2 ab (clone 7), mouse monoclonal Millipore 05-649 
Anti-p-ATM (Ser1981) ab, rabbit polyclonal Abcam Ab79891 
Anti-pH2A.X (Ser139) ab (Alexa Fluor® 488 
conjugate), rabbit monoclonal 
Cell Signaling Technology® #9719 
Rabbit (DA1E) IgG Isotype Control (Alexa Fluor® 488 
conjugate), rabbit monoclonal 
Cell Signaling Technology® #2975 
Secondary sheep anti-mouse ab, HRP-linked GE Healthcare NA931V 
Secondary donkey anti-rabbit ab, HRP-linked GE Healthcare NA9340V 
Secondary goat anti-mouse ab, Alexa-Fluor®488-
linked 
Molecular Probes®, 
Invitrogen 
A-11001 
Secondary goat anti-rabbit ab, Alexa-Fluor®546-
linked 
Molecular Probes®, 
Invitrogen 
A11071 
Secondary goat anti-mouse ab, Alexa-Fluor®546-
linked 
Molecular Probes®, 
Invitrogen 
A-11018 
Secondary goat anti-rabbit ab, Alexa-Fluor®488-
linked 
Molecular Probes®, 
Invitrogen 
A-11070 
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2.3 Irradiation procedures 
2.3.1 Transport of the cells 
Cell culture and all experiments were performed in the Laboratory for Molecular Radiobiology 
of the University Hospital Zurich (USZ). The centre for proton therapy at the Paul Scherrer 
Institute (PSI; Villigen, Switzerland) is located in 1 h distance from the hospital by public 
transport. In order to irradiate the cells with protons, they had to be transported. Cells were 
seeded into 25 cm2 TPP-Vent-flasks. For transport the lids of the flasks were completely 
sealed so that no increase in O2 pressure would occur and the gas atmosphere in the flask 
stayed the same as in the incubator. This could be checked by the colour of the culture 
medium. Phenol red turns bright pink (pH > 8.2) if it has contact to normal air. Flasks were 
placed into a styrofoam box buffered with 37°C temp erature water containers. Carrying of the 
box was accomplished with big caution. Cells were either transported or “pseudotransported” 
in the case of photon irradiation. Afterwards they were placed into a CO2 incubator for ~1h 
before irradiation took place. After irradiation cells were reincubated over night for ~12 hours 
prior to retransport or “pseudotransport”. 
2.3.2 Photon irradiation 
Photon irradiation was performed using a Pantak Therapax, 300 keV at 0.7 Gy/min or a 
Gulmay 200 keV X-ray unit at 1 Gy/min at room temperature. Vigilant-Dosimeter was used 
for quality assurance. The flasks or slides were placed in a field of 20 x 20 cm, which was 
covered by the tubus. 
2.3.3 Proton irradiation 
All proton irradiations were delivered using the spot scanning approach performed at the PSI, 
centre for proton therapy (311) with the cells being placed in the centre of a Spread-Out-
Bragg-Peak (SOBP) with a length of 5 cm and maximum proton energy of 138 MeV. The 
field size orthogonal to the beam was adjusted to the number of cell culture flasks. During 
beam delivery the field size was scanned, which could fit 1, 2, or 4 cell culture flasks or 
microscopy slides (6 x 8; 11 x 8; 11 x 15 cm, respectively). The duration of the whole scan 
was determined by the field size and the dose. Irradiation was performed at room 
temperature and took never longer than 8 minutes, on average 5 minutes. One spot during 
scanning is relatively large, ~7 mm (311, 312). Therefore a cell is almost always covered by 
one spot. Dosimetry of the fields was performed using both small diameter cylindrical 
ionisation chambers (active volume 0.3cm3) and a Farmer NE2571 ionisation chamber using 
the IAEA TRS-398 protocol. 
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Figure  2.1 Photograph of the flask arrangement on the gantry table. 
 
2.4 Proliferation assay 
Cell proliferation was assessed with the colorimetric AlamarBlue® assay that is based on the 
detection of metabolic activity. It is a REDOX indicator correlating with metabolic cellular 
activity. The blue resazurin is converted to pink resorufin via the reduction reactions of 
metabolically active cells. In contrast to MTT (3-(4,5-dimethylthiazol-2)-2, 5 
diphenyltetrazolium bromide), AlamarBlue® can be reduced by Cytochromes due to its 
bigger oxidation reduction potential, and therefore it cannot lead to shut down of the 
respiratory chain and cell cytotoxicity (Manual, Invitrogen). Measurements were performed 4 
h after incubation with AlamarBlue® reagent. Absorption at 570/670 nm was measured using 
an EL 808 Ultra Microplate Reader (BIO-TEK INSTRUMENTS, INC., Switzerland). The 
percentage of the reduced agent was calculated for each well and the blank value was 
subtracted.  
Measurements could only start 44 hours after irradiation. Cells were processed ~20 hours 
after irradiation following recovery and transport. 500 cells were plated per well into 96-well 
plates. Measurements were performed the next day, ~ 44h after irradiation, and the following 
ones at 68h, 92h and 116 h after irradiation. All measurements were carried out in triplicate 
in at least 3 independent experiments. 
 
2.5 Clonogenic survival assay 
Clonogenic survival was determined by the ability of single cells to form colonies in vitro. 20 
hours following irradiation of exponentially growing or plateau phase cells, cells were 
trypsinised, and single cell suspensions were plated on Petri dishes (Falcon, 10cm2). The 
number of plated cells was adjusted to obtain ~ 50-300 colonies per cell culture dish with a 
given treatment. In order to prevent unwanted cell density effects, equal amount of cells was 
plated for similar doses of photon and proton irradiated samples. The dishes were 
maintained at 37°C in 5% CO 2 and allowed to form colonies for different time periods 
depending on the cell system (see Table 2.5).  
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Tabelle  2.5 Clonogenic survival assay conditions 
Cell line Number of cells/flask 
(25 cm2) 
Time from 
plating to 
irradiation 
Time of 
clonogenic 
assay until 
fixation 
Hamster cells in logarithmic growth phase 300 000 24 h 7 – 10 days 
Hamster cells in plateau phase (G0/G1) 1 000 000 50 h 7 – 10 days 
U2OS cells 300 000 24 h 14 days 
Capan-1 cells 1 000 000 48 h 21 days 
BxPC-3 300 000 48 h 17 days 
 
For fixation of the colonies Carnoy’s fixative (methanol/acetic acid; 3:1) or 70% ice cold 
ethanol was used. Staining was performed with a 0.5% crystal violet solution. Colonies with > 
50 cells/colony were counted manually with a GALLENKAMP Colony counter. The survival 
fraction (SF) with a given treatment was determined in the following way: SF = (amount of 
counted colonies)/(amount of seeded cells x PE), where PE is the plating efficiency of 
untreated cells: PE = (amount of counted colonies)/(amount of seeded cells). The survival 
data represent the means and standard deviations of at least three independent experiments 
performed in triplicates.  
In order to calculate RBE values, α- and ß-values for each survival curve had to be 
determined. Survival data were fitted by a weighted, stratified, linear regression according to 
the linear–quadratic formula S(D)/S(0) = exp(αD+ßD²) (Franken, 2006). An SPSS-file was 
created for each survival curve with following variables: dose, number of plated cells, number 
of surviving colonies and PE of that experiment. Furthermore for the quadratic term “D2” = 
dose*dose, for survival “S”= ln(colonies/cells) – ln(PE) and for the weight of the colonies 
found “W”=colonies*cells/(cells – colonies).  A linear regression was performed in SPSS 
(Version 17) as described in Franken et al. (313) and the coefficients provide linear (α) and 
quadratic (ß) parameters. Those were entered into an Excel-file were the formula of Staab et 
al. was used to calculate RBE values at 50, 37, 10 and 1 % survival level (314). 
 
2.6 Flow cytometry 
Flow cytometry allows the simultaneous multiparametric analysis of physical and biochemical 
characteristics of up to thousands of cells per second. Volume and granularity of the cell is 
automatically recorded. If certain molecules, e.g. DNA with a specific dye or proteins with 
54 
specific antibodies, are fluorescently labelled, they can be quantified over the intensity of the 
signal (events/signal intensity). Laser light of a specific wavelength is directed onto the single 
cell and scattered, which is collected by a detector. In the case of fluorescently labelled 
molecules, they are excited and emit light with a certain wavelength, which is detected by 
one or more special fluorescent detectors. In this way the amount of DNA molecules/cell (2N 
or 4N) can be analyzed for thousands of cells. Or the amount of modified proteins (e.g. 
phosphorylation specific fluorescently labelled antibody) will give a fluorescent signal per cell 
with different intensities. A shift in the intensity shows a decrease or increase of protein 
modifications compared to the control. 
  
2.6.1 Cell cycle distribution analysis 
Cells were collected at different time points after irradiation, kept on ice, washed twice with 
PBS, fixed with 70% ice cold ethanol and stored until analysis at -20°C. For preparation, cells 
were rehydrated in PBS and resuspended in 1 ml PBS containing propidium iodide (PI; 
3µg/ml) and RNase A (0.3mg/ml;Qiagen). The cell solutions were incubated on a wheel for 1 
hour at room temperature (RT). PI is bound stoichiometrically by DNA. Fluorescence 
intensity was recorded with a BD FACSCalibur flow cytometer (BD Biosciences; excitation at 
488 nm and emission at 580 and 650 nm). Cell cycle phases were quantified using FlowJo 
software (Vers.7.6, Tree Star Inc.), doublets were excluded. 
 
2.6.2 Intensity of H2AX phosphorylation 
The protocol was adapted from a publication (315). Cells were harvested 30 min after 5 Gy 
of either type of radiation, washed twice with ice cold PBS, and fixed in ice cold 70% ethanol 
over night at 4°C. Next day cells were washed in PB S and rehydrated with permeabilization 
buffer (0.2% Triton X-100, 4% FCS in PBS) for 10 min on ice and stained for 1 h at room 
temperature with Alexa-488 labelled anti phospho-H2AX (Ser139) or unspecific isotype 
control at a concentration of 1 µg/mL. After washing with PBS cells were incubated for 30 
min at room temperature in PBS containing 3µg/ml propidium iodide and 0.3mg/ml RNase. 
Fluorescence intensity was measured using a FACSCalibur (BD Biosciences) and analysis 
was performed using WinMDI 2.9 (free software from facs.scripps.edu in /pub/pc). To 
compare the levels of intracellular H2AX phosphorylation, the mean fluorescence intensity 
ratios (MFIR) were calculated by dividing the geometric mean fluorescence intensity of each 
sample by the geometric mean fluorescence intensity of the control antibody. 
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2.7 siRNA transfection procedures 
For siRNA transfection two different approaches were used. Reverse transfection was used 
for CHO cells and forward transfection for U2OS cells. The latter protocol was adapted after 
Sartori et.al. (Sartori, 2007). All siRNAs were synthesized by Microsynth (Switzerland). 
2.7.1 CHO cells 
A day before plating the cells into the flasks for irradiation reverse transfection of AA8 wild 
type cells was performed after manufactures instructions (Invitrogen). Here the 
liposome/siRNA mix is directly added to cells during plating, when they are still in suspension. 
With the Lipofectamine RNAiMAX reagent this procedure is more efficient and less toxic 
because fewer amount the transfectant is used. Cells were irradiated approximately 48 h 
after transfection. siRNAs were used at a concentration of  40 nM with 1.7 µL/ml 
Lipefectamin RNAiMAX.  
The siRad51-1 was the same as for human U2OS cells. It was selected, because the 
siRNA was already available and had only 1 mismatch at position 15 in the hamster mRNA 
sequence. siRad51-2 was generated with the Microsynth siRNA design tool against 
gi:1552257 of Rad51 mRNA of C.griseus. As the complete C.griseus genome is not yet 
sequenced, a second Blast search was performed against murine sequences to circumvent 
binding at unspecific sites. The two different siRad51 RNAs were used in every experiment in 
order to be able to detect unspecific interactions. siRNA against firefly luciferase was used 
for control transfections as this protein is not expressed in mammalian cells. 
 
Tabelle  2.6 siRNA sequences for treatment of AA8 wild type cells 
Name Sequence Reference 
siLuc 5’-CGTACGCGGAATACTTCGAdTdT-3’ Sequence adapted from Beta 
Cell Biology Consortium 
(Nashville, TN, US) 
siRad51-1 5’-GAGCUUGACAAACUACUUCdTdT-3’ (316), tested against C.griseus 
sequence 
siRad51-2 5’-GCUGGUUUCCAUACGGUGG-TT-3’ Generated with Microsynth-tool 
against mRad51 of C.griseus 
(GI:1552257) 
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2.7.2 U2OS cells 
The human osteosarcoma cells U2OS were plated and transfected 24 hours later, which is 
called forward transfection. At ~ 50% confluency cells were treated with 33 nM siRNA and 
2.9 µl/ml Lipofectamine 2000. Liposome/RNA-bodies were prepared before transfection in 
OPTIMEM medium. Cell culture medium was changed before transfection to 
Penicillin/streptomycin free and 5% FCS containing medium. 16 hours later medium was 
changed to normal growth medium and ~ 8 hours later cells were plated into new flasks for 
control and different dose points. 
Rad51-1, XRCC1 and XRCC4 siRNA sequences were selected out of different publications. 
These sequences had been validated from other researchers for its specificity and therefore 
could be used without the need of a second specific siRNA (316-318). siXRCC3 was 
generated with the Microsynth-siRNA tool against GI:153946429, which is the accession 
number for XRCC3 transcript variant  1. The siRNA sequence covers all three transcript 
variants of XRCC3. siHSP70B was used as control siRNA as this  HSP subtype is not 
expressed in U2OS cells (319). 
 
Tabelle  2.7 siRNA sequences for treatment of U2OS cells 
Name Sequence Reference 
siHSP70B 5’-GGGAGGACAAGACGUUCUAdTdT-3’ (319, 320) 
siRad51-1 5’-GAGCUUGACAAACUACUUCdTdT-3’ (316) 
siXRCC3 5’-UUAAGAAAGCCAAACUGAATT-3’ generated with GI: 153946429 
siXRCC1 5’-CUCGACUCACUGUGCAGAAdTdT-3’ (318) 
siXRCC4 5’-AUAUGUUGGUGAACUGAGAdTdT-3’ (317) 
 
2.8 Western Blot 
Western blotting was used to check the efficiency of protein down-regulation after siRNA 
transfection and to follow the kinetics of the DNA damage response induced protein 
phosphorylations or changes in protein levels. 
At indicated times after transfection cells were collected, counted, and lysates were prepared 
with 10 µL Laemmli-buffer/45 000 cells (2% SDS, 10% glycerol, 0.004% bromphenol blue, 
62.5 mM Tris-HCl, pH 6.8). 
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To follow phosphorylation kinetics after both types of radiation, cells attached to 25 cm² 
flasks were lysed at the indicated time points by incubation with 100 µl of RIPA buffer (50 
mM Tris 7.4, 150 mM NaCl, 1% NP40, 0.25% Sodium deoxycholate, 1mM EDTA; added 
before use 1 µg/mL Pepstatin, Leupeptine, 1 mM PMSF, 1 mM sodium vanadate and 1 mM 
sodium fluoride) for 15 min on ice. After scratching and collection of the lysates, they were 
kept for an additional 15 min on ice and homogenized by pipetting 20 X up and down, before 
they were frozen on dry ice. All lysates were stored at -20°C until analysis.  
An equal amount of protein was subjected to SDS-PAGE to separate the proteins. Due to 
different sizes of the proteins different grades of acrylamid polymerization were used (pATM, 
pDNA-PKcs, Chk2: 8% SDS-gel/ γH2AX: 15% SDS-gel/ all other proteins: 12% SDS-gel).  
Proteins were blotted from the SDS-gel onto Amersham Hybond-P polyvinylidene difluoride 
membranes. Depending on the molecular mass of the protein of interest, the time for transfer 
was different (> 150 kDa = 1.5 h, 100 V at 4°C/< 15 0 kDa = 1 h, 60V at 4°C). Membranes 
were blocked for 1 h with 5% BSA/TBS solution in case of phospho-protein detection 
whereas all others were blocked with 5% milk/TBS solution. All listed antibodies in table 2.4 
were used at the concentration of manufactures recommendation. Anti-phospho antibodies 
were diluted in 5% BSA/TBS, all others in 5% milk/TBS. Primary antibody detection was 
achieved by enhanced chemiluminescence using a corresponding horseradish peroxidase-
conjugated second antibody, according to the manufacturer’s protocol (Amersham, Freiburg, 
Germany). To check for loading of equal protein amounts, membranes were washed 3 x 30 
min in TBS, reblocked and reprobed with anti-ß-actin antibody. 
 
2.9 Immunofluorescence Microscopy 
Immunofluorescence staining was used to quantify initial amounts of γH2AX-foci and to 
determine kinetics of foci formation/disappearance of different repair proteins/protein 
modifications (γH2AX, Rad51, 53BP1, pDNA-PKcs). Cells were plated onto plastic slides to 
prevent the generation of secondary electrons, which occurs when experiments are 
performed with glass slides and low energetic X-rays. In this way an artificial higher absolute 
dose could be prevented. Ibidi-µ-slides VI0.4 slides were used, which are made of special 
plastic that is not autofluorescent and exhibits the same physical characteristics as glass but 
does not interfere with either type of radiation. 
24 hrs prior to irradiation cells were plated onto Ibidi-µ-slides VI0.4 (Ibidi, 80606, Munich, 
Germany) at the same cell density as used for the clonogenic survival assay. At the indicated 
time points after irradiation, cells were fixed and stained with a set of antibodies specific 
against proteins involved in DNA double strand break repair. Cells were washed twice with 
PBS, fixed with 4% formaldehyde/PBS for 20 min, washed with PBS (4 x 5 min) and finally 
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with 0.1 M glycine for storage at 4°C. All samples were stained together. Cells were 
permeabilised for 5 min with 0.2% ice cold Triton-X-100, blocked for 30 min with 
3%BSA/0.1%Tween-20/PBS, followed by 1 h incubation with primary antibodies, diluted 
1:100 in 1%BSA/PBS (mouse-γH2AX Ser139-ab/ mouse-Rad51-ab/rabbit-53BP1-ab/ rabbit-
pDNA-PKcs-ab). After washing with 1%BSA/PBS (4 x 10min), cells were incubated with the 
appropriate secondary antibody (1:1000; Alexa-488 or/and Alexa-546). Finally, cells were 
washed with PBS (4 x 10min), incubated for 15 min with PBS/Dapi (1µg/ml) and washed 
again twice for 10 min with PBS. The channels were filled with Dako Fluorescence Mounting 
medium (Dako) and slides were kept at 4°C until ana lysis. Slides were examined with Leica 
SP5 confocal microscope or with Zeiss Axiovert 25 microscope. At the Zeiss Axiovert, nuclei 
were randomly chosen and analyzed real-time during microscopy without any picture 
generation. With the Leica SP5 z-stacks of at least 50 cells were recorded with a Leica DFC 
350 FX camera and merged for analysis in LAS AF Lite software (Leica, free-version). Foci 
amounts of at least 50 cell nuclei per condition were counted by eye. The experiments were 
repeated at least three times. 
 
2.10 Metaphase spreads 
Another parameter for efficient repair is the quantification of chromosomal aberrations. CHO 
wild type cells were plated in the same density as for clonogenic survival 24 h before 
irradiation. 21 hours after irradiation cells were blocked in metaphase by the addition of 0.1 
µg/ml Colcemid for 3 h. Thereafter, cells were collected, treated with 5 ml hypotonic KCl-
solution (0.075 M, Sigma), and fixed by adding 2 x 5 ml Carnoy’s fixative (3:1; 
Methanol:Acetic acid). Samples were stored at -20°C  until slide preparation. Cell 
concentration was adjusted (~1x106cells/ml) and fixed cells were dropped from ~10 cm 
height onto pre-cleaned wet slides (Menzel-Gläser, Mattrand, Thermo Scientific, 
Braunschweig). To gain better chromosome spreading, slides were put top-down above hot 
water steam and thereafter top-up for 1 min onto a 50°C heating block. Slides were dried at 
least over night, stained with 2% Giemsa for 10 min, washed 4 x in cold water and dried 
again at least over night. Next day they were embedded permanently with Entellan below 24 
x 60 mm cover glasses. Slides were coded before picture acquisition and pictures of at least 
50 metaphases per condition were acquired with a Leica SP5 (bright field) microscope and a 
Leica DFC 290 camera. Metaphase spreads were screened for fragments, rings, dicentrics 
and sister unions. Total amounts and amounts/cell of fragments, rings, dicentrics and sister 
unions were calculated. 
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2.11 Statistical Analysis 
Data were presented as the mean ± standard error of the mean (SEM) of at least three 
independent experiments. The results were tested for significance using the two-sided 
unpaired Student’s t test (Excel 2003 or GraphPadPrism Version 5). Results were 
considered statistically significant when p < 0.05 (*) or highly significant p < 0.001 (**). 
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3 Results 
In this study we were interested in the differential biological response of wild type/mutant cell 
pairs of different DNA repair systems with regard to photon vs. proton irradiation. By using 
the proton spot scanning beam of the Paul Scherrer Institute (PSI) in Villigen, Switzerland, 
we were automatically the first who used such a beam for a huge radiobiological study. The 
relative biological effectiveness (RBE) for proton relative to photon irradiation has been 
studied extensively during the last 60 years, primarily using the traditional proton scattering 
technique. To our best knowledge one study was performed using the proton scanning beam 
of the PSI and few studies using the scanning beam at GSI, in Darmstadt. The aim was to 
determine whether the established RBE for protons also applied to the proton spot scanning 
technique. Gueuleutte et al. measured crypt regeneration in mice, which resulted in a RBE 
for proton relative to photon irradiation of 1.16 (at the middle of the spread out Bragg peak 
(SOBP)) (302). Thus, this study indicates that a generic RBE of 1.1 used in the clinics is also 
applicable for proton spot scanning facilities.  
However, little is known about the molecular cellular response after proton irradiation. A few 
molecular studies have been done, which directly compare conventional radiotherapy with 
proton radiotherapy (mainly scattering technique) using the same experimental settings and 
studying several different end points such as early apoptotic response, micronucleus 
formation, γH2AX foci formation, metastatic potential, and mutation frequency in mouse brain 
(86, 91, 299, 302). Different cell systems and experimental set ups have been used in these 
studies, and therefore it is difficult to draw a clear conclusion. 
Our aim was an extensive unbiased study addressing DNA damage induction and DNA 
repair after proton spot scanning of cells. All experiments were performed in parallel with a 
200 keV X-ray reference radiation. The main end points were clonogenic survival, 
proliferative activity, cell cycle distribution, initial amount of DNA double strand breaks 
(DSBs), DNA repair kinetics, DNA damage response (DDR) kinetics, and chromosomal 
aberrations. 
One reason for the increased effectiveness of protons could be a different complexity of the 
generated DNA damage. An exact quantification of DNA damage, especially of very densely 
packed damage sites, is very difficult or requires very high doses, which might be beyond the 
physiological range. A setting to study indirectly the quality of the DNA damage was 
employed. Using DNA DSB repair mutant cell lines, a difference in their survival fractions 
compared to the wild type cells can indicate problems in the ability to repair certain DNA 
damages, especially the most toxic DSBs. 
Few suitable human cell systems are available to study DNA damage repair systems and 
their influence on survival after proton compared to photon irradiation, as they often grow 
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very slowly or are not able to form clones from single cells. Due to the availability of a huge 
set of characterized DNA repair mutant-/wild type cell pairs and ease in handling, Chinese 
hamster cells were used. All the molecular details were performed in this hamster cell line 
setting. 
Later on we also performed experiments using more clinically relevant human cell systems. 
Due to different cellular responses, the Results section is divided into two parts: hamster cell 
system and human cell systems, however in the end both cell systems will be discussed 
together. 
 
3.1 Chinese hamster cell line system 
All hamster cell lines mentioned in the following chapter are listed in Table 2.1. Two different 
hamster cell systems were used. Chinese hamster ovary (CHO) cell culture was described in 
1958 by Tjio et al. (321). In the same year the male Chinese hamster lung fibroblast cell line 
V79 was introduced (322). These hamster cells possess a very low chromosome number 
(2n=22) compared to other mammalian cells and are an ideal model for genetic studies. The 
doubling time for both cell lines is 12-16 hours and therefore these cells are easy to use in 
cell culture (323). In the recent years, mechanisms of mammalian DNA repair have been 
extensively studied in CHO and V79 cells (135, 211, 266). Analysis of the XRCC genes in 
hamster cells was important for the understanding of mammalian DNA repair processes, 
especially of DSB repair. The ability of different XRCC genes to correct for DNA damage 
hypersensitivity led to the identification of proteins involved in several repair pathways (324).  
However, it is worth mentioning that hamster ovary cells and lung fibroblasts harbour 
mutated p53. Consequently, p21 and Bax genes are not transcribed and will not lead to 
ionizing radiation-induced G1 arrest (325, 326). Therefore, the overall DDR in p53 mutated 
cell lines is different compared to p53 wild type cells. On the other hand many tumour cells 
possess p53 mutations and often display as well a modified DDR, enhanced survival, and 
growth (327). In this regard, CHO cells resemble aggressive tumour cells rather than normal 
cells. 
These two hamster cell systems are well described, easy to use in radiobiological assays 
and in cytogenetic assays. Furthermore many RBE-related studies have been performed 
with these cells (82). Therefore they were chosen to identify possible differences in radiation 
sensitivity towards proton versus photon irradiation. 
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3.1.1 Validation of the experimental set up 
For each experiment the cells for proton treatment had to be transported to the PSI from the 
University Hospital Zurich (USZ) two hours prior to irradiation. After irradiation cells were 
placed back in an incubator having time to recover. The following day the culture flasks were 
transported back to the USZ. To mimic the same conditions, cells for reference irradiation 
with photons were pseudo-transported two times by placing them in the transport container. 
One day after IR exposure, the photon and proton irradiated cells were processed together 
for clonogenic survival assays. Three repetitions of a clonogenic assay with a wild type cell 
line showed no significant variation due to the transport procedures. Survival curves 
exhibited minor standard deviations (Fig. 3.1B, wild type). Moreover, the plating efficiency of  
 
 
Figure  3.1 Response of NER-deficient cells (ERCC2-/-) to photon and proton irradiation. Cells were 
irradiated and (A) cell proliferation and (B) clonogenic cell survival (also for AA8 wild type cells) was 
determined. In (B) survival data and corresponding ratios of SFwild type/SFmutant are plotted. Data 
points represent mean ± SD or bars represent mean ± SEM; n > 3. 
 
control cells for either treatment was the same (Fig. 3.2). Plating efficiencies show the ability 
of control/non-irradiated cells to form a colony. To assess proliferative activity a MTT-like 
assay with AlamarBlue, based on the detection of cellular metabolic activity, was performed. 
This assay was used as fast initial detection of differences in the sensitivity towards the two 
different types of radiation. Furthermore, it should assess if the growth rate of the non-
irradiated cells was not influenced by either type of treatment (transport, other incubator). 
Proliferation rates of the non-irradiated control samples followed up to 5 days were equal for 
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photon and proton experiments (Fig. 3.3). Because of this, we assume that cells were not 
metabolically stressed and had not activated severe stress responses due to the transport. 
Initially, the survival of a nucleotide excision repair (NER) mutant (UV-5) was determined.  As 
NER was never found to be involved in the repair of DNA damage induced by ionizing 
radiation but in the repair of UV-induced DNA damages, no difference compared to the wild 
type cells was expected (120). Determination of the clonogenic survival of UV-5 cells and 
wild type AA8 cells displayed no differences. Both cell lines are more efficiently killed by 
proton irradiation, but to the same extent (Fig 3.1B). The decrease in proliferative activity 
after photon and proton irradiation was in the same range as for wild type cells (Fig. 
3.1A+3.3A). Both assays indicate that neither photon-induced DNA damage nor proton-
induced DNA damage is repaired via NER. 
Since we did use an unbiased approach to uncover molecular differences induced after 
proton irradiation exposure compared to photon exposure, we did not compare the effects 
with photon equivalent doses (0.9 Gy protons vs. 1.0 Gy photons) but the same physical 
doses (1 Gy vs. 1 Gy). The RBE of 1.1 is well known, yet the molecular cause leading to it is 
far from clear. Therefore it would be incorrect to implement a factor from which we do not 
even know if it is valid for all genetic backgrounds and conditions. To study molecular 
parameters after either type of radiation, we did not use equipotent doses, the dose needed 
to kill the same number of cells, but the same physical doses. This is in contrast to many 
other studies and will be explained later on. The main focus in the clonogenic survival assays 
was the differential response comparing wild type versus DNA repair mutant cell lines. For 
better visualisation, the ratios of the survival fractions for wild type versus mutant cells 
(SFwild type/SFmutant) were plotted for both types of radiation at 2 dose points (Fig. 3.1B, 
right bar graph). With the example of NER-/- cells it becomes clear that if the mutant cell line 
behaves the same way as the wild type cell, the ratio stays close to 1, but if a repair mutant 
is highly sensitive to one type of radiation, this ratio would increase drastically. In the next 
chapters different DNA repair mutants were analyzed. 
 
 
Figure  3.2 Plating efficiencies of not irradiated control cells of the different CHO cell lines seeded as 
part of the clonogenic survival assay. CHO cells from exponentially growing cell cultures and from 
plateau phase, growth arrested cell cultures. Data is shown as mean ± SD, n > 3. 
 3.1 Results - Chinese hamster cell line system 
65 
 
3.1.2 Proliferative activity of wild type and different DNA double strand break 
repair mutant cell lines 
The following three chapters will focus on DNA double strand break repair. DNA DSBs are 
the most severe lesions induced by IR, leading directly to cell death if not repaired properly. 
We investigated the two main repair pathways, homologous recombination (HR) and non-
homologous end joining (NHEJ). As fast initial test, if the cells respond differently to the two 
types of radiation, a proliferation assay was performed as described earlier. The different cell 
lines were treated with increasing doses of proton or photon radiation (0, 2, 5, 8 Gy). 
For all cell lines the non-irradiated controls had the same growth rate irrespective of being in 
the photon or proton experimental arm (Fig. 3.3) with NHEJ-deficient cells proliferating as 
fast as wild type cells (Fig. 3.3C+D).  The non-irradiated HR-deficient Irs1sf cells showed a 
one third slower growth rate compared to the corresponding wild type AA8 cell line (Fig. 
3.3A+B). 116 hours after 2 Gy of either type of radiation the proliferative activity of both wild 
type cell lines decreased by only 5-10% (Fig. 3.3A+C). As expected, the proliferative activity 
of the two DSB repair mutants dropped to 40 – 60% after 2 Gy (Fig. 3.3B+D). HR-/- cells 
revealed no difference in growth inhibition between the two types of radiation, whereas the 
NHEJ-/- cells displayed a significant stronger growth inhibition after 2 Gy of proton compared 
to photon irradiation. With higher doses this difference seen with NHEJ-/- cells was not 
visible any more, as proliferation dropped under 10% (Fig. 3.3B+D). For wild type cells higher 
proton radiation exposures (5, 8 Gy) led also to a stronger growth inhibition compared to 
photon radiation, which was significant at 8 Gy in CHO9 wild type cells (Fig. 3.3A+C). 
From these proliferation experiments, we demonstrated greater sensitivity to photon and 
proton radiation by both HR-/- and NHEJ-/- cells as compared to wild type cells. However, 
4.5 days after irradiation exposure with higher doses of protons (5, 8 Gy), fewer wild type 
cells were metabolically active compared to those irradiated with photons, indicating a 
stronger efficacy in cell killing by proton irradiation with the PSI spot scanning beam. HR-
defective cells were dose-dependently growth-inhibited with no difference regarding the two 
types of radiation. As expected, NHEJ-deficient cells were the most radiosensitive cells (291). 
Interestingly, these cells exhibited a differential response to proton versus photon irradiation, 
with greater growth inhibition after low dose (2 Gy) proton irradiation as compared to photon 
irradiation. 
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Figure  3.3 Cell proliferation of different CHO cell lines. Cells were irradiated with increasing doses of 
photons and protons. Proliferative activity at 66, 90, and 116 hours after irradiation and % proliferative 
activity relative to control after 116 hours are plotted. (A) AA8 wild type cells, (B) HR-deficient Irs1sf 
(XRCC3-/-) cells (mutant of AA8) (C) CHO9 wild type cells, D) NHEJ-deficient XR-C1 (DNA-PKcs-/-) 
cells (mutant of CHO9). Data points represent mean ± SD or bars represent mean ± SEM; n > 3; 
*P<0.05. 
 
3.1.3 Clonogenic survival of logarithmically growing wild type and DSB 
repair mutant cell lines 
Measuring proliferation can mask real cell survival, since a few surviving, well-proliferating 
cells may give a strong signal. In contrast, a clonogenic survival assay assesses the potential 
of each single cell to grow into a colony consisting of at least 50 cells. This cell has to repair 
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all damages before it is able to divide at least for another 5-6 generations. Therefore the 
colony formation assay (clonogenic assay) is a more accurate measurement of cell survival. 
In this experiment exponentially growing cells were irradiated, and on the following day cells 
were harvested, counted, and plated for the clonogenic survival assay. At the time of 
irradiation, the cell cycle distribution was equal in all samples (Fig. 3.4, logarithmically 
growing cells). The diverse DSB repair mechanisms show differential activity patterns during 
the course of the cell cycle. Our interest was to investigate all repair mechanisms. Therefore 
exponential growth and not G1-arrested conditions were chosen. We assume that 
aggressively proliferating cancer cells exhibit all cell cycle phases. Fast-proliferating CHO 
cells resemble such a condition. 
 
 
Figure  3.4 Cell cycle distributions at the time point of irradiation in proliferating and plateau phase, 
growth-arrested AA8 and CHO9-wild type and Irs1sf- and XR-C1-mutated CHO cell lines. 
 
In AA8-CHO wild type cells irradiation with protons decreased cell survival by 1.1 ± 0.1 and 
1.8 ± 0.2 fold at 2 and 5 Gy, respectively, when compared to photon irradiated cells (Fig. 
3.5A). Similar results were obtained with a second CHO-wild type cell line (CHO9, Fig. 3.5B). 
The HR-corrupted daughter cell line Irs1sf, which lacks the RecA/Rad51-related protein 
family XRCC3, was more sensitive to both types of irradiation than the corresponding AA8-
wild type cell line (Fig. 3.5A). In contrast to the proliferation results, the HR-deficient cells 
were also more proton-sensitive, but interestingly to a significantly much stronger extent than 
the wild type cells, especially at higher dosages (approx. 8 fold and 30 fold more sensitive 
than wild type in response to proton and photon irradiation, respectively, at 5Gy). The dose-
modifying factor at 50% survival for wild type vs. HR-deficient cells after proton irradiation 
and photon irradiation was 3.44 and 2.66, respectively, which again demonstrated the 
specifically enhanced sensitivity of HR-deficient cells to proton irradiation. 
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Figure  3.5 Clonogenic cell survival of proton and photon irradiated CHO cell lines. Cells were 
irradiated in exponential growth phase. Survival data and corresponding ratios of SFwild 
type/SFmutant are plotted. (A) AA8 wild type cells and corresponding HR-deficient Irs1sf (XRCC3-/-) 
cells; (B) CHO9 wild type cells and corresponding NHEJ-deficient XR-C1 (DNA-PKcs-/-) cells. Data 
points represent mean ± SD or bars represent mean ± SEM; n > 3; *P<0.05. 
 
The NHEJ-corrupted CHO cells (XR-C1, DNA-PKcs-/-), were even more sensitive than the 
HR-deficient cells to photon irradiation (CHO9) (Fig. 3.5B), and both the wild type mother cell 
line (CHO9) and NHEJ-deficient deficient daughter cell line were relatively more sensitive to 
proton irradiation. However, we could not detect an even further increased sensitivity towards 
proton irradiation in the NHEJ-deficient cell line compared to wild type cells as observed in 
the HR-deficient cells ((SFwild type/SFmutant)photon vs. (SFwild type/SFmutant)proton). This is also shown 
in representative plates of a clonogenic assay performed with wild type and NHEJ-deficient 
cells (Fig. 3.6). The more pronounced proton radiosensitivity of HR-deficient cells compared 
to NHEJ-deficient cells is undermined by RBE-calculations at 10% survival level with a value 
of 1.44 for HR-deficient cells, whereas NHEJ-deficient cells revealed an even lower value 
than the wild type cells (1.09 and 1.25, respectively).  
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Figure  3.6 Representative pictures of surviving clones from clonogenic assays. Examples from 
logarithmically growing and growth-arrest survival assays with CHO9 wild type and corresponding 
NHEJ-deficient XR-C1 (DNA-PKcs-/-) cells, (Log=logarithmic). 
 
 
3.1.4 Clonogenic survival of wild type and DSB repair mutant cell lines in 
plateau phase  
Homologous recombination requires an intact sister chromatid and is therefore only active 
during S and G2 phase of the cell cycle (328). Thus confluent (plateau) cells, which are 
arrested in G0/G1-phase of the cell cycle, primarily depend on NHEJ for efficient DNA DSB 
repair. Wild type, HR-deficient, and NHEJ-deficient CHO cells were grown to confluency and 
clonogenic survival was determined in response to proton and photon irradiation (Fig. 3.4 cell 
cycle distribution of plateau-phase cells). Interestingly the differentially enhanced sensitivity 
of HR-deficient cells to proton irradiation was no longer observed, supporting a critical role of 
HR for proton irradiation but only in proliferating cells (Fig. 3.7A). Overall HR-deficient cells 
became more radioresistant. However, they did not reach wild type survival levels. NHEJ and 
potentially lethal damage repair (PLDR) can cope with more DNA damages in non-
proliferating cells, but not all damages can be repaired so that HR-defective cells are still 
more radiosensitive than wild type cells. In wild type cells parts of the DSBs might be 
transferred to S phase and repaired with the help of HR. 
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Figure  3.7 Clonogenic cell survival of proton and photon irradiated CHO cell lines. Cells were 
irradiated in plateau, growth-arrested phase. Survival data and corresponding ratios of SFwild 
type/SFmutant are plotted. (A) AA8 wild type cells and corresponding HR-deficient Irs1sf (XRCC3-/-) 
cells; (B) CHO9 wild type cells and corresponding NHEJ-deficient XR-C1 (DNA-PKcs-/-) cells. Data 
points represent mean ± SD or bars represent mean ± SEM; n > 3; *P<0.05. 
 
In contrast, as expected NHEJ-deficient XR-C1 cells were drastically more radiosensitive in 
plateau phase, as the main repair pathway of G1 phase is missing in those cells. They also 
became significantly more sensitive to proton irradiation in plateau phase (NHEJ cells 
showed a 11 fold and 28 fold increased sensitivity towards proton vs. photon irradiation when 
irradiated in logarithmic or growth arrested phase, respectively at 2 Gy; Fig. 3.5B+3.7B). 
These experiments demonstrate increased sensitivity of HR-deficient cells to proton 
irradiation only when cells are proliferating in S and G2 phase and not in confluent/plateau 
phase cells. Plateau phase NHEJ-deficient cells were significantly hypersensitive to proton 
irradiation, indicating a requirement for NHEJ in repairing proton-induced DNA damage in 
this setting. However, one could also argue that perhaps via alternative repair pathways, part 
of the photon radiation-induced damage can be repaired in NHEJ-deficient plateau cells. In 
the case of proton-radiation exposure, the DNA damage might be more severe and 
alternative pathways cannot repair properly leading to this phenotype. 
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3.1.5 Single strand break repair and base excision repair mutant cell line 
We have limited insight on the role of base excision and single strand break repair (BER and 
SSBR) after proton radiation exposure. In general it is assumed that 105 ionizations, > 1000 
base damages, ~ 1000 single-strand breaks, and ~ 20-40 double-strand breaks are 
generated/cell after exposure to 1 Gy (4). Therefore, besides DSB repair, these two repair 
pathways are important for the survival of a cell after exposure to ionizing radiation (109). 
SSBR uses mainly the same enzyme system as BER. We performed experiments with a cell 
line that lacks XRCC1, which is involved in both pathways. By using this cell line the 
importance of both systems was tested together. 
 
 
Figure  3.8 Response of BER-deficient Em-c11 cells (XRCC1-/-) to photon and proton irradiation. Cells 
were irradiated and (A) cell proliferation and (B, C) clonogenic cell survival (also for CHO9 wild type 
cells) was determined. In (A) proliferative activity at 66, 90, and 116 hours after irradiation and % 
proliferative activity relative to control after 116 hours are plotted. In (B) for exponentially growing and 
(C) for plateau, growth-arrested cells survival data and corresponding ratios of SFwild type/SFmutant 
are plotted. Data points represent mean ± SD or bars represent mean ± SEM; n > 3; *P<0.05, 
**P<0.01. 
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Cell proliferation of Em-c11 (XRCC1-/-) was not significantly different between 2 Gy of 
photon vs. proton irradiation, but 5 and 8 Gy of proton irradiation inhibited cell proliferation 
significantly stronger in comparison to photon radiation exposure (Fig. 3.8A). On the level of 
clonogenic survival, XRCC1-mutant cells were 2.7 or 5.2 fold more sensitive compared to 
wild type cells (CHO9) after 5 Gy of photon or proton radiation, respectively, in logarithmic 
growth phase (Fig. 3.8B). Proton irradiation more efficiently induced cell death in these cells 
at higher doses. Upon irradiation in plateau phase the PLDR effect did not occur. XRCC1-
deficient cells showed no increased radioresistance like HR-deficient and both wild type cells. 
Also plateau irradiated mutant cells were significantly more sensitive to proton irradiation 
than to photon irradiation (Fig. 3.8C). If cells are irradiated in growth-arrested phase, without 
proliferation stress and with more time to repair damages, does not help to increase cell 
survival in the case of a XRCC1-mutant cell. The repair of base damages and single strand 
breaks seems to depend on XRCC1, regardless of the cell cycle or growth stage. 
In our hands XRCC1-deficient hamster cells are significantly more sensitive to proton than to 
photon irradiation at higher doses. Either more initial damages are produced by protons or 
more damage clusters are generated with increasing doses. If a SSB situated close to a DSB 
stays un-repaired, then the DSB repair machinery might have severe problems. Even though 
this experiment demonstrates that single strand breaks/base damages also play a role with 
regard to a differential sensitivity to proton vs. photon irradiation, we focused on DNA double 
strand break repair. 
 
3.1.6 Initial amount of DNA double strand breaks 
A reason for the better effectiveness of protons could be an increase in initial DNA DSBs 
after proton irradiation. Another possibility is that not more DSBs are induced but more 
complex ones. To be able to interpret the differential sensitivity on the level of clonogenic 
survival, the initial amount of DNA DSBs was determined via γH2AX and 53BP1-foci 
quantification. 
Cells were irradiated with 1 Gy of protons or photons and fixed 12 minutes after irradiation. 
This time point was chosen, as in preliminary experiments much fewer γH2AX foci were 
visible in the wild type cells at 30 minutes than at 12 minutes. Partial repair was already 
completed 30 minutes after irradiation. Furthermore with 1 Gy almost no overlay of foci 
appeared and it was possible to count foci more accurately. γH2AX foci were quantified in 
AA8, CHO9, Irs1sf, and XR-C1 cells and showed no difference between the different cell 
lines and between both types of radiation (Fig. 3.9A). In a later experiment 53BP1 foci were 
stained. 53BP1 foci can be used as a marker for ongoing DSB repair and have been used by 
others as a surrogate marker for DSBs, as it is abundant at most of the breaks (329). The 
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maximal foci formation was reported to appear 30 minutes after irradiation (224). 30 minutes 
after 5 Gy the quantification of foci numbers exhibited as well no significant difference for 
both types of radiation (Fig. 3.9B). A dose of 5 Gy was used because the overall amount of 
53BP1 foci was rather sparse in CHO cells. The maximal amount of 53BP1 foci at 30 min 
after 5 Gy was only about one third of the amount of γH2AX foci (AA8 cells: after 5 Gy 30 
γH2AX foci vs. 11 53BP1 foci). γH2AX foci were also quantified 30 minutes after 5 Gy of 
either radiation type, which revealed no differences in AA8 wild type cells with regard to DSB 
induction. 
 
Figure  3.9 Quantification of the initial amount of foci in AA8- and CHO9 wild type and Irs1sf- and XR-
C1-mutant cells. (A) γH2AX-foci 12 min after irradiation with 1 Gy (n=5). (B) 53BP1-foci 30 min after 
irradiation with 5Gy (n=3). Data is shown as mean ± SD. 
 
The initial amount of DNA DSBs is equal, regardless of which type of radiation is used. This 
suggests that the lower survival rate after proton irradiation is not due an increase in initial 
DSBs. 
 
3.1.7 Cell cycle distribution after photon and proton irradiation 
Carbon and iron ions or low energy protons are densely ionizing particles, inducing a more 
pronounced G2 arrest (330). More severe clustered damage might lead to this prolonged 
arrest in G2 phase. Depending on the damage complexity and quantity, the duration of the 
G2 arrest can vary. Therefore we checked the cell cycle distribution at 6, 12, and 24 hours 
after 5 Gy of each type of radiation. 
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A G1 phase arrest was not detected in CHO cells. With propidium iodide stainings we solely 
observed a G2 arrest after low-LET proton irradiation (Fig. 3.10A+B). This was made visible 
through the relative increase in the amount of G2 phase cells when compared to non-
irradiated samples (striped part in Fig.3.10A). The arrest was relatively mild. Only 40-55% of 
the wild type cells arrested in G2 after 6h after 5 Gy, which indicates further checkpoint 
defects. Cell cycle distributions of both wild type cell lines were back to control level 24 hours 
after irradiation, and no significant difference after proton and photon irradiation was  
 
 
Figure  3.10 Cell cycle distributions of AA8- and CHO9-wild type and Irs1sf- and XR-C1-mutant cells at 
6, 12, and 24 hours after irradiation with 5 Gy. (A) Percentage of cells in G1/S/G2-M-phase. (B) 
Percentage of cells in G2 phase. Data are shown as mean ± SD, n > 3. 
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observed. A defective intra-S phase checkpoint has been reported for Irs1sf (XRCC3-/-) cells 
(331). In this case, cells progress through S phase even if they were irradiated because of 
the lack of proper checkpoint responses and might produce highly mis-repaired DNA-
intermediates. Accordingly, 6 hours after irradiation no increase or decrease in the 
percentage of S phase cells was observed, which rather indicates a continued progression 
through S phase (Fig. 3.10A). Sole staining with propidium iodide is not sensitive enough. To 
differentiate between active or arrested S phase cells one would need to measure 
additionally the active incorporation of base analogues (e.g. BrdU). The G2 arrest in HR-/- 
cells was very mild, which indicates as well severe check point defects. We would expect for 
these cells to show a strong G2 arrest due to their repair defect. NHEJ-deficient cells 
exhibited the strongest G2 arrest with 60% of the cells in G2 phase at 12 hours after 
irradiation (Fig. 3.10B), and they still exhibit some arrested cells 24 hours after treatment. 
However, in the case of both repair defective cell lines and both wild type cell lines no 
significant difference in cell cycle distributions was detected with regard to which type of 
radiation was administered. 
 
3.1.8 Clonogenic survival of XRCC3-complemented cells 
The initial amount of DSBs is equal after both types of radiation. Therefore the increased 
radiosensitivity of XRCC3-deficient cells to proton irradiation is rather due to repair problems 
than to an increased initial DNA damage burden after proton in comparison to photon 
radiation. To verify our finding that HR-deficiency leads to increased proton radiosensitivity, 
we used a XRCC3-complemented cell line stably expressing the human wild type XRCC3 
gene (170). The 1SFK8 transfectant is a clone selected for expression of XRCC3, which 
revealed substantial complementation to IR (60%) (170). 
In this experiment AA8 wild type cells from M. Löbrich were used as control cells and the 
Irs1sf/1SFK8 cell pair from Larry H. Thompson was used to check the relationship of HR-
deficiency and proton radiation sensitivity. For this second Irs1sf cell line, the increased 
sensitivity of XRCC3-deficient cells to protons was also demonstrated (Fig. 3.11A). Due to 
XRCC3 complementation, 1SFK8 cells showed an increased radioresistance compared to 
Irs1sf cells. But as shown by Yamada et al. they were not fully complemented, as they did 
not reach the survival level of AA8 wild type cells (Fig. 3.11B). At lower doses, 2 and 3 Gy, 
the higher sensitivity to proton radiation was no longer seen (1.8 fold and 3.6 fold more 
sensitive to proton vs. photon irradiation, for 1SFK8 and Irs1sf, respectively at 2 Gy). At 5 Gy 
the complemented cells were more sensitive to proton than to photon radiation. However, the 
increased sensitivity to proton radiation was less pronounced than in the case of Irs1sf cells. 
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Complementation with the human XRCC3 gene renders the Irs1sf cells only 60% more 
radioresistant. It seems that the accurate activity of XRCC3 requires a fine expression 
balance where a very high or very low level of XRCC3 did not complement certain 
sensitivities (170). Reasons for incomplete complementation might be a loss of  
 
 
Figure  3.11 Clonogenic cell survival of proton and photon irradiated CHO cell lines. Cells were 
irradiated in exponential growth phase. Survival data and corresponding ratios of SFwild 
type/SFmutant are plotted. (A) AA8 wild type cells and corresponding HR-deficient Irs1sf (XRCC3-/-) 
cells; (B) AA8 wild type cells and corresponding XRCC3-complemented 1SFK8 (XRCC3+/+) cells. 
Data points represent mean ± SD or bars represent mean ± SEM; n > 3; *P<0.05. 
 
the expression vector in some cells or the unphysiologic XRCC3 expression levels in 
different cells leading to differential responses. Therefore we might reveal at high doses (5 
Gy) for 1SFK8 cells an increased sensitivity towards proton radiation. However, the 
sensitivity towards proton radiation was lower than in the case of Irs1sf cells. In general we 
could demonstrate that XRCC3 complementation reduced the increased proton 
radiosensitivity of Irs1sf cells, which is another proof that the lack of XRCC3 and 
consequently of HR leads to the superior sensitivity towards proton versus photon irradiation. 
 
3.1.9 Clonogenic survival of Rad51-silenced wild type cells 
A third approach to detect the specificity of the HR-defect and increased sensitivity to proton 
radiation was by down-regulating an important HR-protein in AA8 wild type cells. As the CHO 
mutants are generated by chemical mutagenesis, they harbour often other mutations beside 
the described one (324). If other mutations beside XRCC3-deficiency were the reason for the 
increased sensitivity to proton exposure, the effect would not be detected in HR-silenced 
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AA8 cells or would be mild. Unfortunately the whole genome of the Chinese hamster (C. 
griseus) has not been sequenced so far, and there is no information on the mRNA sequence 
of XRCC3. It was not possible to design a specific siRNA against hamster XRCC3. As a 
substitute Rad51, the major and essential strand transferase for HR, was chosen (138). Two 
different specific siRNAs against Rad51 were used. 
 
 
Figure  3.12 Clonogenic survival of AA8 wild type cells. Cells were irradiated in exponential growth 
phase. Survival data and corresponding ratios of SFwildtype/SFmutant are plotted. (A) Survival of AA8 
wild type cells treated with siLuc and siRad51. (B) Down-regulation of the Rad51 protein level 
validated by western blot. (C) Plating efficiency of siLuc and siRad51-treated control cells. In (A) and 
(C) siRad51-1 and siRad51-2 data were pooled. Data points represent mean ± SD or bars represent 
mean ± SEM, n = 2, *P<0.05. 
 
Down-regulation of Rad51 was detectable up to 96 hours after transfection (Fig. 3.12B). 
Hence Rad51 was silenced for at least another two days after radiation exposure, which was 
sufficient to result in a strong decrease in clonogenic survival (6 fold at 5 Gy of photons, Fig. 
3.12A). Two different siRNAs were used separately during the same experiments, and data 
were pooled for analysis. Both resulted exactly in the same survival levels. Rad51 depleted 
cells showed also superior sensitivity towards proton exposure in comparison to siLuciferase 
treated control cells (Fig. 3.12A). Surprisingly plating efficiency was not strongly reduced 
(90%; Fig. 3.12C) in siRad51-treated AA8 cells, in contrast to the Irs1sf mutant cells (~55%). 
The data demonstrate that Rad51 is highly needed for efficient cell survival during the first 48 
hours after radiation exposure in proliferating cells. During this time period HR is essential to 
repair parts of the DSBs after both photon and proton radiation exposure. In HR-deficient 
cells, other repair pathways will most probably try to repair the damage, and grossly mis-
repaired or non-repaired damage will lead to cell death. This cannot be compensated by the 
re-expression of Rad51 at later time points. Furthermore, cells lacking Rad51 are 
significantly more sensitive to proton exposure than to photon exposure, demonstrating 
another time the importance of HR in proliferating proton exposed cells.  
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3.1.10 DNA repair kinetics 
Irradiation of CHO cells with protons leads to a significantly stronger cell killing compared to 
photon irradiation at equal doses of each radiation type. Furthermore we observed that HR-
deficient cells are much more sensitive to proton irradiation than the corresponding wild type 
cells or complemented cells. Quantification of the initial amount of γH2AX foci and 53BP1 
foci exhibited equal initial amounts of DNA DSBs. Furthermore proton as well as photon 
irradiated cells revealed equal percentages of cells arrested in G2 phase. These results point 
to more complex DNA damage generation by proton exposure, which is most probably more 
difficult to repair. To detect possible repair problems due to a different damage complexity 
after proton exposure, we followed the induction and removal of DNA repair foci. DNA repair 
proteins are recruited to the DNA damage site or proteins at the damage site are modified, 
which appear as discrete foci in immunofluorescence microscopy. Differential repair kinetics 
can reveal problems of a certain pathway to repair the induced DNA damages. In the 
following sections, the kinetics of different DNA repair pathways were analyzed. We decided 
not to compare equipotent doses with regards to cell killing but equal physical doses, which 
induced the same amount of γH2AX foci and consequently the same amount of DSBs. Our 
assumption is that with equipotent doses the initial amount of γH2AX foci and thus DSBs 
would be completely different. Different amounts of DSBs can induce differentially strong 
stress responses, making it difficult to compare different conditions (332). 
 
3.1.10.1 γH2AX repair kinetics 
Hundreds to thousands of H2AX molecules become rapidly phosphorylated by the three 
kinases, ATM, ATR, and pDNA-PKcs at each nascent DNA DSB (98). Phosphorylated H2AX, 
named γH2AX, is used as a marker for DNA damage, especially for DSBs. γH2AX foci 
disappearance is a marker for general progression of DSB repair (333). Long lasting γH2AX 
foci stand for damage sites that are difficult to repair or that are not repaired at all (334). If 
proton radiation produces a severely more complex DNA damage, the removal of γH2AX foci 
could be hampered. 
Removal of γH2AX foci was determined over 24 hours in the different cell lines in response 
to 1 Gy of ionizing radiation. Repair kinetics were similar in both wild type cell lines in 
response to proton and photon irradiation. Over 50% of γH2AX foci were removed in an 
initial fast repair phase of 3 hours (Fig. 3.13). γH2AX foci removal was delayed in both 
mutant cell lines, with only 20 – 30% of γH2AX foci reduction during this initial time period. 
Delayed disappearance of γH2AX foci was only prominent in the HR-deficient cells in 
response to proton-irradiation (80% vs. 70% residual γH2AX-foci at the 3h time point in 
response to proton vs. photon irradiation). The amount of residual γH2AX foci 24 hours after 
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irradiation was also highest in the HR-corrupted cell line in response to proton-irradiation 
(45% vs. 27% residual γH2AX foci after proton vs. photon irradiation, respectively) (Fig. 3.13). 
Cell cycle analysis at 6, 12 and 24 h after irradiation displayed no difference in cell cycle 
distribution for the HR-mutated cells in response to 5 Gy of the two types of radiation (Fig. 
3.10). Using a low dose of 1 Gy excludes that cell cycle differences are the cause for this 
finding.  
 
 
Figure  3.13 Quantification of residual γH2AX foci 3, 6, and 24 hours after proton and photon 
irradiation with 1 Gy in AA8- and CHO9- wild type and Irs1sf- and XR-C1-mutated cells. Initial amount 
of foci is set as 1; the dotted line indicates the background level of γH2AX foci in not irradiated cells. 
Data points represent mean ± SEM; n = 3; *P<0.05. 
 
 
In a later experiment, HR-deficient cells and wild type cells were irradiated with 5 Gy. Thirty 
minutes after irradiation of the wild type cells, the initial amount of γH2AX foci was also equal 
for both types of radiation (Fig 3.14A). Foci disappeared with the same kinetics when 
compared to the 1 Gy results and were not different between the two types of radiation. 
XRCC3-deficient cells revealed significantly more residual foci vs. the wild type cells at 3, 6, 
and 12 hours for both types of IR (Fig. 3.14B), and at this high dose proton-generated 
residual γH2AX foci became only significantly different 12 hours after irradiation from photon 
irradiated samples. This can be seen in the microscopy pictures (Fig. 3.14D). These results 
on the level of residual γH2AX foci correlate with enhanced sensitivity of HR-mutated cells to 
proton-based irradiation. 
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Figure  3.14 Quantification of initial and residual γH2AX foci 0.5, 1, 3, 6, 12, and 24 hours after proton 
and photon irradiation with 5 Gy. (A) Kinetic of γH2AX foci formation and disappearance in AA8 wild 
type cells. (B) γH2AX foci amount in AA8 wild type and HR-deficient Irs1sf (XRCC3-/-) cells. 
Representative immunofluorescence pictures of (C) AA8 wild type and (D) HR-deficient cells with 
γH2AX-foci and Dapi-stained nuclei 6h and 12h after irradiation (5 Gy). Data points represent mean ± 
SEM. n=3; *P=0.05. 
 
Comparing the kinetics of γH2AX foci disappearance in NHEJ-mutated and wild type 
counterpart cells, overall DNA damage repair in NHEJ-mutated cells was also delayed, but 
no difference in the repair kinetics in response to the two types of irradiation was observed 
(Fig. 3.13). The low level of residual γH2AX foci at 24 hours in these otherwise highly 
radiosensitive cells is due to the fact that γH2AX foci could only be counted in cells with 
intact nuclei, but nuclear cell death-related fragmentation in these cells already started prior 
to the 24 hour time point. 
γH2AX repair kinetics are equal after both types of radiation in wild type cells, indicating that 
the repair does not seem to be more hampered in the proton-irradiated wild type cells. NHEJ-
deficient cells also showed equal but slower repair kinetics after both types of IR. In contrast, 
HR-deficient cells revealed significantly slower repair kinetics after 1 Gy of proton radiation 
vs. photon radiation. After 5 Gy photon irradiated samples also showed a longer foci half life, 
indicating the huge damage burden after higher doses. However, 12 hours after 5 Gy, HR-
deficient cells showed more residual foci in the proton vs. photon irradiated samples. This 
slower γH2AX foci removal or more prominent residual amount of DSBs at 12 hours after 
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proton irradiation correlates with the enhanced sensitivity of HR-mutated cells to proton-
based irradiation. 
 
3.1.10.2 Rad51 foci repair kinetics 
So far we demonstrated that HR-defective cells have more problems to repair proton-
generated DSBs. In the wild type setting it is not possible to rule out whether certain repair 
pathways have more problems to repair proton-induced DNA damages. To have a closer 
look on specific repair pathways, we probed for the following different DNA repair 
proteins/mediators: Rad51, 53BP1, and pDNA-PKcs. The dose of 5 Gy was chosen due to 
the strong effect seen in the clonogenic assay. Furthermore the actual amount of Rad51 foci 
was very low at lower doses like 1 Gy and almost impossible to count. 
The Rad51 protein is required for strand invasion during homologous recombination (335). 
The differences in clonogenic survival and γH2AX repair kinetics point to the importance of 
HR to repair a fraction of proton-induced DSBs. Therefore the kinetics of this repair pathway 
was followed, which might show more induced Rad51 foci after proton exposure. 
 
 
Figure  3.15 Quantification of initial and residual Rad51 foci 0, 0.5, 1, 3, 6, and 12 hours after proton 
and photon irradiation with 5 Gy in AA8- and CHO9- wild type and Irs1sf- and XR-C1-mutated cells. 
Data points represent mean ± SEM; n = 3; *P<0.05. 
 
The amount of ionizing radiation-induced Rad51-foci was highest in both wild type cell lines 1 
hour following irradiation and returned to basal levels 10 hours following both types of 
irradiation (Fig. 3.15). In the XRCC3-mutated HR-corrupted Irsf1sf cell line, a slight increase 
of Rad51-foci at 3 and 6 hours after irradiation was observed in response to both types of 
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irradiation, indicating that lack of the Rad51-downstream resolvase XRCC3 also affects 
correct Rad51-foci formation, as also observed by others (164, 173). Interestingly the amount 
of Rad51-foci formed in the NHEJ-corrupted cells in response to both types of irradiation 
almost tripled in comparison to the amount of Rad51 foci induced in wild type cells, 
demonstrating compensation for the lack of the competitive NHEJ-DNA-repair machinery in 
these cells (Fig. 3.15) (336). Of note the amount of Rad51 foci remained high for a much 
longer time period in these cells, indicating a very slow HR-dependent DSB repair capacity in 
the absence of NHEJ. The amount of cells with over 20 Rad51 foci was significantly higher in 
the NHEJ-mutant cells compared to the wild type cells at all time points (Fig.3.15). Pictures 
of nuclei with Rad51 foci illustrate as well the tremendous increase of Rad51 foci in NHEJ-
mutant cells compared to wild type cells (Fig. 3.16). The size of early formed Rad51 foci was 
small at 0.5 and 1 hour after treatment, whereas Rad51 foci at 6 and 12 hours after 
irradiation increased to 4 times the size of the early ones, indicating extensive resection and 
therefore foci growth in NHEJ-mutant cells (Fig. 3.16).  
 
Figure  3.16 Representative immunofluorescence pictures for Rad51 foci formation in (A) CHO9 wild 
type cells and (B) NHEJ-deficient XR-C1 (DNA-PKcs-/-) cells 0, 1, and 6 hours after photon and 
proton irradiation with 5 Gy. Cells were stained for Rad51 and Dapi indicates nuclei. Scale bar 
represents 10 µm. 
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In the case of wild type cells where all DSB repair pathways are intact, we revealed no 
difference in Rad51 foci kinetics following either type of radiation. Even though NHEJ-
deficient cells displayed overall more Rad51 foci, also no significant difference between the 
two radiation types could be detected. 
 
 
3.1.10.3 p53-binding protein 1 foci repair kinetics 
53BP1 is involved in DNA DSB repair and promotes ATM-dependent repair of DSBs located 
in heterochromatic areas (227). 53BP1 colocalizes with Mre11/NBS and γH2AX foci, but its 
foci formation after exposure to IR is not dependent on ATM, NBS or wild type p53 (224). 
Several groups demonstrated that the maximal amount of 53BP1-foci is reached 30 minutes 
after irradiation (224). Furthermore it is in general believed that 53BP1 as a mediator for DSB 
repair is not involved in HR repair but supports NHEJ by suppressing ATM-dependent 
processing of broken DNA ends for HR in BRCA1-deficient cells (230). 
For both wild type cell lines and the HR-mutant cell line, maximal 53BP1-foci formation was 
detected 30 minutes after exposure. The kinetics of 53BP1 foci disappearance were equal 
for both types of radiation and back to control levels after 12 hours in the wild type cells (Fig 
3.17). This is also the case for the HR-mutant cell line, which shows only a slight delay in foci 
removal after 6h. 53BP1-dependent repair seems to have no problems with proton-
generated DNA damage and proceeds with the same speed in these cell lines. In all three 
cell lines the amount of 53BP1-positive cells (>1 53BP1-focus/cell) stayed high at ~ 90% until 
6 hours after exposure to IR but decreased to 30-40% at 12 hours (Fig. 3.18). NHEJ-mutant 
cells exhibited a delayed maximal of 53BP1 foci formation appearing at 3h after proton 
irradiation, which was significantly different from the photon irradiated time course (max at 1h; 
p<0.05) (Fig. 3.17). Overall 53BP1 stayed much longer at damage sites in the NHEJ-mutant 
cells and showed still >10 foci/cell at 12 hours after irradiation with over 80% 53BP1 foci 
positive cells (Fig. 3.17 + 3.18). This cell line had a stronger and prolonged G2 arrest than 
the other three cell lines, which might correlate with this finding. 53BP1 is involved as a 
mediator for NHEJ in G2 phase DSB repair but not in Rad51-dependent repair (53BP1 and 
Rad51-foci did not colocalize, data not shown) (230). 
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Figure  3.17 Quantification of initial and residual 53BP1 foci 0, 0.5, 1, 3, 6, and 12 hours after proton 
and photon irradiation with 5 Gy in AA8- and CHO9- wild type and Irs1sf- and XR-C1-mutated cells. 
Data points represent mean ± SEM; n = 3; *P<0.05. 
 
 
Figure  3.18 Amount of 53BP1 foci positive cells 0, 0.5, 1, 3, 6, and 12 hours after proton and photon 
irradiation with 5 Gy in AA8- and CHO9-wild type and Irs1sf- and XR-C1-mutant cells. Cells with more 
than 1 53BP1 focus were counted as positive. Representative values of one experiment. 
 
53BP1 foci formation and disappearance is the same in both wild type cells and HR-deficient 
cells, regardless which type of radiation is used. But formation is significantly different in 
NHEJ-deficient cells between the two types of IR, and foci removal is significantly slower 
when compared to the other 3 cell lines. 53BP1 appears to be an important mediator protein 
for DSB repair in DNA-PKcs-deficient cells. 
 3.1 Results - Chinese hamster cell line system 
85 
3.1.10.4 Phospho-DNA-Pkcs foci repair kinetics 
A additional marker to probe NHEJ at the damage site is to follow foci formation of 
phosphorylated DNA-PKcs (337). This analysis could only be performed for 2 cell lines, the 
HR-deficient and its corresponding wild type cell line. For heavy ion exposure it was reported 
that the classical NHEJ pathway has difficulties to cope with small fragmented DNA damages 
(337). 
In the AA8-wild type cell line a maximum of foci was detected 1 h after irradiation in response 
to both types of irradiation but to a reduced level in proton-irradiated cells (P=0.04; Fig. 
3.19A). Decay of pDNA-PKc foci was similar at the 3 h and 6 h time points and reached 
again basal levels at the 12 h time point. In the HR-mutated cell line a slight, but statistically 
not significant, increase in pDNA-PKcs foci was again observed in the photon irradiated cells 
1 hour after irradiation. Of note the amount of pDNA-PKc foci remained at a high level for an 
extended time period in these HR-deficient cells and in response to both types of irradiation, 
which correlates with the overall delayed kinetics of γH2AX-foci removal in these cells after 5 
Gy (see above Fig. 3.13). 
 
Figure  3.19 (A) Quantification of initial and residual pDNA-PKcs (S2056) foci 0, 0.5, 1, 3, 6, and 12 
hours after proton and photon irradiation with 5 Gy in AA8-wild type and Irs1sf-mutated cells. Data 
points represent mean ± SEM; n = 3; *P<0.05. (B) Representative immunofluorescence pictures for 
pDNA-PKcs foci formation in AA8- wild type cells 0, 1, and 3 hours after photon and proton irradiation 
with 5 Gy. Cells were stained for pDNA-PKcs and Dapi indicates nuclei. Scale bar represents 10 µm. 
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In the wild type cells formation of pDNA-PKcs foci after irradiation with protons appears to be 
less efficient than after irradiation with photons. Foci removal was equal and back to normal 
levels after 12 hours. pDNA-PKcs dependent repair appears to have difficulties in the HR-
defective cell line, as the amount of foci remains high until 12 hours after exposure. 
 
3.1.11 DNA damage response after both types of radiation 
We were interested to explore the overall DNA damage response after exposure to the two 
types of radiation. ATM is the primary mediator in the response to DSBs. 
Autophosphorylation of ATM at serine1981 occurs within seconds after exposure to ionizing 
radiation (338). Lysates at 15, 30, 60, 180, and 360 minutes after irradiation were analyzed 
(here we show only 30, 60, 180 min).  
Analysis of ATM-phosphorylation in lysates derived from proton and photon irradiated wild 
type and HR-deficient cells revealed equal kinetics after 5 Gy (Fig. 3.20). ATM was still 
phosphorylated at 60 minutes after IR exposure. After 180 minutes the signal was already 
strongly decreased. Phosphorylation of downstream targets such as Chk1 and Chk2 could 
not be detected with commercially available anti-human antibodies. The appearance of Chk2 
double bands was probed, which are due to hyperphosphorylation of the protein. The 
appearance of these Chk2 double bands was equal in response to both types of radiation 
with a maximal hyperphosphorylation at 180 min after irradiation (Fig. 3.20). However, in the 
HR-mutant cells the appearance and duration was less pronounced. Consequently, 
activation of the DNA damage response is equally fast after 5 Gy of either type of radiation. 
Unfortunately it was not possible to use an antibody specific for phosphorylation/activation of 
ATR, another important mediator of the DNA damage response (96). 
 
Figure  3.20 DNA damage response after photon and proton irradiation with 5 Gy. Western blot lysates 
were probed for different markers pATM, pDNA-PKcs, Chk2 and for actin as loading control. Lysates 
of (A) AA8 wild type and (B) HR-deficient Irs1sf (XRCC3-/-) cells were analyzed. Representative 
western blot of 3 experiments with each 3 blots. 
 
DNA-PKcs is a PI3K related kinase, which promotes DNA repair by phosphorylation of key 
proteins. Autophosphorylation at serine2056 leads to kinase activation after exposure to 
ionizing radiation (196). The duration and intensity of this phosphorylation was equal after 
proton and photon irradiation in both cell lines (Fig. 3.20). This is in contrast to pDNA-PKcs-
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foci formation, showing differential outcomes of overall phosphorylation status and the actual 
recruitment to active DNA repair loci (Fig. 3.20 + 3.19). Therefore it cannot be assumed that 
these two markers directly correlate with each other. 
In summary, the overall DNA damage response is equal after exposure to either type of 
radiation for both wild type and HR-deficient cells. 
 
3.1.12 Chromosomal aberrations 
Besides the differential maxima detected for pDNA-PKcs foci formation, the other endpoints 
probed so far revealed equal repair kinetics after both types of radiation in the wild type cells. 
Out of these time course studies, it is not possible to conclude if the repair was erroneous or 
accurate. The proton efficacy on the level of clonogenic survival could be due to a higher 
percentage of mis-repaired DNA damage after proton irradiation exposure. Therefore both 
wild type cells were processed for the analysis of chromosomal aberrations. Metaphase 
spreads of logarithmically growing wild type cells were prepared 24 hours after irradiation 
with 5 Gy. At this time point, cells irradiated in G1 phase should be the main population in the 
fixed metaphase cell population. A certain percentage of cells irradiated in G2 phase, which 
already passed twice through mitosis, can also exist. Or cells irradiated in S phase, which 
arrested for ~22 hours in the following G2 phase, can be abundant. The abundance of cells 
with sister unions indicates that part of the cell population was irradiated in S and G2 phase. 
Sister unions form when both sister chromatids harbour a DSB, which are later mis-repaired. 
Dicentrics arise during G1 phase from double strand breaks in two different pre-replication 
chromosomes and are subsequently erroneously connected. Rings arise during G1 from two 
DSBs in the different arms of a pre-replication chromosome. In both cases, fragments are 
generated as well. During S phase this fragment is duplicated, showing two equally sized 
fragments close to each other, and the duplication of the chromosome with the 2 
centromeres leads to the typical structure of a dicentric (Fig. 3.21C). Single fragments occur  
 
Tabelle  3.1 Aberration frequency (± SEM) 
  0 Gy Photon 5 Gy Photon 0 Gy Proton 5 Gy Proton 
Fragments 0.013±0.008 0.997±0.251 0 1.151±0.713 
Dicentrics 0 0.110±0.056 0 0.357±0.149 
Rings 0 0.037±0.023 0 0.088±0.024 AA
8 
Sister Unions 0 0.130±0.030 0 0.411±0.067 
  
0 Gy Photon 5 Gy Photon 0 Gy Proton 5 Gy Proton 
Fragments 0.007±0.008 0.639±0.202 0.040±0.000 1.270±0.310 
Dicentrics 0.013±0.008 0.113±0.021 0.007±0.008 0.147±0.014 
Rings 0 0.043±0.023 0 0.034±0.022 CH
O
9 
Sister Unions 0 0.073±0.028 0 0.136±0.035 
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when a DSB generated in G2 phase is not repaired at all. 
Quantification of fragments, dicentrics, rings and sister unions resulted in a 1.4 – 2.3 fold 
higher ratio of aberrations/cell after proton versus photon irradiation (Fig. 3.21B and Table 
3.1). The increased amount of aberrations and breaks after proton irradiation was not only 
due to the higher percentage of cells possessing aberrations, as the fold increase 
determined solely in cells harbouring at least one aberration was still 1.7±0.3 for AA8 cells 
and 1.2±0.2 for CHO9 cells (data not shown). Tests comparing whole aberration induction 
result in a significant difference between proton and photon irradiated samples for both wild 
type cell lines (Mann-Whitney Test; p<0.05). 
 
 
Figure  3.21 Quantification of different chromosome aberrations 24 hours after photon and proton 
irradiation with 5 Gy in AA8- and CHO9-wild type cells. (A) Total amount of fragments, dicentrics, rings, 
sister unions detected in 50 cells of a representative experiment. (B) Efficiency of proton-irradiation in 
aberration induction (ratio amount of aberration protons/amount of aberration photons). Data represent 
mean ± SD, n = 3. (C) Representative pictures of metaphase spreads for control and irradiated cells 
(aberrations indicated with white circles). 
 
These results suggest that the accuracy of DNA repair in proton-irradiated cells is lower than 
in photon irradiated cells most probably due to more complex proton-induced DNA damage. 
Protons induced significantly more DNA fragments and lethal aberrations such as sister  
unions, which most probably lead to the better effectiveness (RBE = 1.1) of proton vs. photon 
irradiation. 
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3.1.13 Clonogenic survival of additional homologous recombination 
mutant cell lines 
To confirm the significance of HR-deficiency and the increased sensitivity to proton vs. 
photon irradiation, two additional cell systems, which lack important proteins involved in HR 
repair, were probed for clonogenic survival in response to both types of irradiation. These 
two cell systems have been generated from hamster lung fibroblasts. 
Rad51c is a Rad51 paralog, which forms complexes with XRCC3 and XRCC2 and is 
involved in HR repair (339, 340). A hamster mutant cell line deficient in Rad51c protein (CL-
V4B cells) displayed a significantly higher sensitivity to proton radiation when compared to 
the corresponding wild type cells (V79B cells), at 3, 5 and 8 Gy (Fig. 3.22A). BRCA2 also 
plays an important role as mediator protein in homologous recombination. BRCA2 is required 
for the efficient formation of the Rad51 nucleofilaments (127). We therefore also tested a 
BRCA2-mutant cell pair. For this mutation significant differences were only detected at higher 
doses, 5 and 8 Gy (Fig. 3.22B). The plating efficiencies were not influenced by the 
experimental set up. For both wild type cells it was 100%, for Rad51c-mutants ~ 73% and for 
BRCA2-mutants ~ 50%. 
 
 
Figure  3.22 Clonogenic cell survival of proton and photon irradiated hamster lung fibroblasts. Cells 
were irradiated in exponential growth phase. Survival data and corresponding ratios of SFwild 
type/SFmutant are plotted. (A) V79B wild type cells and corresponding HR-deficient CL-V4B (Rad51c-
/-) cells. (B) V79 wild type cells and corresponding HR-deficient V-C8 (BRCA2-/-) cells. Data points 
represent mean ± SD or bars represent mean ± SEM; n > 4; *P<0.05. 
 
As all tested HR-mutant/wild type systems revealed a significant increase in the proton 
radiosensitivity of HR-deficient cells, HR repair is probably more important for proton-induced 
DNA damages than for photon-induced ones. Rad51c-deficient and BRCA2-deficient cells 
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display this effect only at doses starting from 3 or 5 Gy, respectively. Most probably this is 
due because these two proteins are not essential but promote homologous recombination. 
 
3.2 Human cell systems 
For clinical relevance of the data we aimed to verify our finding that HR-deficiency leads to a 
higher sensitivity towards proton irradiation in a human cell system. Because HR is essential 
during normal proliferation, very few human cell systems lacking functional HR are available. 
Those HR-defective cells grow very slowly and have a very low plating efficiency. These 
points make it difficult to study HR-deficiency in a human system. However, a widely used 
model cell line for all different kinds of DNA repair studies is a human osteosarcoma cell line 
(U2OS). The cell line expresses wild type p53 and RB, but is deficient in p16. U2OS-cells are 
derived from the bone tissue of a fifteen-year-old human female and established in 1964 (by 
Ponten and Saksela). These cells are very robust, easily treated with different siRNAs, and 
form colonies within 14 days. Therefore they were used for a siRNA screen in our 
experiments. 
BRCA2 mutations are found in human breast, ovarian, and prostate cancer patients (176, 
341, 342). In the last decade BRCA2 related studies revealed its mediator function for 
efficient HR. Isolated patient tumour cells deficient in BRCA2-/- became a nice model to 
study HR defects. Capan-1 is a human pancreas adenocarcinoma cell line, which harbours 
loss of heterozygosity (LOH) in one BRCA2 allele and a truncated form of BRCA2 in the 
second allele. Fortunately these cells are able to grow into clones (343). BxPC-3 is often 
used as a control cell line together with Capan-1 cells. It is a well differentiated pancreatic 
adenocarcinoma cell line, which matches the mutation status of a number of tumour 
suppressor genes with Capan-1 cells. Neither of the cell lines contains functional p53, p16, 
or RB (186).  
These two cell systems, U2OS and pancreas cells, were used in the second part of this 
study. 
 
3.2.1 U2OS osteosarcoma cells 
3.2.1.1 Clonogenic survival 
In order to investigate the relevance of HR, NHEJ, and BER for the treatment response to 
proton irradiation in a human setting, U2OS cells were treated with different siRNAs against 
Rad51, XRCC3, XRCC4, and XRCC1. 48 hours after transfection proliferating cells were 
irradiated and plated for clonogenic survival assays a day later.  
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HSP70B was used as a target for control siRNA, as the HSP70B isotype is not expressed in 
these cells (344). The sensitivity of U2OS control cells towards proton irradiation (1.49±0.1 
and 2.52±0.3 at 2 and 5 Gy; SFphoton/SFproton) was even higher than in CHO wild type 
cells (1.1±0.1 and 1.8±0.2 at 2 and 5 Gy; SFphoton/SFproton). Plating efficiency (PE) was 
60% for all siRNA treatments apart from treatment with siRad51, which resulted in a plating 
efficiency of 9%, and treatment with siXRCC1 resulted in a PE of 30% (Fig. 3.23). Treatment 
with Lipofectamine 2000 alone resulted in a reduction of cell proliferation compared to 
untreated cells, but the radiosensitivity was not affected (data not shown).  
 
 
 
Figure  3.23 Plating efficiencies of control cells from clonogenic survival assays with siRNA-treated 
U2OS cells. siRNA against HSP70B was used as control; siRad51 and siXRCC3 were used to down-
regulate HR, siXRCC1 to down-regulate BER, and siXRCC4 to down-regulate NHEJ. Data points 
represent mean ± SD, n > 3. 
 
Down-regulation of two different proteins involved in HR (Rad51 and XRCC3) revealed no 
increased sensitivity to proton radiation exposure compared to control cells (Fig. 3.24 A+B).  
However, silencing of the essential HR recombinase Rad51 resulted in a 6 fold 
radiosensitization after 5 Gy with photon or proton irradiation whereas siXRCC3 treated cells 
showed only a 2 fold radiosensitization (Fig. 3.24A+B, bar graphs). This result demonstrates 
the essential nature of Rad51 and the promoting function of XRCC3 for HR. There was 
nearly complete down-regulation of both proteins at the time point of irradiation as 
determined by western blotting (Fig. 3.24, right site, 48h point). We down-regulated as well 
XRCC1, due to our interesting finding of XRCC1-deficient CHO cells being significantly more 
sensitive to proton irradiation. Treatment with siXRCC1 resulted in a sensitization of 2.4 and  
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Figure  3.24 Clonogenic cell survival of U2OS cells treated with different siRNAs before exposure to 
photon and proton irradiation. Cells were irradiated in exponential growth phase. Survival data and 
corresponding ratios of SFcontrol/SFsilenced are plotted. Efficiency of protein down-regulation is 
shown by western blots. siHSP70B was used as irrelevant control siRNA in (A, B, C, and D). In (A) 
siRad51- (HR-/-) treated cells, in (B) siXRCC3- (HR-/-) treated cells, in (C) siXRCC1- (BER-/-) treated 
cells, and in (D) siXRCC4- (NHEJ-/-) treated cells were analyzed. Data points represent mean ± SD or 
bars represent mean ± SEM; n > 3. 
 
3.8 fold after 5 Gy of photon and proton irradiation, respectively, but revealed no enhanced 
sensitivity towards proton irradiation when compared to siHSP70B control (Fig. 3.24C). As a 
control we targeted as well an important NHEJ protein, XRCC4, which is an adapter protein 
involved at the NHEJ ligation step together with ligase IV. We achieved a radiosensitization 
of 2.1 and 3.2 fold at 5 Gy (for photon and proton irradiation respectively) but proton treated 
cells were not significantly more sensitive than control cells (Fig. 3.24D). 
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Due to increased complexity of the assay (transfection efficiency, plus several plating steps 
with the siRNA-transfected cells), the standard deviation in between the different clonogenic 
assays was elevated. However, all siRNA treatments resulted in the expected 
radiosensitization in response to photon irradiation. But proton radiation exposure led to the 
same degree of radiosensitization as photon radiation. Therefore we could not detect the 
hypersensitivity of HR-/BER-deficient cells towards proton radiation exposure in the U2OS 
background. With its p53 wild type status U2OS cells might show a different DNA damage 
response and a different hierarchy of the DNA double strand break repair mechanisms 
leading to this conflicting result. 
 
3.2.1.2 Initial amount of DNA double strand breaks 
The RBE10 for proton vs. photon irradiation at 10% survival level is 1.29±0.06 for U2OS cells. 
We quantified the initial amount of DNA DSBs by counting γH2AX foci and by measuring 
γH2AX fluorescence intensity with a flow cytometer. The aim was to determine if the 
enhanced cytotoxicity of proton radiation exposure is due to generation of more initial DNA 
DSBs by proton irradiation or not. 
The initial amount of γH2AX foci is ~ 30 foci/cell in U2OS cells instead of ~ 20 foci/cell in the 
case of CHO cells. This is due to more nuclear DNA content and the bigger nuclear size of 
human osteosarcoma cells. Twelve minutes after 1 Gy irradiation the amount of γH2AX foci 
was equal comparing both types of radiation (Fig. 3.25A). Flow cytometry revealed, for a 
higher dose (5 Gy), the same fold increase in γH2AX-fluorescence intensity following either 
type of radiation (Fig. 3.25B). The intensity was measured after 30 minutes, as more time is 
required to reach maximal phosphorylation of H2AX at higher doses. 
With two different approaches it was demonstrated that proton and photon irradiation 
generate equal amounts of initial DSBs. Therefore we speculate that the enhanced cell 
toxicity after proton irradiation is not due to an increased DSB induction. 
 
3.2.1.3 γH2AX repair kinetics 
Kinetics of DNA repair was only followed in normal non-transfected U2OS cells. As silencing 
of the different repair pathways did not result in a significant difference in proton 
radiosensitivity in comparison to control cells, repair kinetics were not expected to be 
different between the two types of radiation. 
The disappearance of γH2AX foci was followed after 1 Gy of either type of radiation. No 
difference was detected between the two radiation treatments. Similar to the repair kinetics of 
CHO wild type cells, repair followed a fast kinetic with only 21% of the DNA damage left 
unrepaired 6 hours after radiation exposure (Fig. 3.25C). It can be speculated whether 
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exposure to a higher dose would have shown a different γH2AX kinetic at later time points. 
However, cell lysates at different time points after irradiation with 5 Gy were probed by 
western blotting for γH2AX and revealed no difference between the two treatment modalities 
(Fig. 3.25D). Maximal phosphorylation of H2AX appeared after 10 minutes, and the strong 
γH2AX signal was already decreased after 2.5 hours. 
 
Figure  3.25 Quantification of initial and residual γH2AX foci 0.2, 3, 6, and 24 hours after proton and 
photon irradiation with 1 Gy in U2OS cells. (A) γH2AX foci amount after 12 min. (B) Quantification of 
the intensity of H2AX phosphorylation by flow cytometry 30 min after 5 Gy. (C) Kinetics of γH2AX foci 
after 1 Gy (initial amount of foci is set as 1). (D) Representative kinetic of H2AX phosphorylation from 
western blots with whole cell lysates after irradiation with 5 Gy. Data points represent mean ± SD; n>3. 
 
These experiments show that, similar to hamster cells, human cells also followed fast DSB 
repair kinetics, which was equal regardless of the radiation source. With very similar amounts 
of induced DSBs, this leads to the speculation that the DNA damage could be less accurately 
repaired after proton than after photon irradiation.  
 
3.2.1.4 Cell cycle analysis 
Cell cycle analysis was performed in non-transfected U2OS cells to determine why these 
cells respond differently to radiation in comparison to CHO cells. 
Twelve hours after irradiation, a dose dependent increase in the G2 cell population was 
identified for both types of radiation (Fig. 3.26A). Indeed, U2OS cells displayed a very strong 
G2 arrest, with over 80% of the cells in G2 phase 12 hours after irradiation (Fig. 3.26), 
whereas in the case of CHO wild type cells, only 40-50 % arrested in G2 phase 12 hours 
after radiation exposure (Fig. 3.10). Even after 24 hours ~ 60% of the cells stayed in G2 
phase, when wild type CHO cells showed already normal, recovered cell cycle distributions. 
For U2OS cells also no difference was detected with regard to photon and proton irradiation. 
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In summary, U2OS cells display a very prominent G2 arrest after either type of radiation 
exposure. Despite its positive p53-status, only a mild or no G1 arrest was detected after  
 
 
Figure  3.26 Cell cycle distribution of U2OS cells after photon and proton irradiation. (A) 
Representative histograms of an experiment with dose escalation 12 hours after irradiation. (B) 
Percentage of cells in G2 phase at 12 and 24 hours. (C) Percentage of cells in G1/S/G2-M phase at 
12 and 24 hours. Data points represent mean ± SD, n = 3. 
 
radiation exposure. When U2OS cells were irradiated with higher doses (5, 8 Gy), the G2 
arrest lasted in some cases 24 hours and even longer after radiation exposure. In contrast, 
CHO cells could already progress to mitosis at this time. Too early onset of cell cycle 
progression as with CHO cells can lead to transfer of improperly repaired or unrepaired DNA 
damage to mitosis. In that case breaks and other damages will be duplicated and might lead 
to severe chromosome damages. Due to intact cell cycle checkpoints, U2OS cells will arrest 
until all DNA damage is properly repaired, which will lead to fewer chromosomal aberrations. 
This differential checkpoint response might be the main difference between U2OS and CHO 
cells, leading to the contradictory results. 
 
3.2.2 Human pancreas adenocarcinoma cells 
Finally we tested an additional human system with intrinsic HR-deficiency and mutated p53. 
The pancreatic adenocarcinoma cells, Capan-1 and BxPC-3, are often used for BRCA2-
related studies. We performed clonogenic assays to detect the relative sensitivity towards 
proton versus photon irradiation. 
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Surprisingly, Capan-1 (BRCA2-/-) cells showed the same survival behaviour after photon 
irradiation as BRCA2-positive BxPC-3 cells. Meaning BRCA2-defective Capan-1 cells are 
thus in our hands more radioresistant than shown by others (345). The reason for this is not 
clear. Drastically different plating efficiencies were not the cause for this behaviour. Both cell 
lines exhibited a plating efficiency ~ 12%, which was similar between photon and proton 
irradiation experiments. However, we still observed at a high dose (8 Gy) a significantly 
enhanced sensitivity of Capan-1 (BRCA2-/-) cells towards proton versus photon irradiation, 
which was not seen in the case of BxPC-3 cells (p=0.02; Fig. 3.27). At lower doses, 2 and 5 
Gy, the increased sensitivity of HR-deficient cells was not detectable. 
 
 
Figure  3.27 Clonogenic cell survival of proton and photon irradiated human pancreas 
adenocarcinoma cells. Cells were irradiated in exponential growth phase. Survival data and 
corresponding ratios of SFwild type/SFmutant are plotted. Survival of BxPC3 (BRCA2-proficient) and 
Capan-1 cells (BRCA2-deficient) is shown. Data points represent mean ± SD or bars represent mean 
± SEM; n > 3; *P<0.05. 
 
Human pancreatic adenocarcinoma cells with a deleted and a truncated BRCA2 allele 
(Capan-1 cells) start to show a superior sensitivity towards proton radiation exposure at 8 Gy. 
In the case of BRCA2-deficient hamster lung fibroblasts (V-C8 cells), we revealed as well 
only at higher doses (5 and 8 Gy) this enhanced radiosensitivity after proton radiation 
exposure. A reason might be that BRCA2 is rather a mediator for an efficient HR process 
than an essential HR protein like Rad51. Furthermore, a Rad52-dependent HR process can 
overtake repair if the BRCA2 protein is missing and even more mediators like BRCA1, SFR1, 
SWS1 or XRCC3 could substitute for BRCA2 (346, 347). When the DNA damage burden is 
huge, the BRCA2 protein becomes more important in order to deal with the damage in a 
faster and more efficient manner. 
 
 
 
 4.1 Efficiency of proton irradiation in different cell systems – different parameters 
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4 Discussion 
4.1 Efficiency of proton irradiation in different cell systems – 
different parameters 
The radiobiological properties of high energy, sparsely ionizing protons have been 
considered to be close to the properties of 250-keV X-rays. This is also illustrated in a similar 
oxygen enhancement ratio for proton irradiation as for photon irradiation and a high 
dependence on an intact DNA repair machinery for cell survival (52, 53). Most of the 
comparative studies have been performed in vitro with tumour or untransformed primary 
normal tissue cells or with laboratory animal systems to define the relative biological 
effectiveness (RBE) of proton vs. photon irradiation (82). These studies let to the clinically 
used RBE of 1.1, meaning that proton irradiation kills about 10% more of the cells than 
photon irradiation when the same physical dose is administered. But the cause for the 
increased efficacy of protons on the molecular level is not clear. Proton irradiation-induced 
DNA damage might be quantitatively or qualitatively different compared to photon irradiation-
induced DNA damage. Furthermore the RBE might be different depending on the genetic 
background of the tumour or the tumour entity. 
In this PhD thesis, I have investigated several molecular and cellular end points in response 
to photon and proton irradiation using genetically defined biological systems. A special focus 
has been placed on the involvement of DNA double strand break (DNA DSB) repair after 
proton vs. photon irradiation. A panel of different cell lines was used to reveal a possible 
differential sensitivity to proton radiation depending on the repair status or genetic 
background of the cell. To the best of our knowledge this study is the first to investigate a 
differential requirement of DNA DSB machineries to counteract cell killing in response to 
proton irradiation in comparison to photon irradiation. 
As has been demonstrated by others, the present work could validate the better efficacy of 
proton irradiation with regard to cell killing for the proton spot scanning beam. This holds true 
for several cell types: Chinese hamster ovary cells, Chinese hamster lung fibroblasts, human 
osteosarcoma cells, and pancreas adenocarcinoma cells. In this study generally the 
calculated ratios of the survival level of photons divided by the survival level of protons at a 
certain dose point (SFphotons/SFprotons) are shown. Why we preferred to compare the 
survival levels at the same physical dose will be explained later on. If this ratios were plotted 
for increasing dose points, the efficacy of proton irradiation was enhanced, which was 
specifically prominent in the case of exponentially growing HR-deficient CHO cells. These 
increasing ratios point towards a more severe DNA damage after proton vs. photon radiation 
exposure. An explanation might be that with higher doses the amount of the severe DNA 
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damages increases, leading to the better efficacy of protons. RBE calculations have been 
performed additionally. The RBE is the ratio of iso-effective doses of photon and proton 
irradiation. In that case the dose values of the photon and the proton survival plots, which are 
needed to induce same survival, are divided by each other. We believe that this is the best 
method regarding survival and clinical applications, but not regarding molecular signalling 
pathways, as at very different physical doses signalling pathways are most probably 
differentially strong induced. It was demonstrated by others that the RBE decreases with 
increasing dose or lower survival levels (82). This could be shown as well with our 
experimental set-up. In our hands, all non-mutated Chinese hamster cell lines and the 
human U2OS cell line displayed a RBE of 1.2 – 1.3 for proton irradiation. These values are 
slightly higher than the described one of 1.1. However, in vitro experiments were previously 
documented to result in higher values than 1.1, especially with hamster cells which have a 
low alpha/beta ratio (82). Furthermore spot scanning might lead to a slightly increased RBE 
(302). Crypt regeneration assays in mice intestines using spot scanning resulted in slightly 
higher RBE-values compared to other proton facilities. One factor might be the movement of 
the mice intestines from breathing during irradiation, but parameters like the high dose rate 
during spot scanning could also increase the RBE. For sarcoma cells an intrinsic higher 
sensitivity to proton radiation was previously reported (82), which corresponds to the data we 
obtained with the human osteosarcoma U2OS cells. 
So far the molecular and cellular events and damages leading to this better efficacy of 
protons have not been identified. Several endpoints are indicative and were already studied 
by other researchers, which were also checked in this study. In the following sections the 
initial DNA damage induction, the cell cycle arrest induction, the apoptosis induction, and the 
possible influence of the dose rate after proton irradiation will be discussed. 
A simple reason for the better cell killing efficacy of protons could be that protons induce 
initially more DNA DSB than photons. To our best knowledge only one other research group 
has quantified the real amount of initial DNA DSBs after proton irradiation and compared to 
photon irradiation. Most groups analyzed later time points (0.5 or 1h) but at these time points 
a fundamental amount of repair has already taken place, and therefore it resembles rather a 
difference in repair kinetics (86, 348). Hada and Sutherland were the sole investigators really 
analyzing initial DNA damage. T7-DNA was exposed in vitro to different types of radiation 
and with a special technique exact amounts of physical damages could be quantified (290). 
The entities they quantified were DSBs, Fpg-oxypurine non-DSB clusters, and Nfo-abasic 
non-DSB clusters. Interestingly, the yields of all damages decreased with increasing LET. 
This is due to the more localized deposition of the energy of heavy particles leading to less 
but highly complex DNA damages. However, low-LET protons were in the same range of 
damage induction as X-rays. A difference between both low-LET radiation types was still 
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detected. Namely, the frequency of DSBs versus abasic and oxybase clusters was higher for 
high-energy, low-LET protons than for X-rays. This indicates that photon irradiation induces 
the same amount of complex clusters as proton irradiation but more non-DSB clusters. Thus 
proton irradiation generates more damage clusters, which include directly generated DSBs 
(direct DSBs). But DSBs can be also generated indirectly. In the case of photon irradiated 
cells, abasic and oxybase clusters can be converted to DSBs during early repair processes. 
Base excision repair can indirectly generate DSBs (indirect DSBs). This is a fast process, 
finishing usually within 30 minutes after radiation exposure, and generates SSBs as an 
intermediate. SSBs opposite to another SSB will generate indirectly a DSB. In that case, it 
would not be possible to differentiate between directly or indirectly induced DSBs or γH2AX 
foci at 12 or 30 min after 1 Gy or 5 Gy, respectively (290). Besides this study working with 
nucleolytic enzymes to differentiate between the breaks, we were some of the first who 
checked DNA DSB induction after both types of radiation with the foci quantification 
technique. Using equal doses of ionizing radiation the amount of initially-induced DNA DSBs 
were assessed in an RBE-unbiased approach. Based on the results using the two DSB 
markers, γH2AX and 53BP1 foci, the initial amounts of DNA DSBs induced by both types of 
IR were equal, which corroborates our approach to investigate the treatment and DNA 
damage response on the molecular and cellular level using the same doses of ionizing 
radiation (1 Gy protons and 1 Gy photons), even though they are not equipotent with regard 
to clonogenic survival. By the means of dosimetry, 1 Gy of photon or proton radiation heat 
water to the same extent and deposits therefore the same energy amount in water or tissue, 
regardless which type of radiation is used. As the initial amount of DSB was the same, we 
assume that the clonogenic survival differences result from a differential severity of the DNA 
damage. Complex damage is defined to harbour clusters of SSBs, DSBs, and base damages 
in a region of 2 or more helical turns of the DNA and these cannot be differentiated by foci 
counting techniques and also not by other techniques beside the one described above. The 
exact physical-chemical interactions of proton radiation tracks on the molecular level are not 
clear and are most likely different compared to a photon track. A more localized energy 
deposition derived from around a proton track might result in more severe damage in the 
DNA double strand break helix in comparison to the damage induced by the broader track 
structure of the photon secondary electrons (49). 
An additional parameter that is usually investigated after radiation exposure is an IR-induced 
cell cycle distribution. For example if a cell arrests significantly longer or faster in G2 phase 
this could indicate a more severe DNA damage burden, as the cell requires several attempts 
to repair the damage and therefore also more time is needed for the repair attempts. We and 
other research groups were checking a possible differentially strong induction of cell cycle 
checkpoints. In contrast to other research groups who detected a strong G2 arrest after low 
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energy proton-radiation exposure (83, 349), we did not detect significant differences in cell 
cycle arrest induction and duration of the arrest between proton (high energy, as used in this 
study) and photon irradiated CHO cells. Also human U2OS cells exhibited no difference in 
the growth arrest behaviour after both types of radiation. But compared to CHO cells, U2OS 
cells displayed a different overall response. 12 hours after 5 or 8 Gy, 80 – 90 % of U2OS 
cells arrested in G2 phase compared to 40 % of CHO cells (Fig. 3.28). Furthermore the G2 
arrest in U2OS cells lasted longer than in CHO cells. Even if U2OS cells harbour an over-
amplification of Mdm2 and a lack of p16INKa, their wild type p53 appears to work with regard 
to the induction of a prolonged G2 arrest (350, 351). In general the G2 arrest is independent 
of the p53-status, but especially the prolonged G2 arrest in that phase was shown to depend 
on p53 (352). This means that U2OS cells arrest properly in contrast to CHO cells, which 
don’t arrest properly and erroneous repair due to proliferation stress might not take place in 
U2OS cells. Other research groups who observed prominent G2 arrests used low energy 
protons. Due to known differential effects after low vs. high energy proton irradiation, these 
data might differ from ours. Yet, CHO cells are anyway not very efficient in the induction and 
duration of cell cycle arrests. They have already a corrupted G1-checkpoint due to the lack of 
p53, and some CHO cells lack also an intact S-phase checkpoint due to radioresistant DNA 
synthesis (RDS) (182, 353).  
The induction of apoptosis is also a parameter often tested in response to irradiation, even if 
at low doses it is not the primary mode of cell death induced in fibroblasts and other non-
lymphocyte cell types. Other research groups detected significant differences in apoptosis 
induction between proton and photon irradiated cells (86). We did not exactly test for 
apoptotic cells but could check 2 parameters in parallel to other experiments. When the cells 
were processed for clonogenic survival assays (~20 hours after radiation exposure) we did 
only observe few dead, floating cells, independent of the types of irradiation. During cell cycle 
analysis we observed no sub-G1 peaks (12, 24 h after exposure), which could indicate 
fragmented DNA of apoptotic cells. However, a careful examination should include multiple 
types of cell lines investigated over increasing doses of IR and at multiple time points. Other 
studies observed IR-induced apoptosis in CHO cells 2-3 days after IR exposure (354, 355). 
Apoptosis is the most prominent type of cell death in lymphocytes. The reported apoptosis 
fractions for CHO cells were not higher than 5 % compared to control for CHO wild type cells 
(355). However, a stronger inhibition of the proliferative activity after proton exposure could 
be observed for the CHO wild type cells in our proliferation assays (at 5 and 8 Gy) almost 5 
days after exposure (116 hours, Fig. 3.3). We assume that at this late time point cell death is 
rather due to mitotic catastrophe or senescence leading probably to secondary apoptosis 
(356). 
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Another factor that has to be closely discussed and could influence cell survival is the 
different dose rate between the photon and proton radiation techniques. In this study photon 
irradiation was administered with 1 Gy/min and proton irradiation with dose rates ranging 
from 1 to 300 Gy/min. Obviously, this is at maximum a 300 fold difference. At dose rates 
below 1 Gy/min better cell survival was reported due to sublethal damage repair. However, 
we assume that sublethal damage repair would not occur in both cases of radiation, as dose-
rates were above 1 Gy/min (357, 358). On the other hand, investigating biological effects at 
dose rates above 4 Gy/min was not possible, due to technical limitations of the linear 
accelerators. Since 2010, with the implementation of the TrueBeam (Varian), dose rates up 
to 24 Gy/min can be reached (359). It can not be excluded that the faster damage deposition 
by proton spot scanning is one reason for the more severe DNA damage pattern/interaction. 
In summary we investigated the better proton efficacy not only on the level of cell survival, 
but also on the level of DNA damage induction, cell cycle arrest induction, and apoptosis 
induction. For the three parameters beside cell survival we did not detect a difference in 
efficacy after both types of radiation. Since we did not observe immediate cell death 
responses like apoptosis, we assume proton-irradiated cells die through mitotic catastrophe. 
In the next chapters the kinetics and the accuracy of DNA repair after both types of radiation 
will be discussed. 
 
4.2 DNA damage induction and repair after proton radiation 
exposure in different cell lines  
 
The influence of mutated DNA repair machineries on the radiation response towards heavy 
particle radiation like alpha-particles was tested before (360). To our best knowledge this 
was never tested for low-LET proton radiation. As proton radiation is becoming more and 
more important in the clinical setting, it is of high interest to study the influence of different 
genetic settings on the radiation response towards protons. 
 
4.2.1 Nucleotide excision repair and proton irradiation 
Overall, clonogenic survival was lower in all proton irradiated than in photon irradiated cell 
systems, which translates into the well-investigated RBE. NER-deficient cells were not 
differentially sensitive to proton irradiation in comparison to wild type cells. NER is in general 
involved in the repair of UV-light induced DNA damages and in interstrand-crosslink (ICL) 
repair (120). Therefore, proton irradiation does not likely generate more ICLs than photon 
irradiation. NER is not an essential repair pathway for survival after both types of IR. As the 
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OER was reported to be equal, we also assume that its importance for the repair of proton-
induced DNA damage is not increasing in hypoxic situations, where NER is responsible to 
repair protein crosslink (122, 237). 
 
4.2.2 Homologous recombination and proton irradiation 
Interestingly, proliferating cells lacking intact homologous recombination were even more 
sensitive to proton than to photon irradiation, as determined in the homologous 
recombination-corrupted daughter cell line and the siRad51-treated wild type mother cell line. 
The increased sensitivity of HR-deficient cells after proton vs. photon irradiation could be 
reversed in plateau phase XRCC3-deficient cells, where HR is anyway not abundant. This 
reveals a requirement for HR after proton irradiation in exponentially growing CHO cells, 
which cannot be compensated by other pathways. The importance of HR was also shown in 
studies with heavy particles (361, 362). Irs2 cells (XRCC2-/-) were more sensitive to α-
particles than Xrs-5 cells (Ku70/80-/-) (360). 
Further evidence is the significantly slower γH2AX foci repair kinetics in the XRCC3-deficient 
cells after proton irradiation compared to photon radiation exposure. The formation and 
disappearance of γH2AX foci is a common marker for DSBs and their removal for DSB repair 
(266, 333). To our best knowledge this was never demonstrated before. These results 
suggest that the residual repair machineries seem to have problems to cope with a certain 
percentage of proton-generated DSBs.  
In contrast to γH2AX foci, the repair kinetics of 53BP1 foci were equal in the HR-mutant cells 
after both types of IR. 53BP1 foci are also used as DSB markers (224, 363). However, 
disappearance kinetics of 53BP1 foci compared to γH2AX foci have been slightly faster in γ-
ray irradiated MCF10A cells and in non-cycling Fe-ion irradiated cells (329). In our 
experiments the initial amount of 53BP1 foci was only one third of the γH2AX foci amount at 
30 minutes after 5 Gy. It is possible that the low amount of foci could be due to problems with 
the used antibody. Furthermore, perhaps due to the rather small 53BP1 foci sizes at 30 
minutes after exposure not all foci have been counted. Groesser et al. also documented a 
lower amount of 53BP1 foci compared to γH2AX foci in cycling cells irradiated with higher 
doses like 2 Gy (329). It might be that 53BP1 is more quickly saturated at higher doses and 
cannot bind to all DSBs any more. In this case 53BP1 foci could not be used as sole DSB 
markers at high dose levels. Furthermore 53BP1 might not localize to each DSB in certain 
cell cycle phases. Some research groups showed that 53BP1 is possibly involved in a 
specific NHEJ-pathway that facilitates ATM dependent repair in heterochromatin 
independently from DNA-PKcs (224, 227). Maybe this specific 53BP1-dependent repair 
pathway does repair a certain set of damages with the same efficiency in HR-deficient cells 
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regardless of the type of irradiation exposure. Another possibility is that γH2AX foci could 
mark other residual damages besides DSBs. But in S/G2 phase cells, 53BP1 foci won’t 
colocalize with Rad51 foci, however γH2AX foci will. Therefore we assume that not all DSBs 
are marked by 53BP1 colocalization but rather by H2AX phosphorylation. Consequently the 
specific 53BP1-dependent sub-repair pathway might fix a certain percentage of damages 
with the same kinetics after both types of radiation in HR-mutant cells.  
Foci formation of phosphorylated DNA-PKcs was used as marker for ongoing NHEJ. The 
kinetic profile showed that this pathway was working much slower in HR-deficient cells than 
in wild type cells. pDNA-PKcs foci remained at DSBs for a longer time and only started to 
decline 12 hours after exposure. This pattern was the same in photon and proton irradiated 
cells. Classical NHEJ might not be able to repair those breaks properly, which are normally 
processed by HR. The pathway can get blocked for example when NHEJ proteins try to 
repair breaks at replication forks or when the corresponding second DSB end is too far away 
(364). Also on the western blot level, phosphorylated DNA-PKcs was longer abundant in the 
HR-deficient cells (Fig. 3.22). After DNA-PKcs is activated at a break, it normally undergoes 
further conformational changes to be released again (196). If this step is blocked, it cannot 
leave the break and prevents binding of other repair proteins. However, pDNA-PKcs foci 
might still get resolved at later time points. It was demonstrated that HR can take over repair 
also at late NHEJ steps (245), and perhaps other repair pathways do the same. 
Unfortunately we did not check later time points where finally pDNA-PKcs foci might become 
resolved. Our data indicate that pDNA-PKcs foci stay significantly longer at certain DSBs in 
HR-deficient cells in contrast to the corresponding wild type cells. However, no difference 
between photon and proton irradiated cells was detected, but we assume that repair still 
progressed at later time points and was most probably more successful after photon 
irradiation. 
In general we reason that a certain percentage of proton radiation generated complex DSBs 
can only be repaired by HR. This statement is undermined by three other HR mutant/wild 
type systems where all mutant cells showed a significant higher sensitivity to proton 
irradiation than the wild type cells. However, for the BRCA2-deficient cells (hamster and 
human) we could only demonstrate significant differences at higher doses, 5 and 8 Gy. We 
argue that the mediator BRCA2 is not as essential as the HR core proteins like Rad51 and 
XRCC3. Other backup pathways like Rad52-dependent HR might substitute and lead to the 
smaller effect (346).  
In contrast, silencing of Rad51 or XRCC3 in U2OS cells did not increase the cellular 
sensitivity towards proton irradiation. Down-regulation of Rad51 in both cell systems (CHO 
and U2OS) revealed a differential sensitivity of the cells. CHO cells displayed a 90% plating 
efficiency even when Rad51 was down-regulated and U2OS cells revealed a 9% plating 
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efficiency (15% of control). From these findings one could assume that CHO cells do depend 
to a lower extent on HR. Normally cells are highly sensitive to siRad51 treatment, as the 
repair of DNA damages generated during replication does highly depend on active HR (365). 
It is not clear why CHO cells are so resistant towards a siRad51 treatment. To explain the 
differential sensitivities towards proton irradiation we assume the p53 status might have an 
influence because this status is different in the two cell systems. It was reported that p53 
regulates the levels of HR (144, 150). Furthermore unrepaired or mis-repaired DNA damage 
might be better tolerated by CHO cells, which resemble aberrant tumour cells, but not by 
U2OS cells, which most probably would induce a cell death program. 
In the case of high-LET α-particles, which induce complex DNA damage clusters, it has been 
demonstrated that HR is highly important for the repair in S phase. Even a second pathway 
SSA, which we did not check in our experiments, was more prominent than NHEJ in CHO S 
phase cells (291). Furthermore classical NHEJ has problems to repair DSBs in damage 
clusters induced by heavy particles (366, 367). Wang et al. demonstrated in an elegant 
assay that Ku proteins cannot bind to overly small DNA fragments. Therefore cellular NHEJ 
is partially inhibited after heavy ion exposure. Low-energy proton particles deposit a larger 
energy density within a small radius around the primary track and do cause a different 
damage pattern than the secondary electron tracks of photon beams (303). With increasing 
depth in the SOBP, the amount of low-energy proton particles increases and therefore some 
proton tracks in our experiments might show the behaviour described by Friedland inducing 
the same damage pattern as described by Wang. Based on this concept the treatment 
outcome after proton irradiation might be differentially affected by various genetic 
backgrounds. 
 
4.2.3 Non-homologous end joining and proton irradiation 
NHEJ-mutant cells are even more sensitive to normal photon irradiation than HR-mutated 
cells (Fig. 3.5). However, proliferating NHEJ mutant cells showed almost equal survival rates 
after proton and photon irradiation exposure. Furthermore they repaired photon and proton 
radiation induced DSBs with the same speed, indicating that the residual repair machinery 
could deal equally efficiently with photon- and proton-induced DNA damages.  
Irradiation in plateau phase causes that only few residual repair pathways (only backup 
NHEJ) work. NHEJ-deficient cells displayed a low level of survival after photon irradiation, 
whereas survival dropped down completely after proton irradiation. Under these conditions 
NHEJ-deficient cells were significantly more sensitive towards proton vs. photon irradiation. 
This finding suggests that after proton radiation exposure a specific DNA damage cannot be 
accurately repaired by alternative pathways in G1/G0, whereas for photon radiation induced 
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DNA damage it is partially possible. If NHEJ-deficient cells proliferate, the proton-radiation 
specific DNA damage can be repaired by other active repair pathways in S/G2 phase like HR 
or SSA and G1 phase cells can progress to S/G2 phase where the DSBs get repaired, 
leading to the equal survival of photon and proton irradiated cells. 
On the molecular level we observed that 3-fold more DSBs are occupied by Rad51 and 
53BP1 foci in proliferating NHEJ-deficient cells than in wild type cells. Cells lacking NHEJ 
have unoccupied breaks where other repair proteins can bind to. Significantly more Rad51 
foci have been detected by others in NHEJ-deficient cells (368). However, not all breaks are 
suitable for HR, for example if the sister chromatid or homologous chromosome is too distant. 
When the DNA end is already resected almost no other repair pathway can continue. Only if 
the resection was not too extensive, MMEJ or SSA could continue with the repair. The 
Rad51 foci number was high until 12 hours after exposure, indicating that no other pathway 
could overtake the repair. Another possibility is that Rad51-dependent repair progresses. 
Foci are resolved, but at the same time still new foci are formed, appearing as no change in 
foci numbers. What argues against this is that with time Rad51 foci grow in size, meaning 
that resection most probably still takes place at the same locus. Unusually large Rad51 
filaments may present DSBs, which did not yet find a partner for HR or are irreparable and 
thereby might lead to cell death (156). However, this problem for homologous recombination 
appeared to be similar after both types of radiation. Based on these data we argue that HR 
cannot cope properly with all abundant DSBs in NHEJ-deficient cells. However, we cannot 
exclude the possibility that the repair might just take longer. In our experimental set-up we 
could not detect any differences between photon and proton irradiation induced molecular 
responses in NHEJ-deficient cells. 
With 53BP1 foci, the same result was obtained, foci grew in size and remained significantly 
longer than in wild type cells. Interestingly, three hours after proton exposure significantly 
more foci were detected in NHEJ-deficient cells than after photon irradiation. However, 6 and 
12 hours after both types of IR the amount of foci was again about the same. Maybe when 
classical NHEJ is missing, more proton-induced breaks are repaired via 53BP1-dependent 
repair. Another possibility could be that proton irradiated cells arrest faster than photon 
exposed ones. Unfortunately at this early time point the cell cycle distribution was not 
checked. If more cells would be arrested in G2 phase, consequently also more 53BP1 foci 
might be abundant and counted.  
In these experiments, Rad51- and 53BP1-dependent repair pathways are working without 
the action of DNA-PKcs and try to compensate for the NHEJ-defect. However, both 
pathways seem to have problems to repair certain breaks or take an extraordinary amount of 
time. Unfortunately we cannot conclude from these data, which repair pathway leads to the 
better survival of NHEJ-deficient cells after proton exposure compared to HR-deficient ones. 
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Later experimental time points (24, 48h) would have been useful to detect the time at which 
Rad51 and 53BP1 foci become resolved. 
In general we identified that lack of NHEJ does not lead to an increased sensitivity towards 
proton irradiation in proliferating cells. The proton radiosensitivity of proliferating NHEJ-
deficient cells was below the level of wild type cells (RBE10=1.09 vs. 1.2), meaning that a 
certain fraction of proton-induced damage is most probably better repaired by HR. To prove 
that HR can better repair proton-irradiation induced DNA damages than photon-induced ones, 
NHEJ-deficient and wild type cells should be irradiated in late-S/G2 phase where HR can 
properly work. When HR does repair proton-generated DSBs more accurately than other 
repair pathways, the cell survival should equal photon irradiated ones or might even be better 
(291). 
 
4.2.4 Base excision repair and proton irradiation 
Base excision repair mutants were also of interest. Complex DNA double strand breaks 
harbour several SSBs and base damages around the break. If the repair of these single 
strand damages is prevented, DSB repair machineries encounter more problems at the 
break due to the surrounding lesions. Repair might not occur due to docking problems of the 
repair proteins. Exponentially growing XRCC1-mutant cells were significantly more sensitive 
to proton irradiation than the wild type cells at doses of 5 and 8 Gy. Unfortunately due to time 
reasons we could not follow these findings mechanistically. Interestingly XRCC1-deficient 
cells irradiated in plateau phase did not become more radioresistant like HR-deficient cells. 
Therefore NHEJ-dependent repair seems to have severe problems when SSBs and base 
damages are not repaired before it starts working. PLD repair is also not possible in XRCC1-
deficient plateau cells. In contrast to the finding in CHO cells, XRCC1 silencing in U2OS cells 
did not lead to the superior sensitivity towards proton irradiation. A proper cell cycle arrest 
might lead to the engagement of long patch BER instead of short patch BER, which is not 
necessarily dependent on XRCC1 (110). Overall these data additionally point towards a 
more complex DNA damage induction after proton irradiation exposure, and inhibition of 
SSBR could increase the therapeutic window of proton radiotherapy. 
 
4.2.5 Wild type cells and proton irradiation 
Since wild type cells also showed a significantly higher sensitivity after proton vs. photon 
irradiation, we aimed to explain this finding as well on a molecular level. However, the overall 
smaller differences in comparison to HR-mutants are more difficult to detect with these 
parameters. 
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The repair kinetics after proton vs. photon irradiation in CHO wild type cells were not 
significantly different for γH2AX, Rad51, and 53BP1 foci removal. Neither Rad51-dependent 
repair nor 53BP1-dependent repair appears to have problems with proton-induced DSBs in 
the wild type background. On the other hand it is possible that already very small differences 
might be relevant and translate into the lower survival of wild type cells after proton 
irradiation. For example 3 hours after 5 Gy of radiation the amount of 53BP1 foci was slightly 
higher in the proton irradiated samples compared to the photon irradiated ones (Fig. 3.18). 
Twelve hours after 5 Gy AA8 wild type cells showed more γH2AX foci after proton irradiation, 
which was not significantly different but still might indicate as well repair problems after 
proton radiation in the wild type cells. We assume that after application of even higher 
radiation doses, one would detect most probably a significant difference for residual γH2AX 
foci between proton and photon irradiated cells in the wild type cells. 
The maximal appearance of Rad51 foci was rather early in CHO wild type cells, showing up 
at 1 hour after radiation exposure whereas in human cells it was described 3-6 hours after 
exposure to IR (164, 368). Most probably this later maximal Rad51 foci formation would also 
hold true for human U2OS cells, which we did not determine. These differences between 
CHO and U2OS cells point towards a differential DNA double strand break repair hierarchy. 
HR is more dominant at early time points after radiation in CHO cells than in human p53-
proficient U2OS cells. Possibly Rad51 is kept inactive at earlier time points in human p53-
proficient cells and only used at later time points to repair very difficult breaks in U2OS cells. 
In CHO cells Rad51 is presumably not inhibited and can immediately “go” to the breaks and 
take part in repair. However, the involvement of Rad51 at repair loci was to the same extent 
after both types of radiation. From this picture we conclude Rad51-dependent repair is 
equally important after either type of radiation. Assuming that this pathway is working error-
free, other repair pathways must mis-repair or let DSBs go unrepaired after proton irradiation 
to result in ultimate differences in survival. 
A significant difference was detected for pDNA-PKcs-foci formation. In the AA8-wild type cell 
line a maximum of foci was detected 1 h after both types of radiation but to a reduced level in 
proton-irradiated cells (P = 0.04; Fig. 3.21A). Decay of pDNA-PKc-foci was similar at the 3h 
and 6h time point and reached again basal levels at the 12h time point, indicating that DNA-
PKcs is not as efficiently recruited or phosphorylated at proton induced breaks. The question 
is what happens with the breaks where no phosphorylation of DNA-PKcs appears. Quantities 
of 53BP1 and Rad51 foci were not different at this time point. Therefore this percentage of 
breaks might be repaired via another pathway than 53BP1- or Rad51-dependent repair. SSA 
could be involved. However, this pathway is known to be mutagenic and might mis-repair an 
enhanced fraction of proton-generated DSBs (369). The breaks could be also left unrepaired 
and lead to more fragment/break formation. But this is in contrast to the equal γH2AX foci 
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kinetics after both types of radiation, pointing rather to the involvement and mis-repair 
through other repair pathways.  
Most probably small DNA fragments having a size below 1 Mb cannot be detected equally 
well by foci-staining techniques as bigger fragments. If more small DNA fragments are 
generated by proton irradiation, this could make a difference. On the other hand, if γH2AX 
foci contain few small fragments, repair should follow a slow kinetic, which it does not. Either 
such breaks are not formed after proton irradiation or they are not marked by our staining 
techniques.  
Furthermore the total amount of pS2056-DNA-PKcs foci was lower than the one of γH2AX-
foci. This result is in contrast to the general assumption that almost all breaks are repaired 
via classical NHEJ. On the other hand DNA repair is divided into a fast and a slow 
component with classical NHEJ being responsible for the fast part. This very fast initial repair 
kinetic can already be finished at 1-30 minutes after exposure to IR. Maybe the maximal foci 
amount at 1 hour after irradiation in wild type cells represents the second wave of repair 
efforts where classical NHEJ is more pronounced after photon radiation than after proton 
irradiation. 
Tumour cells become more resistant when irradiated in stationary, plateau phase (370). This 
effect is due to repair of potentially lethal damage (PLD). When growth-arrested plateau-
phase CHO wild type cells were irradiated, they became also more radioresistant but to the 
same extent after both types of IR. Therefore the effectiveness of proton irradiation was the 
same in plateau and proliferating wild type cells. Neither classical NHEJ nor other repair 
pathways in G1 phase or PLDR could properly repair a certain percentage of DNA damage 
induced after proton irradiation. In exponentially growing cells the abundant repair pathways 
do also presumably mis-repair a certain percentage of proton-induced DSBs.  
NHEJ proteins show the highest affinity for DSBs and are normally the first ones locating to 
the breaks. Therefore NHEJ is responsible for the first, fast repair phase and later on in the 
second slow repair phase other repair pathways join to repair DSBs. Within the first thirty 
minutes to three hours after exposure to IR a large percentage of breaks is repaired mainly 
due to classical NHEJ and B-NHEJ. If NHEJ tries to repair breaks with complex damage 
structures, it seems not to need more time (γH2AX and 53BP1 foci kinetic is equal) but might 
mis-repair those damages with a higher probability after proton irradiation, translating into the 
lower survival of proton-irradiated wild type cells. The detection of more dicentrics and rings 
after proton vs. photon irradiation is pointing to this hypothesis. At later time points the slow 
repair component becomes important. HR proteins might continue to repair those breaks 
where NHEJ was blocked. Even during the slow repair phase NHEJ is still involved, but 
might take more time at complex DSBs. After irradiation with high doses, NHEJ proteins 
might be all occupied, and free breaks are left for other repair pathways. This saturation 
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effect could be the reason for the drastically increased sensitivity of HR-deficient cells at 5 
and 8 Gy.  
In conclusion we detected no differences in the DSB repair kinetics of the wild type cells 
(γH2AX foci) after low doses (1 Gy) of both types of radiation. At higher doses (5 Gy) we 
started to see differences. However, they showed only a trend without significance. We 
assume that at higher doses (8, 10 Gy) proton-irradiated cells would display significantly 
more residual DSBs correlating with the lower cell survival of CHO wild type cells. Rad51-
dependent repair appears to be involved to equal amounts after both types of radiation. Due 
to the assumption that HR is error-free, we propose parts of the proton-generated DSBs are 
mis-repaired by another repair pathway, most presumably by NHEJ or SSA. 
 
On the physical-chemical level, the difference between photon and proton irradiation 
exposure is unclear. If you follow the track of a single proton particle it is not exactly clear 
why and how the interactions of protons with matter change in the depth of the tissue. Proton 
irradiation exerts a direct effect, by the proton particle itself and indirect ones, by generating 
secondary electrons or short range electrons. Due to these short range electrons, protons 
may induce a more localized damage around its track. Another reason for a different damage 
complexity could be a minimal enhanced LET. The SOBP consists of a mixture of multiple 
near-monoenergetic proton beams. Some proton particles reach already the Bragg peak at 
this certain depth. At the Bragg peak they become so slow that they display low-LET 
characteristics. These protons might shift the DNA damage profile. This differential DNA 
damage complexity is most probably leading to the lower cell survival. 
Others have determined RBE-values close to 1.0 or even lower ones (82, 371), which 
indicates that certain cell lines can repair the proton damage very well, which is leading to 
equal survival levels. These cells most probably have an intact DNA damage response (DDR) 
and a certain set of repair proteins helping them to accurately repair proton-generated DNA 
damages. Also many in vivo experiments show a small RBE. Intact normal tissue should 
exhibit intact DDRs and intact repair pathways and might therefore repair proton-induced 
DNA damage more efficiently and accurately than highly mutated tumour cells. In that case, 
the intact response of normal tissue would improve the therapeutic ratio of proton 
radiotherapy. In this chapter we have also shown that certain mutations in DNA repair 
pathways make tumour cells more sensitive to proton irradiation compared to normal cells. 
Mutations in the HR- or BER-pathway might increase as well the therapeutic ratio for proton 
radiotherapy. Putting our results together with previous work, we showed that the genetic 
background of the tumour (maybe also of the patients normal tissue in the case of germline 
mutations) is influencing the therapeutic ratio of proton radiotherapy. 
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4.3 Accuracy (and hierarchy) of repair after DNA damage induction 
by protons 
We questioned two possible outcomes after proton vs. photon irradiation: either the DNA 
damage is more often mis-repaired or even not repaired. 
For HR-mutants we could correlate the longer abundance of γH2AX-foci after proton 
exposure to the significantly reduced survival after proton irradiation. However, in wild type 
cells we saw equal kinetics for γH2AX, 53BP1, and Rad51 foci after both types of radiation. 
Only the amount of pDNA-PKcs foci led to the impression that NHEJ has difficulties with 
proton-induced damages or requires extended periods of time to be activated. Regardless of 
the superior sensitivity of HR-mutant cells, a clear reason for the classic RBE of 1.1 was not 
demonstrated. We quantified the amount of chromosomal aberrations in both CHO wild type 
cell lines (AA8 and CHO9). In this experiment we detected an increased amount of 
fragments, dicentrics, and rings pointing towards induced and mis-repaired damage in G1 
phase. Also many more sister unions could be counted after proton vs. photon irradiation. 
Rationales for this result could be enhanced mis-repair in S-phase irradiated cells after 
proton irradiation, or unrepaired DNA damage was transferred to S phase and mis-repaired, 
or more cells were present in S phase during proton irradiation exposure. The chance for the 
latter possibility is rather small, as cell cycle data revealed equal distributions and because 
we see many G1 induced aberrations as well. In conclusion proton-induced DNA damage 
appears to be more often mis-repaired than the damage after photon exposure, most 
probably leading to the RBE of CHO cells. 
Two fold more sister unions indicate that the damage was erroneously repaired in G2. SSA 
displays a high activity during this phase (291). Therefore this more error-prone repair 
pathway and NHEJ could lead to mis-repair of the damage, as not all DSBs are substrates 
for HR. 
In the case of heavy particle exposure Ritter et al. discussed that the RBE for aberration 
induction is strongly dependent on the time between radiation exposure and harvest. This is 
due to more prominent cell cycle delays and loss of heavily damaged cells after heavy 
particle irradiation (372). In that case the RBE for aberration induction with carbon ions was 
lower than in reality, as the cells were blocked in G2 phase and did not continue progression 
to M phase. Premature chromosome condensation (PCC) techniques could unmask these 
discrepancies. But in the case of low-LET proton radiation exposure we did not detect a 
stronger G2 arrest ~ 24 hours after irradiation. Only at very late time points, growth was 
significantly inhibited in the proliferation assays. As our samples were prepared 24 hours 
after irradiation, we exclude this effect for low-LET protons. 
What is the rationale for the huge differences regarding chromosomal aberration induction 
after proton vs. photon radiation exposure? CHO cells are highly proliferative cells and 
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genetically unstable (373). Therefore chromosomal aberrations might manifest faster in these 
cells due to fast growth behaviour without proper cell cycle arrests. Clonogenic survival and 
the SFphoton/SFproton ratio at a dose of 5 Gy (1.9±0.4) correlate with the numerical 
enhanced chromosomal aberrations after proton irradiation. 
This mutagenic potential of proton irradiation was already shown in some cell-based and 
mice-studies (297, 299). In peripheral lymphocytes the efficiency of proton irradiation 
exposure was higher at lower doses and decreased with dose. Interestingly the aberration 
frequency increased also with greater depth in the SOBP. A variation of aberration induction 
along the SOBP points towards a differential damage induction within the beam, leading to 
areas with different probabilities of aberration induction.  
In summary, proton irradiation induces more lethal chromosomal aberrations at least at this 
high dose (5 Gy). This might be the reason for the increased cytotoxicity of proton irradiation. 
More severe proton-induced DNA damages are repaired erroneously, leading to cell death. 
Proper mitosis is not possible with dicentrics or sister unions and the cells might not undergo 
cytokinesis and ending up in a binucleated cell, which dies through mitotic catastrophe or 
undergoes senescence. 
 
4.4 Translational significance 
There is presently a widening gap between the rapid introduction of proton radiotherapy in 
clinical practice worldwide and the apparent lack of solid radiobiological evidence and data to 
support the expansion of new clinical indications, particularly when combined with other 
treatment modalities. The major difference between photon- and particular proton-based 
radiotherapy is the spatial distribution of energy deposition. Proton particles enter tissue with 
a low dose, and the maximum dose deposition occurs within the so-called Bragg peak at a 
depth depending on the controllable beam energy. Behind this Bragg peak region – or 
Spread-out-Bragg Peak (SOBP) in clinical applications – no significant dose is deposited. For 
photon irradiation in contrast, the maximum dose is deposited close to the entrance surface 
of the tissue that is irradiated and also behind the targeted tumour tissue. The physical 
characteristic of proton radiation provides more localized delivery of the radiation dose to the 
tumour site than can be achieved with photon-based radiotherapy. The improved dose 
distribution is exploited either by allowing higher doses to the tumour without increased 
normal tissue toxicity or by reducing adverse effects at equally effective tumour doses. 
Radiobiology experiments conducted several decades ago revealed an approximately 10 % 
higher biologic effectiveness (RBE) of proton compared to photon irradiation (82). In today’s 
clinical practice a generic RBE of 1.1 is employed and seems to be reasonable due to the 
huge set of experiments that have been performed. However, the RBE can vary heavily 
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according to the tissue, cell line, or the end point investigated (82). There is still a huge black 
hole with regard to the exact biological events induced along a proton radiation track. It was 
shown that efficiency can vary along the plateau and SOBP region and is maximal at the 
distal end of the SOBP and the distal penumbra (374). 
A few other studies discussed a possible differential DNA damage induction by proton and 
photon irradiation (86, 298). In the present study we elucidated in a clear way that the initial 
amount of DNA double strand break induction is equal after both types of irradiation with 
respect to γH2AX and 53BP1 foci induction. The repair kinetic was also the same in most cell 
lines studied, but we assume the quality of the damage and of the repair products is 
differentially complex after both types of radiation, leading to the better effectiveness of 
proton radiation exposure. Repair products with worse quality are highly mis-repaired 
products consisting of complex chromosomal aberrations. This mis-repaired DNA damage 
must contribute in large part to the RBE, though we do not exclude other factors contributing 
to the RBE, e.g. protein damage/stress. An increased part of the proton-induced DNA 
damage is more severe (more complex) and cannot be properly repaired. Chinese hamster 
cells lacking intact HR display a drastically stronger decrease in cell survival after proton 
irradiation than in wild type cells. This reveals that HR is essential to repair parts of these 
complex breaks.  
When proton irradiation induces a more severe damage, this happens most probably also in 
normal tissue. It cannot be prevented that some parts of healthy tissues are irradiated during 
proton radiotherapy. Studies with lymphocytes by Manti et al. revealed that proton-induced 
aberrations could be more efficiently transferred to later generations, meaning that mutations 
might be better propagated after proton-radiation exposure (298). This can happen in healthy, 
co-irradiated tissue and lead to secondary diseases at later time points. Therefore care must 
be taken when irradiating small children. As little healthy tissue as possible should be co-
irradiated during treatment. In older patients, healthy tissue fibroblasts are usually in the G0 
phase of the cell cycle. These cells do not divide anymore and could not propagate 
mutations to later cell generations. However, in the case of children, these tissues are still 
growing. In this case, mutations can be propagated and can lead to diseases at later time 
points during life. Even in adolescents secondary cancer can occur. Fibroblasts are 
stimulated to proliferate during the normal wound healing process (375). In response to 
radiation, a certain percentage of cells dies in the irradiated tissue, leaving free space that 
stimulates surviving cells to grow, providing an opportunity to forward mutations. On the 
other side, normal tissue cells possess intact DNA damage response mechanisms. This 
might prevent the transfer of mutations. Whereas in tumour cells or CHO cells, secondary 
mutations are most probably very efficiently transferred to later generations due to 
deregulated DNA damage checkpoints. 
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If a patient harbours already a heterozygotic mutation in the HR pathway (BRCA1/ BRCA2/ 
XRCC3) and experiences a complete loss in the tumour compartment it might respond 
significantly stronger to proton irradiation than with an RBE of 1.1. We showed here that 
BRCA2 or XRCC3 mutations or Rad51 depletion in a p53-mutated background leads to an 
increased proton radiosensitivity, which was not observed in p53-proficient cells. This implies 
that in addition to the HR-mutation the cell has to harbour a deregulated cell cycle checkpoint 
response in order to be highly sensitive to proton radiation exposure. In this case one could 
argue normal tissue with BRCA2-/+ has still an intact DDR and would not be more sensitive 
to proton irradiation, but tumour tissue with acquired BRCA2-/- often has additionally a 
deregulated DDR (e.g. p53-mutation) and would be highly proton sensitive. Personalized 
medicine will be more and more important in the future. Determination of the tumour’s 
BRCA1- or 2-status and p53-status could channel patients defective in both markers to 
proton radiotherapy. Then a lower dose could be prescribed and lead to palliation of the 
patient’s side effects. However, this has to be proven in a tumour model. 
In the USA more and more prostate cancer patients are treated with proton radiotherapy. In a 
recent study 3.1 % of all cases carried a BRCA founder mutation. A BRCA2 founder mutation 
was associated with a three-fold increase in prostate cancer risk. Mutation carriers had 
significantly greater risk of recurrence and prostate cancer-specific death than non-carriers 
(341, 342, 376). Due to our findings and the more aggressive phenotype of BRCA2 mutation 
carriers, those patients should be treated with proton radiotherapy. Maybe a hypofractionated 
regimen would give good results in the case of very aggressive and relatively radioresistant 
tumours. 
In the recent years enormous knowledge was acquired on the molecular mechanism of DDR 
and DNA DSB repair. With this knowledge strong efforts were made to establish specific 
DNA repair inhibitors (377, 378). The most specific and promising drugs are Parp-inhibitors 
(379). Unfortunately no specific HR-inhibitor exists yet. But Parp-inhibitors are for example 
used due to their synthetic lethality characteristics. HR-deficient cells treated with a Parp-
inhibitor all die. Parp-1 is involved in repairing single strand breaks, which occur in daily 
routine due to oxidative stress. If SSBs stay unrepaired until DNA replication, they lead to 
breaks that must be repaired by HR. HR-deficient cells cannot do this and most probably die. 
However, in the case of radiotherapy the inhibition of SSB repair is also important, as we 
showed that cells lacking SSB repair are quite radiosensitive and highly sensitive to protons 
at higher doses. Combination of those with proton therapy might be very effective. This has 
to be proven in HR-defective and other cell systems. 
Tumours start to become hypoxic already at a size of 1 – 2 mm or when the nearest vessel is 
200 µm distant (380, 381). Hypoxic cells have down-regulated Rad51-protein levels and 
consequently reduced HR-activities (382, 383). The hypoxic status of the tumour is not 
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equally distributed. Compartments of the tumour with different oxygen levels could respond 
differentially to proton irradiation exposure. However, as the OER was reported to be equal 
for both radiation types, no influence might exist (52, 53). On the other hand hypoxic cells do 
generally not proliferate very fast. When they stay in G1/G0 phase due to unfavourable 
growth conditions, cells will not propagate chromosomal aberrations and most probably not 
die. 
Our study shows that on the chemical-molecular level, proton irradiation induces a differential 
DNA damage in comparison to photon irradiation exposure. CHO cells, which resemble p53-
deficient, fast proliferating tumour cells, are highly sensitive to proton irradiation and even 
more sensitive in a situation in which HR is deregulated. 
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5 Outlook 
The following major questions are of interest:  
(1) Dissecting the proton radiosensitivity during the cell cycle 
(2) Verification of the importance of homologous recombination 
(3) In vivo normal tissue response 
(4) Dose rate effects and RBE differences along the SOBP 
5.1 Dissecting the proton radiosensitivity during the cell cycle 
A good approach for a more precise analysis of the different involvement of repair pathways 
is to analyze the behaviour of cell lines in G1 and G2 phase of the cell cycle. Clonogenic 
assays, repair kinetics, and chromosomal aberration induction analyzed exactly during these 
phases could elucidate the cell cycle phase, were the main mis-repair after proton irradiation 
occurs and could elucidate the responsibility of the different repair pathways. 
It is not clear if HR could possibly reduce the RBE to 1 or even more due to accurate repair 
of proton-generated DSBs. Irradiation of late-S/G2 phase synchronized wild type and NHEJ-
deficient cells followed by clonogenic survival assays should reveal if the proton survival 
curve reaches the one of photon irradiated cells or not. During this cell cycle phase the 
chance exists that all damages, which need HR for proper repair, could be reached by 
Rad51 as it is expressed in this phase. This experiment might reveal that HR is able to repair 
proton damage accurately and to increase cell survival. Another group showed after 
reexpression of the missing HR-protein that these cells survived even better after alpha 
particle irradiation than after photon irradiation (291). If this can be demonstrated one has to 
be careful with tumours, which show over-activated HR. In that case the RBE might be lower 
than 1.1 and the therapeutic ratio would be decreased. But it has been reported that an 
elevated HR status of the tumours did not correlate with the level of radioresistance after 
photon radiotherapy (384).  
It will be interesting to probe for γH2AX-foci repair kinetics in G1 arrested (plateau phase) 
cells where only NHEJ is active and in G2 synchronized cells where mainly NHEJ and HR 
repair DSBs. This could be performed in wild type cells, detecting more precisely if 
differential repair kinetics, which could not be visualized in the unsynchronized population, 
occur in the wild type cells after both types of radiation. Furthermore it could be performed in 
HR-mutant cells to reveal if in G2 phase cells the described differential repair kinetic will be 
even more pronounced. In the case NHEJ is working with fast kinetics, regardless of the 
radiation source administered to G1 phase cells, no difference in the wild type repair kinetics 
should be observed, and the same should be revealed for HR-mutant cells. But it is possible 
that after proton exposure of G1 phase cells not all DSBs (γH2AX foci) could be repaired and 
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might be transferred to S phase to be repaired via HR. In that case more residual γH2AX foci 
might be detected after proton-radiation exposure. Cells irradiated in G2 phase use mainly 
NHEJ and HR for repair. In that phase NHEJ starts to become less accurate (108, 385). A 
reason for this might be the different chromatin structure in G1 and G2 phase. Irradiated G2 
phase wild type cells might show a repair defect after proton exposure depending on the 
failure of NHEJ to repair certain damages. In the HR-mutant cells the slower repair kinetic 
after proton irradiation exposure should then be even more pronounced in G2 phase. 
An important missing experiment is the analysis of chromosomal aberration induction in the 
HR-mutant cells. In the wild type cells a difference in the aberration production after proton 
versus photon exposure could be detected. However, the repair kinetics had been equal. 
Therefore we anticipate a more drastic difference in aberration induction in the mutant cells 
after proton vs. photon irradiation. This experiment would be performed with lower doses of 1 
- 2 Gy, as the cells are anyway more sensitive due to their lack of HR. 
Irradiation of exponentially growing cells and metaphase preparation 24 hours later generally 
includes cells, which have been irradiated in G1 phase but could also involve cells, which 
where irradiated in G2 phase and already finished a cell cycle at the time of fixation. A more 
precise analysis of the exact types of aberration induction in the different cell cycle phases 
could give another hint towards the phase, in which main mis-repair takes place. Cell fixation 
16 hours after irradiation would exclude cells, which finished another cycle and include only 
cells, which had been irradiated in G1 phase. Fixation at 3 - 6 hours after irradiation would 
only include cells, which have been irradiated in G2 phase and which had to repair the 
damage in that phase. This could show if proton irradiation is more severe for G1 or G2 
phase cells with regard to aberration induction and if HR-mutant cells show significantly more 
aberrations after proton exposure compared to the wild-type cells. 
With the chemical premature chromosome condensation (PCC) technique it would be also 
possible to quantify the initial break induction in G2 phase cells. In that cell cycle phase 
chromosome condensation with Calyculin A treatment takes only 5 minutes due to the higher 
levels of cyclin B and allows almost immediate fixation, which could give a second readout 
about initial break induction. Specific analysis of G1 phase repair would be also of interest. 
However, chemical chromosome condensation is not possible as no cyclin B is expressed in 
that cell cycle phase. Another option for the detection of G1 phase repair capacity would be 
to irradiate plateau phase cells and applying another premature chromosome condensation 
(PCC). G1 phase cells can be fused with mitotic cells leading to PCC as the right signals are 
abundant (386). Condensation will be finished only 30 minutes after fusion and during 
analysis one has to differentiate between the mitotic chromosomes of the donor cells and the 
haploid chromosomes of the cell of interest. In G1 phase cells mainly breaks/gaps can be 
detected. 
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5.2 Verification of the importance of homologous recombination 
It has never shown before that an HR-defect in human cancer cells does lead to superior 
sensitivity towards proton irradiation. Therefore it is of high importance to proof our finding in 
a human cellular setting and later on in an in vivo setting. 
As we assume that the HR-defect only leads to this increased sensitivity towards proton 
radiation in a p53-deficient background, Saos-2 osteosarcoma cells would be a good model. 
These cells are deficient in p53 (387, 388). Saos-2 cells, ectopically expressing or not 
expressing p53, could be treated with siRad51, irradiated, and processed for clonogenic 
survival. Depletion of Rad51 in the p53-deficient cells should lead to the increased sensitivity 
towards proton irradiation in contrast to p53-expressing cells. Other cell pairs could be tested 
as well like BRCA1-deficient breast cancer cells (HCC1937 and HCC1937-wt BRCA1) and 
another BRCA2-deficient lymphoblast cell line (EUFA423 and EUFA423/wt BRCA2). 
However, it was shown that BRCA1-deficiency does not lead to a direct HR-defect but to a 
defect in transcription coupled repair (TCR) (345). 
Another experiment, which could proof the importance of HR in a human setting, is to treat 
different p53-deficient tumour cells with HR-inhibitors. Unfortunately no specific inhibitor for 
HR exists. A possibility would be to use an ATM-inhibitor from KuDOS (Ku55933), which 
inhibits whole DNA damage signalling and rather both DSB repair pathways (25). It might 
lead to a stronger cytotoxicity in combination with proton than with photon irradiation. Parp-
inhibitors like Iniparib, Olaparib, and ABT-888 could be also tested together with proton 
radiotherapy (377). In general Parp-inhibitors reduce the level of BER and they are 
synthetically lethal in HR-defective tumours (389). They might be even beneficial in HR 
proficient but p53-mutated cells, as inhibition of BER in CHO cells let to an increased proton 
radiosensitivity (see chapter 3.1.5). If BRCA2-deficient tumours would be treated with a 
combination of Parp-inhibitors and proton radiotherapy they might display a superior 
response in comparison to the combination with photon radiotherapy. 
In case the experiments proposed in this chapter would reveal superior cell kill in clonogenic 
survival assays, the ultimate experiment to proof the clinical relevance would be to treat HR-
deficient tumour xenografts with proton and photon radiotherapy. When tumours treated with 
proton radiation regress faster than photon-treated tumours, even if they were treated with 
photon-equivalent doses, this would show that the effective dose of proton radiation is bigger 
than anticipated for HR-defective tumours leading to a further reduction in the total dose in 
proton irradiation plans for BRCA2-deficient tumours. Unfortunately almost no established 
HR-deficient tumour models exist. A formerly used and possible model is the intramuscularly 
implantation of V-C8 (BRCA2-/-) or complemented V-C8 cells into the thigh of CD-1 nude 
mice (390). Regarding the limited possibilities to grow BRCA2-deficient tumours, a second 
option would be to test the combination of proton radiotherapy and the described ATM- or 
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Parp-inhibitors. Tumours with p53-deficient background would be grown to a certain size and 
the drug would be administered before exposure to IR. As end point tumour growth delay 
could be measured, however in this case maybe tumour control might be a more relevant 
endpoint. 
These experiments would change the general assumption that the proton RBE of 1.1 is the 
same for different tumour types independent of the genetic backgrounds. Further studies 
would follow analyzing the sensitivity of other tumour types and tumour mutations. 
 
5.3 In vivo normal tissue responses 
Another important aspect to look at is the normal tissue response after proton radiotherapy 
treatment. Even with the further reduction of dose given to the healthy tissue with proton 
intensity modulated therapy (IMPT) it is still important to know the responses of the normal 
tissue and the frequency of mutations induced. Some research is ongoing with regard to 
space missions, but the fluences and doses of proton radiation to which astronauts are 
exposed do not resemble the situation when normal tissue is exposed to proton particles 
during radiotherapy. 
Many studies in mice investigate lymphocyte and intestine crypt regeneration. However, 
these are acute responding tissues (early responding tissues). Critical other tissue sites are 
for example the lungs, the brain, and the rectum, which are late responding tissues. In the 
lungs fibrosis can occur, leading to severe problems for the patient. It is not so easy to define 
relevant end-points for late-responding normal tissues. Apoptosis will not or very mildly occur 
as this is a feature of fast regenerating, early responding normal tissue. One could stain for 
other cell death markers like for senescence markers (SA-ß-Gal, PML, and p16INK4a) in thin 
tissue sections at 4, 8, 12, weeks after exposure (391, 392). A lower H&E staining would 
indicate reduced proliferative activity in the irradiated tissue and could be compared to 
photon irradiated tissue. Severe prolonged activation of certain signalling pathways could be 
as well used as a marker to differentiate between photon and proton radiation induced 
normal tissue responses. Prolonged p53 phosphorylation or p21 activation from 5 days up to 
2 weeks after radiation exposure might point to a severe damage response and can lead to 
the transformation of normal cells (24). 
Another important endpoint is chromosomal aberration induction. But cells of these tissues 
do almost not grow and it is nearly not possible to bring them to mitosis. In that case it might 
be possible to extract cells from the normal tissue that was irradiated and from another place 
that was not irradiated. After having the cells in medium premature chromosome 
condensation with the phosphatase inhibitor Calyculin A would help to prepare nuclear 
spreads with condensed chromosomes in G1 and G2 (386). However, the significance of 
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chromosomal aberrations for normal tissue that is almost not growing might be not that big. 
Anyhow a study in 2005 with the lacZ reporter transgene assay revealed a significantly 
increased mutant frequency in brain tissue at 8 weeks after exposure (299). Unfortunately, 
these data were not compared to photon irradiated samples. But it was determined that the 
same assay performed with spleen tissue showed no induction of mutant frequencies at 16 
weeks after exposure indicating that different tissues can clear cells to a better extend or are 
more prone to aberration induction. A large study in the USA analyzed the risk of a 
secondary solid tumour formation at any time post-diagnosis of prostate cancer. It was 
significantly greater after radiotherapy than after surgery (about 6 %). The relative risk 
increased up to 34 % after 10 years and more. Sites of secondary cancer were the bladder, 
rectum, and even the lung (16). Therefore chromosome aberration analysis of radiation-
exposed normal tissue could be a good marker for inter-comparison between the photon- 
and proton-induced aberration amount and possible secondary cancer risk. 
 
5.4 Dose rate effects and RBE differences along the SOBP 
The dose rate can have an effect on cell survival. Dose rates above 1 Gy/min kill cells with 
the same efficiency. Below 1 Gy/min sublethal damage repair can take place and can lead to 
better cell survival after radiotherapy. If dose rates above 4 Gy/min can further reduce the 
cell survival could never be shown before, as this is the maximal dose rate reached with a 
linear accelerator so far. Only recently a research group demonstrated with the TrueBeam 
(Varian) that survival of human glioma cell lines could be further decreased at a dose rate of 
24 Gy/min compared to 6 Gy/min (359). A possible explanation for this might be a higher 
probability of photon radiation tracks to interact with each other. This finding should be taken 
with caution as it was only demonstrated once. However, it would be interesting to find out, if 
the dose rate has an influence on survival in the case of proton radiation. Modulating the 
dose-rate for different exposures and plating the cells afterwards for clonogenic survival 
could show if it can influence survival in the case of proton-radiation exposure. For proton 
radiation this has never been tested before and is of special interest in the case of spot 
scanning where the dose rate can differ in each spot. 
It is clear that the RBE rises at the distal part of the SOBP due lower proton energies, which 
translate into higher LET-values. However, the RBE in the plateau-region and along the 
SOBP is not well defined. Petrovic et al. showed with a 62 MeV beam that the RBE for 
radioresistant melanoma cells increases drastically at the distal declining edge (RBE = 7) but 
is also bigger for centre SOBP proton particles compared to plateau proton particles (RBE = 
1.68 vs. 2.08, respectively) (374). The RBE varies with the cell line and the beam used. Here 
melanoma cells were used but the question is, if normal skin cells respond also with this 
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stronger RBE to protons. If proton radiation is really 1.68 fold more efficient than photon 
radiation in the plateau region, skin will receive a too high dose. Some radiooncologists 
performing proton radiotherapy report severe skin reactions, which might essentially be due 
to a bigger RBE in the plateau region (393). But recent studies report only mild skin reactions 
(394, 395). In general skin toxicities appear to be more pronounced in scattered proton 
radiotherapy. The RBE of skin tissue of different patients also varied between patients (396). 
Here a differential repair status of the normal tissue or other factors could play a role. 
The huge RBE in the distal declining part of the SOBP cannot solely be used to treat tumour 
tissue. Unfortunately due to the safety margins used in radiotherapy planning, mainly healthy 
tissue receives that huge biological effective dose. This is also the case for carbon ion 
treatment. The question is, if it is good to sacrifice parts of the healthy tissue for the 
beneficial saving of the other 95 % of healthy tissue behind the tumour, which will receive no 
dose. To verify the RBE along the proton beam at PSI, cell culture flasks could be placed in a 
row in the beam and processed later for clonogenic survival assays. A possible in vivo 
experiment would be the irradiation of spleens of mice, which are placed in a row along the 
treatment table. That could give more physiological relevant insights. Spleens would be 
collected and checked for apoptotic cell death and DNA damage induction. 
The best would be to compare all those factors in an inter-clinical study as they should be 
anyway defined for each proton gantry, which is on clinical duty. After that study one could 
hopefully exclude inter-clinical variations and concentrate on the genetic background of the 
patients that might influence the relative biological effectiveness of proton radiation. 
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